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Cardiac disease is the leading cause of death in the United States, despite the continuing efforts 
contributed to scientific research and disease management in the past few decades. However many 
advances have been made in cardiovascular research in recent decades and one of the advances is the 
development of human induced pluripotent stem cell(iPSC)-based disease models. The human iPSC-
based disease models are derived from the somatic cells of patients with cardiac diseases and capture the 
genotypes of the original patients, which make them more ideal for mimicking human diseases compared 
with conventional rodent models. So far, the iPSC-based disease models have been used to model several 
types of cardiac diseases, one of which is the focus of this work-Timothy syndrome.   
Timothy syndrome is caused by the missense mutations in the CACNA1C gene encoding the 
voltage-gated calcium channel CaV1.2, which plays an essential role in cardiac function. The disease is a 
multisystem disorder that is featured by long QT syndrome and syndactyly. Timothy syndrome patients are 
treated clinically with beta-adrenergic blockers, calcium channel blockers, and sodium channel blockers. 
However, these regimens are insufficient to prevent lethal arrhythmias in Timothy syndrome patients, 
especially infants with Timothy syndrome. Therefore, new therapeutics to prevent the lethal arrhythmias in 
Timothy syndrome patients are needed until the age when an implantable defibrillator is available.  
The iPSC-based model of Timothy syndrome was first reported in 2011. The previous report 
showed that the Timothy syndrome iPSC-derived cardiomyocytes demonstrated several cellular 
phenotypes including abnormal contractions, abnormal electrophysiological properties and abnormal 
calcium handling, which were consistent with the clinical features of the patients that the iPSCs were 
derived from. In addition, the authors demonstrated that Roscovitine, a cyclin-dependent kinase (CDK) 
inhibitor, could rescue the cellular phenotypes in Timothy syndrome cardiomyocytes. However, the 
mechanisms underlying the beneficial effects of Roscovitine on Timothy syndrome cardiomyocytes were 
not fully elucidated. This work will employ the iPSC-based model of Timothy syndrome to investigate the 
mechanisms underlying the beneficial effects of Roscovitine on Timothy syndrome cardiomyocytes and 
search for additional therapeutic compounds and targets for Timothy syndrome.  
In chapter 1 of this work, we presented new methods to generate iPSCs from human skin fibroblasts 
or hair keratinocytes, and to differentiate iPSCs into cardiomyocytes in a monolayer format. The major 
advantage of the two new methods is that they are technically simple and generally applicable for samples 
from healthy control donors and patients with cardiac diseases. The new methods enabled us to generate 
a sufficient amount of Timothy syndrome cardiomyocytes from iPSCs derived from the skin fibroblasts of 
Timothy syndrome patients, which became the foundation for the subsequent mechanistic study.  
Chapter 2 presents the identification of CDK5 as a new therapeutic target for Timothy syndrome. 
As introduced above, the previous report demonstrated that Roscovitine, a CDK inhibitor, could rescue the 
cellular phenotypes in Timothy syndrome cardiomyocytes. However, the mechanisms underlying the 
beneficial effects of Roscovitine on Timothy syndrome cardiomyocytes were not fully elucidated. To identify 
additional therapeutic compounds for Timothy syndrome and investigate the mechanisms underlying the 
therapeutic effects of Roscovitine on Timothy syndrome cardiomyocytes, we conducted a phenotypic 
screen using Timothy syndrome cardiomyocytes to screen through twenty Roscovitine analogs and four 
CDK inhibitors with different specificities for different CDKs. Four positive compounds were identified from 
the screen. When we summarized the CDK targets of the four positive compounds and the lead compound 
Roscovitine, it was found that four out of the five positive compounds shared a common CDK target, which 
is CDK5, indicating that CDK5 could be involved in the pathogenesis of Timothy syndrome as a therapeutic 
target. We next validated CDK5 as a new therapeutic target for Timothy syndrome using two independent 
approaches. The two approaches are expressing a dominant negative mutant of CDK5 and expressing 
short hairpin RNAs targeting CDK5 in Timothy syndrome cardiomyocytes using lentiviruses. Both 
approaches led to CDK5 inhibition in Timothy syndrome cardiomyocytes and we examined the changes in 
the cellular phenotypes in Timothy syndrome cardiomyocytes with CDK5 inhibition. The results indicated 
that CDK5 inhibition alleviated all the previously-reported phenotypes in Timothy syndrome cardiomyocytes. 
To investigate the mechanisms underlying the beneficial effects of CDK5 inhibition on Timothy syndrome 
cardiomyocytes, we examined the expression of CDK5 activator p35 and the activity of CDK5 in Timothy 
syndrome cardiomyocytes. We found that Timothy syndrome cardiomyocytes showed a higher expression 
of CDK5 activator p35 and a higher activity of CDK5 compared with control cardiomyocytes. When we over-
expressed CDK5 in control cardiomyocytes, we found that CDK5 over-expression caused a change in the 
function of CaV1.2 channels in control cardiomyocytes that resembled the phenotype in Timothy syndrome 
cardiomyocytes. In summary of the results, we propose that in Timothy syndrome cardiomyocytes, the 
increased expression of CDK5 activator p35 causes CDK5 hyper-activation, which enhances the abnormal 
function of the mutant CaV1.2 channels, leading to more severe phenotypes. Thus, CDK5 inhibition 
alleviates the phenotypes in Timothy syndrome cardiomyocytes. The results in this chapter reveal that 
CDK5 is a new therapeutic target for Timothy syndrome and CDK5-specific inhibitors can potentially be 
developed into new therapeutics for Timothy syndrome.  
However, we found that the currently-available chemical inhibitors for CDK5 are not highly-selective 
and have several significant side effects that make them not ideal candidates to be developed into new 
therapeutics for cardiac diseases. Therefore new therapeutic compounds and targets are still needed for 
Timothy syndrome.  
Chapter 3 presents the identification of the sigma-1 receptor as a new therapeutic target for Timothy 
syndrome. Due to the side effects associated with the currently-available chemical inhibitors for CDK5, we 
made an effort to search for an additional therapeutic target and therapeutic compounds for Timothy 
syndrome. We reasoned that instead of directly inhibiting CDK5, we could potentially alleviate the 
phenotypes in Timothy syndrome cardiomyocytes by affecting the CDK5 activator p35 and this idea led us 
to the sigma-1 receptor. After we looked into the sigma-1 receptor, we found that in addition to being 
reported to modulate p35 protein level, the sigma-1 receptor had also been reported to modulate calcium 
homeostasis, which is another favorable effect for Timothy syndrome cardiomyocytes. Therefore we 
hypothesized that the activation of the sigma-1 receptor could be beneficial for Timothy syndrome 
cardiomyocytes, which feature an increased expression of p35 and a dysregulation of calcium homeostasis. 
To test this hypothesis, we examined the effects of two sigma-1 receptor agonists, one of which is a FDA-
approved drug, on the phenotypes in Timothy syndrome cardiomyocytes. The results demonstrated that 
the treatment of the two sigma-1 receptor agonists alleviated the previously-reported phenotypes in Timothy 
syndrome cardiomyocytes. We also examined the effects of the two sigma-1 receptor agonists on the 
functions of control cardiomyocytes and found that the treatment of the two sigma-1 receptor agonists did 
not have significant side effects on the regular contractions and normal calcium transients in control 
cardiomyocytes. Overall, the results reveal that the sigma-1 receptor is a new therapeutic target for Timothy 
syndrome. The results also demonstrate that the two sigma-1 receptor agonists that we tested are 
promising lead compounds that can developed into novel therapeutics for Timothy syndrome in the future.  
Since one of the sigma-1 receptor agonists that we tested is a FDA-approved drug, this drug could 
potentially be used directly in Timothy syndrome patients for treating the cardiac arrhythmias in the near 
future. 
In summary, this work is a proof of concept that the iPSC-based models of cardiac diseases can 
be used to generate novel insights into disease pathogenesis, and to identify new therapeutic targets and 
compounds for cardiac diseases, and in particular for Timothy syndrome. The therapeutic targets and 
compounds that we have identified in this work would be helpful for the development of novel therapeutics 
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Cardiac disease is the leading cause of death in the United States1, despite the continuing efforts 
contributed to scientific research and disease management in the past few decades. However, many 
advances have been made in cardiovascular research and one of the advances is the development of 
induced pluripotent stem cell(iPSC)-based disease models. The iPSC-based disease models are derived 
from the somatic cells of patients with cardiac diseases and capture the genotypes of the original patients, 
which make them more ideal for mimicking human diseases compared with conventional rodent models. 
Several studies have already demonstrated that iPSC-derived cardiomyocytes can be used in preclinical 
safety screens to examine cardiac toxicity 2-4. However, there are few studies, if any, that use iPSC-based 
models of cardiac diseases to identify novel therapeutic targets and develop new therapeutics based on 
those targets. Therefore, it is of great interest to explore the potential application of iPSC-based models of 
human cardiac diseases for this purpose. This work will focus on the optimization of the generation of iPSC-
based models of human cardiac diseases and in particular the use of an iPSC-based model of Timothy 
syndrome to investigate disease mechanisms and to search for new therapeutic targets for this disease. 
 
The generation of iPSC-based models of cardiac diseases 
It has been known for decades that the human development begins with an embryo, which 
proliferates and differentiates into every part of the human body including the heart. It was once thought 
that the differentiation process was irreversible but this idea was disproved in 2006, when the first method 
to generate iPSCs from human somatic cells was reported by Yamanaka and Takahashi 5. In the original 
publication, the authors demonstrated, for the first time, that the terminally-differentiated human adult 
fibroblasts could be reprogrammed to pluripotency by expressing four transgenes (Oct 3/4, Sox2, c-Myc 
and klf4) using retroviruses. The reprogrammed fibroblasts, which were named as iPSCs by the authors, 
could be subsequently differentiated into all three germ layers (ectoderm, mesoderm, endoderm) and 
eventually into many different cell types including cardiac cells. The development of iPSC technology 
provided a distinct opportunity for scientific researchers to study human developmental biology and 
investigate human disease mechanisms in vitro, and numerous scientists have since made remarkable 
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scientific discoveries using iPSCs or iPSC-derived cells. As the first method to generate iPSCs, the 
Yamanaka retroviral method has been widely used for the reprogramming of somatic cells to pluripotency. 
However, there are several disadvantages associated with the retroviral method including a low efficiency 
of reprogramming and a concern for random integrations of the transgenes into the genome. Compared 
with the retroviral method, non-integrative methods for cellular reprogramming, which can minimize the risk 
of random mutations and tumor development, are preferred. Several non-integrative methods to generate 
iPSCs from somatic cells have been reported in recent few years 6-11. Many of them utilized Sendai RNA 
viruses to introduce the desired transgenes or used transfection to deliver the mRNAs encoding the 
transgenes under RNase-free conditions into somatic cells for the generation of iPSCs 7, 8, 11. Episomal 
vectors containing the transgenes, which are easier to be handled compared with mRNAs or RNA viruses, 
have also been used for the reprogramming of human fibroblasts but electroporation was required for the 
delivery of episomal vectors into the cells 9. The delivery of episomal vectors using electroporation requires 
specific equipment and millions of cells to minimize toxicity and optimize the efficiency of gene transduction, 
which is not ideal for the reprogramming of human somatic cells, especially for the reprogramming of 
precious samples from patients with rare diseases. A non-integrative method that only requires simple 
procedures to deliver the episomal vectors into the somatic cells for cellular reprogramming would be a 
helpful addition to the currently available methods for the cellular reprogramming of somatic cells into 
iPSCs.  
For modelling human cardiac diseases, the key step after iPSC generation is to differentiate the 
iPSCs into cardiomyocytes. The methods to differentiate human pluripotent stem cells into cardiomyocytes 
were developed based on the lessons we learned from embryonic heart development, and a directed 
differentiation of iPSCs into cardiomyocytes was achieved by a sequential treatment with growth factors or 
chemical compounds that affect the signaling pathways determining cardiac cell fate 12. In general, two 
basic methods have been reported for the cardiac differentiation of iPSCs, which are the formation of 
embryoid bodies (EBs), and culturing iPSCs as a monolayer. The formation of EBs refers to the technique 
of re-suspending the iPSC colonies in low attachment dishes to form spherical aggregates. After EB 
formation, the EBs are treated with growth factors or small molecules sequentially for the directed 
differentiation 13. The formation of EBs is technically complicated and time consuming, which has led to the 
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development of monolayer-based cardiac differentiation methods. Another advantage of monolayer-based 
cardiac differentiation methods is that the monolayer culture allows the cells to be exposed to the 
differentiation factors uniformly, which greatly enhances the differentiation efficiency. Several monolayer-
based cardiac differentiation methods have been reported in recent few years 14-19. The first three protocols 
reported for monolayer cardiac differentiation require the use of recombinant proteins for the directed 
differentiation, which increases the cost of every round of cardiac differentiation 14, 16, 17. To reduce the cost, 
recently-reported protocols have used inexpensive chemical compounds to replace the expensive 
recombinant proteins for the monolayer differentiation 15, 18, 19. However, all the monolayer cardiac 
differentiation protocols have demonstrated a high cardiac differentiation efficiency in iPSCs derived from 
the somatic cells of healthy donors, but not in iPSCs derived from the somatic cells of patients with cardiac 
diseases. Therefore, the currently-available protocols need to be optimized, or a new monolayer 
differentiation protocol needs to be developed, in order to efficiently differentiate patient-specific iPSCs into 
cardiomyocytes for the use of the investigation of disease mechanisms and the identification of new 
therapeutic targets.  
 
The iPSC-based model of Long QT syndrome 
With respect to applications, iPSC-based disease models have been used to model several types 
of cardiac diseases such as Long QT (LQT) syndrome, hypertrophic cardiomyopathy and dilated 
cardiomyopathy 20, among which we are particularly interested in LQT syndrome. LQT syndrome is a 
disorder characterized by a prolongation of the QT interval on electrocardiogram 21. One of the two major 
types of LQT syndrome is congenital LQT syndrome, which is caused by genetic mutations. Congenital 
LQT syndrome is responsible for a significant proportion of sudden cardiac deaths in young people without 
structural heart diseases and it causes thousands of death annually 22. Therefore, the development of novel 
effective therapeutics for congenital LQT syndrome, especially for the sub-types of congenital LQT 
syndrome that do not have effective therapeutics, is a priority. 
iPSCs were used to model congenital LQT syndrome for the first time in 2010 23. In this study, the 
iPSCs were derived from two patients carrying a missense mutation in the KCNQ1 gene encoding the alpha 
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subunit of the potassium channels generating the slow outward potassium current (IKs). The mutations in 
KCNQ1 are associated with LQT syndrome type 1. Compared with control cardiomyocytes, the 
cardiomyocytes derived from the iPSCs generated from the two patients carrying the missense mutation in 
KCNQ1 demonstrated a significantly reduced IKs and a vulnerability to catecholamine-induced 
tachyarrhythmia, which could be rescued by a pre-treatment with beta blockers. The phenotypes observed 
in the patient-specific cardiomyocytes derived from the iPSCs generated from the two patients with LQT 
syndrome type 1 were consistent with the patients’ profiles and with previous findings using heterologous 
expression systems and animal models, which indicated that iPSC-based models of LQT syndrome could 
be useful as human models to investigate disease mechanisms and to search for new therapeutics.  
So far, four iPSC-based models of LQT syndrome have been reported 20. One of them is the iPSC-
based model of Timothy syndrome (Congenital LQT syndrome type 8), which was previously reported by 
my mentor Dr. Yazawa and his colleagues 24. Timothy syndrome, which is caused by the missense 
mutations in CACNA1C encoding the voltage-gated calcium channel alpha 1C subunit CaV1.2, is a 
multisystem disorder that is featured by LQT syndrome and syndactyly 25-28. Timothy syndrome patients 
are treated clinically with beta-adrenergic blockers, calcium channel blockers, and sodium channel blockers 
29, 30. However, these regimens are insufficient to prevent lethal arrhythmias in Timothy syndrome patients, 
especially infants with Timothy syndrome 31-33. Therefore, new therapeutics to prevent lethal arrhythmias in 
Timothy syndrome patients are necessary until the age when an implantable defibrillator is available. 
Previously, Dr. Yazawa and his colleagues generated iPSCs from the skin fibroblasts of two 
Timothy syndrome patients carrying the G1216A mutation in the CACNA1C gene leading to the G406R 
mutation in CaV1.2 and examined the phenotypes in Timothy syndrome cardiomyocytes derived from the 
patient-specific iPSCs. They found that Timothy syndrome cardiomyocytes demonstrated significantly 
prolonged spontaneous action potentials, irregular spontaneous calcium transients and a delayed voltage-
dependent inactivation of CaV1.2 channels, when compared with control cardiomyocytes (Figure I1A-I1J). 
They also found that Roscovitine (also named as CY-202 or Seliciclib), a cyclin-dependent kinase (CDK) 
inhibitor, could rescue the phenotypes in Timothy syndrome cardiomyocytes (Figure I2A-I2F). Another 
study conducted by Dr. Yazawa’s colleagues revealed that Roscovitine could also rescue the phenotypes 
in Timothy syndrome iPSC-derived neurons 32. Although Roscovitine showed beneficial effects on the 
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phenotypes in Timothy syndrome cardiomyocytes and neurons, the mechanisms underlying the therapeutic 
effects of Roscovitine are not fully elucidated. There is one previous report indicating that high dose (100 
μM) Roscovitine treatment directly enhanced the inactivation of CaV1.2 channels with Timothy syndrome 
mutations in a heterologous over-expression system 34. However, the authors did not provide any evidence 
for the direct interaction between Roscovitine and CaV1.2 channels with Timothy syndrome mutations, and 
the high dose used in the study raised a concern of non-specific interactions of Roscovitine with other 
proteins. Thus further studies are needed to provide more insights into the mechanisms underlying the 





Figure I1: The Ca2+ signaling and electrophysiological features of Timothy syndrome (TS) 
cardiomyocytes. (A, B, C, D) Representative line-scan images (A, C, top) and spontaneous 
Ca2+ transients (A, C, bottom) in control (left) and TS cardiomyocytes (right). TS cardiomyocytes 
showed more irregular timing (B) and amplitude (D) of spontaneous Ca2+ transients compared to 
control cells (control, n=102 cells in 4 lines; TS, n=149 in 4 lines, mean ± s.e.m.; *P<0.05, **P<0.01, 
student’s t-test). (E) Voltage-clamp recording of Ba2+ currents in control (black) and TS (red) 
cardiomyocytes show a defect in voltage-dependent channel inactivation (VDI) following a voltage 
pulse from −90 to −10 mV. (F) VDI in control and TS cardiomyocytes at 350 ms after the start of the 
pulse (**P<0.01; student’s t-test). (G) The current-voltage relationship of TS (●) and control (○) 
Ba2+ currents (mean ± s.e.m.) is statistically identical. There were no significant differences in the 
peak amplitude of Ba2+ currents between control and TS cardiomyocytes (data not shown). (H) 
Spontaneous action potentials (AP) in control and TS ventricular-like myocytes measured in current-
clamp mode. Boxes show the regions indicated by underlines at an expanded time scale. Arrowheads 
show putative delayed afterdepolarizations (DADs). Dashed lines show 0 mV. (I) AP duration in TS 
and control ventricular cardiomyocytes. (J) Putative DADs in TS and control ventricular-like 
cardiomyocytes (control, n=22 cells in 4 lines; TS, n=14 in 4 lines, mean ± s.e.m.). Statistical analyses 









Figure I2: Roscovitine rescues the cellular phenotypes of Timothy syndrome (TS) 
cardiomyocytes. (A) Spontaneous Ca2+ transients in TS cardiomyocytes before (black) and after 
treatment with 33.3 μM Roscovitine (red) as well as after wash out (blue). Arrowheads show irregular 
Ca2+ elevations. (B) Effects of Roscovitine on the relative irregularity of the amplitude and timing of 
the spontaneous Ca2+ transients in TS cardiomyocytes (n=8 cells in 2 lines, *P<0.05, **P<0.01). (C) 
Ba2+ currents in TS cardiomyocytes recorded in voltage-clamp mode before (black) during (red) and 
after (blue) treatment with 33.3 μM Roscovitine. Roscovitine promoted the inactivation of currents in 
TS cardiomyocytes. (D) Effects of Roscovitine on the voltage-dependent inactivation (VDI) of CaV1.2 
in TS cardiomyocytes (n=5 cells from 2 lines, **P<0.01). (E) Spontaneous action potentials recorded 
in current-clamp recording before, during and after treatment with Roscovitine. Arrowheads show 
putative delayed afterdepolarizations (DADs). (F) Roscovitine prevented the action potential 
prolongation observed in TS cardiomyocytes (n=8 cells in 2 lines, **P<0.01, mean ± s.e.m.). This 





Roscovitine and CDKs 
The therapeutic compound Roscovitine was first identified as an inhibitor for CDK2 using an in vitro 
enzymatic screen in 1997 35. A follow-up study from the same group showed that Roscovitine demonstrated 
a high selectivity against CDK1, CDK2 and CDK5 with IC50 values of 0.65, 0.7 and 0.2 μM respectively 
when it was investigated in a specificity screen using 25 highly purified kinases 36. Roscovitine showed 
inhibitory effects on cell proliferation and DNA synthesis in vitro and significantly inhibited tumor growth in 
several cancer xenograft mouse models 37. Currently, this compound is in clinical trials for treating several 
types of cancers 37.  
Several studies have been conducted to investigate the mechanisms underlying the inhibitory 
effects of Roscovitine on CDKs. Direct co-crystallization of Roscovitine with CDK2 and CDK5/p25 revealed 
that Roscovitine serves as an adenosine triphosphate (ATP)-competitive inhibitor and inhibits CDKs by 
competing with ATP for the ATP-binding site of CDKs 35, 38. Among the three CDK targets of Roscovitine, 
CDK1 and CDK2 have been shown to play important roles in cell-cycle progression, which provides insights 
into the mechanisms underlying the anti-proliferative effect of Roscovitine 39. The last target CDK5 is an 
unusual member of the CDK family. CDK5, just like other CDKs, is a proline directed serine/threonine 
kinase. However, unlike other CDKs that are usually activated by cyclins, CDK5 is known to be activated 
by two non-cyclin proteins, p35 and p39 40. The CDK5 activators, p35 and p39, both carry a myristoylation 
motif that targets them to the cell membrane and CDK5 is thought to be a membrane associated CDK 41.  
In addition to p35 and p39, recent studies indicate that CDK5 activity is also regulated by phosphorylation 
at Tyr15 by several kinases such as Abl, Fyn or ephrin receptor A (EphA) 42-44. Moreover, a recent report 
indicated that CDK5 could be activated by a cyclin protein named cyclin I as well and cyclin I mediates the 
nuclear localization of CDK5 45. Although CDK5 is expressed in both mitotic cells and post-mitotic cells, its 
activity is thought to be more restricted to terminally differentiated cells such as neurons due to the 
expression of its activators p35 and p39 41. CDK5 has been showed to play an important role in the 
pathogenesis of several neurodegenerative diseases such as Alzheimer disease, Parkinson’s disease and 
Huntington’s disease 46. Whether CDK5 plays a role in the pathogenesis of LQT syndrome or in cardiac 




Objective of This Work 
The contents of this work will build on the themes discussed above, and present novel observations 
that contribute to the understanding of the mechanisms underlying the beneficial effects of Roscovitine on 
Timothy syndrome iPSC-derived cardiomyocytes and the identification of new therapeutic targets for 
Timothy syndrome. In doing so, this work will provide a foundation for the development of novel therapeutics 
for treating Timothy syndrome in the future. Chapter I describes the optimization of the generation of human 
iPSC-based models of cardiac diseases. We developed new methods for the generation of iPSCs from 
human fibroblasts and hair keratinocytes, and the differentiation of iPSCs into cardiomyocytes. The new 
methods provide a platform to generate new human iPSC-based models of cardiac diseases and a 
foundation for the following study to investigate the mechanisms underlying the beneficial effects of 
Roscovitine on Timothy syndrome cardiomyocytes. Chapter 2 presents the identification of CDK5 as a new 
therapeutic target for Timothy syndrome. Our experiments reveal that Roscovitine exhibits its beneficial 
effects on Timothy syndrome cardiomyocytes in part by inhibiting CDK5 and the inhibition of CDK5 
alleviates all the previously-reported phenotypes in Timothy syndrome cardiomyocytes. The results 
demonstrate that CDK5 is a new therapeutic target for Timothy syndrome. However, it was found that the 
currently available inhibitors with a relative specificity for CDK5 have significant side effects that make them 
not ideal candidates as new therapeutics for cardiac diseases. Thus we continued to search for additional 
therapeutic targets and compounds for Timothy syndrome. Chapter 3 presents the identification of the 
sigma-1 receptor as a new therapeutic target for Timothy syndrome. The sigma-1 receptor has been 
reported previously to regulate the protein expression of CDK5 activator p35 and modulate calcium 
homeostasis. We hypothesized that the treatment of sigma-1 receptor agonists would be beneficial for 
Timothy syndrome cardiomyocytes, which also feature an increased expression of p35 and abnormal 
calcium handling. Our experiments demonstrate that the use of sigma-1 receptor agonists, Fluvoxamine 
and PRE-084, alleviates the previously-reported phenotypes in Timothy syndrome cardiomyocytes. The 
results demonstrate that the sigma-1 receptor is a new therapeutic target for Timothy syndrome. Overall, 
this work is a proof of concept that the human iPSC-based disease model can be used to identify novel 


















Due to the scarcity of human cardiomyocytes, rodent models have been widely used to investigate 
the mechanisms underlying human cardiac diseases, despite the fact that there are significant differences 
in the resting heart rate and electrical properties between rodent cardiomyocytes and human 
cardiomyocytes. In recent decades, advances in technology provide us with a new type of disease models, 
the human iPSC-based models of cardiac diseases. The model is useful for studying the pathogenesis of 
cardiac diseases using human cardiomyocytes in vitro. Although there are still some limitations with the 
human iPSC-based models of cardiac diseases such as the immaturity of iPSC-derived cardiomyocytes, 
many reports and studies have indicated that the iPSC-based models of cardiac diseases can recapitulate 
the genotypes and the major phenotypes in several types of inherited cardiac diseases such as congenital 
LQT syndrome, hypertrophic cardiomyopathy and dilated cardiomyopathy 20, making them useful tools for 
scientific research.  However, the application of human iPSC-based models of cardiac diseases in research 
is still limited, for reasons like the technical expertise needed to generate the iPSC-based disease models 
in the lab. New protocols that are technically simple and generally applicable for the generation of human 
iPSC-based models of cardiac diseases would be helpful for labs just starting to generate the iPSC-based 
disease models. This chapter will present a new protocol for the generation of iPSCs from human fibroblasts 
and hair keratinocytes using single lipofection, which is a simple and commonly-used technique in research 
labs. A new monolayer-based cardiac differentiation protocol will also be presented in this chapter, which 
can be applied for iPSCs derived from the somatic cells of both healthy donors and patients with cardiac 
diseases. Together, the protocols provide a platform to generate human iPSC-based models of cardiac 
diseases and a foundation for the subsequent study to investigate their disease mechanisms. 
 
Results 
Cellular reprogramming to pluripotency using single lipofection 
To develop a technically-simple method for cellular reprogramming, we examined whether we could 
use single lipofection to deliver the episomal vectors containing the transgenes into human fibroblasts for 
cellular reprogramming. We first tested several types of lipofection reagents to deliver an episomal vector 
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containing green fluorescent protein (GFP) into IMR90 healthy human embryonic lung fibroblasts plated in 
24-well plates. We found that using lipofectamine LTX (LF-LTX) or Lipofectamine 2000 (LF-2K) for 
transfecting IMR90 human lung fibroblasts with the GFP-containing episomal vector provided a higher 
percentage of GFP-positive cells at day 5 after lipofection, compared with other lipofection reagents (Figure 
1.1A and 1.1B). When we quantified the cell density of IMR90 fibroblasts at day 5 after lipofection, we 
found that using LF-LTX for lipofection provided a relatively higher cell density, compared with other 
lipofection reagents (Figure 1.1C). Therefore LF-LTX was used in the protocol for lipofection. To examine 
whether we could use LF-LTX to transfect patient fibroblasts, we used LF-LTX to transfect the fibroblasts 
from patients with cardiac diseases and further optimized the lipofection conditions. The result indicated 
that LF-LTX could be used to transfect patient fibroblasts. Moreover, culturing the transfected cells in the 
recovery media supplemented with 20% fetal bovine serum (FBS) after lipofection enhanced the survival 
of the transfected cells and provided a higher percentage of GFP-positive cells at day 4 or day 5 after 
lipofection (Figure 1.1D and 1.1E). We summarized the optimized conditions for lipofection and generated 
the protocol shown in Figure 1.1F. We next examined whether this protocol could be used to deliver 
episomal vectors into other human cells such as hair follicle keratinocytes that could be obtained in a less 
invasive way. We found that the protocol could be used to deliver the GFP-containing episomal vector into 
healthy hair follicle keratinocytes and the cell recovery after lipofection was better when we used the 
recovery media supplemented with 20% FBS, compared with using the regular human hair follicle 
keratinocyte culture media (Figure 1.1G and 1.1H). We then used this protocol to deliver three episomal 
vectors containing the transgenes (Oct3/4, shp53, Sox2, Klf4, L-Myc, Lin28) that have been used previously 
for cellular reprogramming 9, and successfully generated multiple independent iPSC lines from the 
fibroblasts of two healthy donors and two patients with Timothy syndrome, and healthy human hair follicle 
keratinocytes that were plated in wells in 24-well plates under hypoxia (5% O2) and feeder-free conditions 
(Figure 1.2, Figure 1.3A and 1.3B, and Table 1.1). To examine whether this protocol is generally 
applicable for the reprogramming of samples from patients with cardiac diseases, we used this protocol for 
the reprogramming of fibroblast samples from patients with inherited congenital heart diseases, and 
successfully reprogrammed the patient fibroblasts into iPSCs (Figure 1.2, Figure 1.3B, and Table 1.1), 
despite the variations in reprogramming efficiency. The results demonstrate that the protocol we have 
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developed is generally applicable for the cellular reprogramming of samples from control healthy donors 
and patients with cardiac diseases. Next, we characterized the iPSC lines and confirmed the pluripotency 
using reverse transcription polymerase chain reaction (RT-PCR) to validate the expression of the 
pluripotency gene NANOG (Figure 1.3C), immunocytochemistry with two antibodies against two 
pluripotency markers TRA-1-60 and TRA-1-81 (Figure 1.3D), teratoma formation assay (Figure 1.3E), 
karyotyping (Figure 1.3F) and in vitro differentiation (Figure 1.3G). An advantage of using episomal vectors 
for the cellular reprogramming is the episomal vectors are not supposed to be integrated into the genome, 
which will minimize the risk of random mutations potentially caused by the reprogramming procedure. In 
order to investigate whether the episomal vectors were silenced in the iPSCs, we examined the expression 
of EBNA1, a reporter gene that is included in the sequences of all three episomal vectors, in the cDNA 
samples from the newly-generated iPSC lines using real-time RT-PCR. The result demonstrated that there 
was no expression of EBNA1 in the samples from the newly-generated iPSC lines, indicating that the 
episomal vectors were silenced in the newly-generated iPSC lines (Figure 1.3H). In summary, the results 
demonstrate that our protocol can be used to derive iPSCs from human fibroblasts and hair keratinocytes.  
Monolayer cardiac differentiation of iPSCs 
In order to use human iPSC-based models of cardiac diseases to investigate disease mechanisms 
and search for new therapeutics, an efficient method to generate a sufficient amount of iPSC-derived 
cardiomyocytes from control iPSCs and patient-specific iPSCs is necessary. To enhance the differentiation 
efficiency and reduce the cost of every round of cardiac differentiation, we started with monolayer-based 
cardiac differentiation and used small chemical compounds instead of recombinant factors to direct the 
cardiac differentiation of iPSCs. Previous studies in the field of developmental biology have shown that the 
activation of bone morphogenetic protein (BMP) signaling, Nodal signaling and canonical Wnt signaling 
promotes the mesoderm induction and cardiogenesis at an early stage while the inhibition of canonical Wnt 
signaling promotes the cardiac specification at a later stage 13, 47, 48. Therefore, we chose to use two 
glycogen synthase kinase 3 (GSK3) inhibitors CHIR99021 and BIO, which inhibit GSK3 and induce the up-
regulation of endogenous BMP4 signaling and Nodal signaling, to direct mesoderm differentiation in the 
first four days and a Wnt inhibitor IWP-3 to direct the cardiac differentiation of iPSCs from day 5 to day 10 
in our protocol. We optimized the oxygen concentration and the dose of the GSK3 inhibitors for the protocol 
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(Table 1.3) and developed a new monolayer cardiac differentiation protocol that is shown in Figure 1.4A. 
Using this protocol, monolayer cardiomyocytes could be generated from the iPSCs derived from healthy 
donors and Timothy syndrome patients (Figure 1.4B). The fluorescence-activated cell sorting (FACS) 
analysis using the antibody against sarcomeric alpha-actinin revealed that the average differentiation 
efficiency of this protocol for control iPSCs and Timothy syndrome iPSCs was similar and approximately 
60% (Figure 1.4C). Moreover, we confirmed the gene expression of alpha-actinin (ACTN2), cardiac 
troponin T(TNNT2) and Myosin heavy chain 7(MYH7) in the cardiomyocyte samples at day 19 after 
differentiation (Figure 1.4D).  In addition, single control and Timothy syndrome cardiomyocytes 
demonstrated organized sarcomere arrangements in the immunostaining using the antibody against 
sarcomeric alpha-actinin (Figure 1.4E). Lastly, to validate the cellular phenotypes in Timothy syndrome 
cardiomyocytes, we constructed a lentivirus containing a genetically encoded calcium indicator R-GECO1, 
to infect control and Timothy syndrome cardiomyocytes for calcium imaging 49. Calcium imaging revealed 
that control cardiomyocytes demonstrated normal spontaneous calcium transients and Timothy syndrome 
cardiomyocytes demonstrated abnormal spontaneous calcium transients, which was consistent with the 
previous findings 24 (Figure 1.5A and 1.5B). The continuous imaging of Timothy syndrome cardiomyocytes 
using the R-GECO1 indicator at day 23 and day 40 after differentiation revealed that there is a progression 
in the phenotype of Timothy syndrome cardiomyocytes over time (Figure 1.5B). We also validated the 
previous finding that the treatment of Roscovitine alleviated the abnormal spontaneous calcium transients 
in Timothy syndrome cardiomyocytes 24 (Figure 1.5C). In summary, the results demonstrate that our 
protocol can be used to derive cardiomyocytes from control and patient-specific iPSCs.  
 
Discussion 
Here we presented a protocol for the generation of iPSCs from human fibroblasts and hair 
keratinocytes and a protocol for the differentiation of iPSCs into human cardiomyocytes.  The new protocol 
using single lipofection for the non-integrative cellular reprogramming provides a technically-simple 
approach to generate iPSCs from human somatic cells although the efficiency of iPSC generation using 
our protocol may not be as high as the efficiency using other technically more complicated methods 6-11. 
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The iPSCs generated from the fibroblasts of healthy control donors and Timothy syndrome patients are 
important materials for the following mechanistic investigations to understand the therapeutic mechanisms 
of Roscovitine on Timothy syndrome. In addition, to confirm the general applicability of the protocol for the 
cellular reprogramming of samples from patients with cardiac diseases, we used this protocol to reprogram 
the fibroblasts from several patients with congenital heart diseases into iPSCs (Table 1.1). These iPSC 
lines are useful for future studies to examine the potential phenotypes in the patient-specific cardiomyocytes 
and investigate the mechanisms underlying congenital heart diseases caused by different mutations. 
For the monolayer cardiac differentiation protocol, its distinct advantage is that the protocol is 
generally applicable for differentiating both control and patient-specific iPSCs into cardiomyocytes, with a 
moderate efficiency. One of the major limitations of this protocol is that it involves the use of FBS in the 
differentiation media that prevents the use of the differentiated human cardiomyocytes for regenerative 
medicine. The FBS in the culture media has also been reported to mask the hypertrophic phenotype in 
patient-specific cardiomyocytes 50. Thus, a serum-free derivative version of the current protocol will be more 
ideal for expanding the applications of this protocol for basic research and heart regeneration. To address 
this limitation, we developed a serum-free version of the monolayer differentiation method and the results 
are included in the future direction part of the thesis. Another limitation of the protocol is that the 
differentiation efficiency is moderate (approximately 60%). For our study, we were able to get a sufficient 
amount of cardiomyocytes with the moderate differentiation efficiency using this protocol for further studies 
although lactate selection could be used to further enrich the purity of the monolayer cardiomyocytes as 
reported previously 51. Beside the cardiomyocytes, the rest of the cells in the monolayer culture could be 
endothelial-like cells 52 or epicardial-like cells 53 based on previous reports. We observed that the non-
cardiomyocyte cells in the monolayer culture are not proliferative and do not affect the contractions of the 
monolayer cardiomyocytes. Thus we were able to either use the intact monolayer cardiomyocytes directly 
for a contraction assay for chemical tests, or isolate and dissociate the cardiomyocytes from the monolayer 
for single cell based experiments such as patch clamping and calcium imaging in the following studies. In 
summary, the cardiac differentiation protocol provides an efficient method to generate control 
cardiomyocytes and Timothy syndrome cardiomyocytes for the following studies to understand the 
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mechanisms underlying the beneficial effects of Roscovitine on the phenotypes in Timothy syndrome 
cardiomyocytes, which will be presented in chapter 2. 
 
Outcome of the study 
U.S. patent application: 
Methods for cardiac differentiation of human induced pluripotent stem cells. Serial No.: 62/212,195  
Publication:  
LouJin Song, Daniel W. Awari, Elizabeth Y. Han, Eugenia Uche-Anya, Seon-Hye E. Park, Yoko A. Yabe, 
Wendy K. Chung, Masayuki Yazawa. (2015). Dual Optical Recordings for Action Potentials and Calcium 
Handling in Induced Pluripotent Stem Cell Models of Cardiac Arrhythmias Using Genetically Encoded 
Fluorescent Indicators. Stem Cells Translational Medicine. 4(5):468-75. doi: 10.5966/sctm.2014-
0245.Pubmed ID PMID:25769651 54.  
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Figure 1.1: Optimization of single lipofection in human fibroblasts and hair follicle
keratinocytes. (A, B, C) Phase contrast images (left) and fluorescent images (right) of IMR90
cells transfected with TransFectin, X-fect, Fugene HD, Lipofectamine 2000 (LF-2K) and
Lipofectamine LTX (LF-LTX). An episomal vector pCXLE-EGFP (enhanced green fluorescent
protein) was used as a reporter to examine the efficiency of gene transduction in IMR90 cells.
Arrowheads show EGFP-positive cells with X-fect and Fugene HD because of a lower expression.
The percentage of EGFP-positive cells (B) and relative cell density (C) at day five after lipofection
were examined. The results revealed that LF-LTX showed a higher efficiency of transfection and
induced relatively less cell death than other candidates in human fibroblasts (n=3 per group; *
P<0.05, **P<0.01 with one-way ANOVA (Bonferroni post-hoc); n.s., not significant). (D)
Lipofectamine LTX and the pCXLE-EGFP episomal vector were used for the transfection in patient
fibroblasts to examine whether this protocol works for the skin fibroblasts of a Timothy syndrome
patient (TS7634) in 24-well plates. After lipofection, culture media was changed to 10% or 20%
FBS-containing Dulbecco’s Modified Eagle Media (DMEM) without antibiotics. (E) Identical
conditions of lipofection were tested in the fibroblasts from a patient with congenital heart disease,
CDH01-0634. DMEM media containing 20% FBS was used after lipofection. (F) Outline of the
lipofection protocol using Lipofectamine LTX (LF-LTX) in human skin fibroblasts. (G)
Lipofectamine LTX and the pCXLE-EGFP episomal vector were used for the transfection in human
hair follicle keratinocytes (HHFK) to examine whether this protocol works for keratinocytes in 20%
FBS-containing DMEM (top) and keratinocyte-specific media (FK, bottom). (H) Outline of the
lipofection protocol using Lipofectamine LTX (LF-LTX) in human hair follicle keratinocytes (HHFK).
Scale bar, 250 μm. This figure is reproduced from Song, et al 54.






Figure 1.2: Generation of iPSCs from control and patient fibroblasts and hair keratinocytes. 
(A) Phase contrast images of patient iPSC colonies on plates before picking up (passage 0).  (B) 
Naming of iPSC lines derived from control fibroblasts and patient-specific fibroblasts.  Different 
experiment number demonstrates that we generated independent lines from a patient. The names 
of our previously generated iPSC lines using retroviruses were also changed, for instance, NH1-1 to 
“NH-R1-1” & T7643-61 to “TS2-R6-1” to know whether retroviruses (R) or episomal vectors (E) were 
used for reprogramming and to avoid confusions.  (C) Phase contrast images of iPSC lines that were 
picked up and stored for further studies.  Control (normal human dermal fibroblasts (NHDF) and 
IMR90 healthy human embryonic lung fibroblasts (IM)) and patient fibroblasts were reprogrammed 
using the optimized lipofection protocol.  *We found that IM-E2-1 was unstable in E8 media at an 
early passage (arrow head) and we did not characterize this line further.  (D) Phase contrast images 
of iPSC lines generated from human hair follicle keratinocytes (FK) using single lipofection.  Scale 
bar, 100 μm. This figure is reproduced from Song, et al 54.  
Acknowledgment: Dr. Masayuki Yazawa contributed to the generation and maintenance of the iPSC 
lines. Drs. Wendy K. Chung, P. Lanzano and J. Wynn provided the fibroblasts of patients with 
congenital heart diseases (CDH). Drs. W. Froehlich-Santino, J. Bernstein, J. Hallmayer, and R. E. 




Figure 1.3: Characterization of iPSCs generated using the single lipofection based protocol
for cellular reprogramming. (A) Outline of the reprogramming of skin fibroblasts into iPSCs using
lipofection with Lipofectamine LTX in 24-well plate scale. (B) The number of iPSC-like colonies
generated from human skin fibroblasts and hair keratinocytes (FK) plated in 24-well plate scale
(n=4-8 from two independent rounds of experiments). FK*, no iPSC-like colonies (n/a) were found
in cases that used human hair keratinocyte media at day 2-6. (C) Gene expression of the
pluripotent marker NANOG and housekeeping gene GAPDH in iPSC lines. Embryonic stem cell
line H9 (positive control, P. Con), untreated patient fibroblasts (Fib, negative control, N. Con) and
transfected fibroblasts using the episomal vectors (collected at day 5 after lipofection) were used as
controls. (D) Representative immunocytochemistry staining of CHD patient iPSCs (CH1-E4-12)
using antibodies to TRA-1-60 (red, left) and TRA-1-81 (red, right), and Hoechst33285 stain (blue)
for nuclei. Sixteen lines were used for immunocytochemistry and all lines were positive for the two
pluripotency markers. Scale bar, 50 μm. (E) Representative sections of teratoma formed by control
iPSC line (IM-E1-7) stained using Hematoxylin and Eosin Y. Scale bar, 100 μm. Eleven lines were
used for this assay and all lines could form teratoma in mice. (F) Ten iPSC lines were tested and
normal karyotype was observed in all tested control and patient-specific iPSC lines. (G)
Representative immunocytochemistry staining of differentiated neurons from control iPSC line IM-
E1-6 at day 42 using antibody to MAP2 (red) and nuclei stain (blue, Hoechst). Scale bar, 25 μm.
(H) EBNA1 gene expression in generated iPSC lines normalized to GAPDH expression using real-
time RT-PCR. Transfected fibroblasts with the episomal vectors were harvested at day 5 after
lipofection as a positive control for EBNA1 expression while H9 lysate was used as a negative
control. Primer sets for EBNA1 were used as previously reported 9. There were no differences in
EBNA1 expression between negative control H9 and all newly-generated iPSC lines. This result
revealed that the exogenous genes in the episomal vectors used for reprogramming were silenced
in all generated iPSC lines. This figure is reproduced from Song, et al 54.
Acknowledgment: Yoko A. Yabe and Dr. Masayuki Yazawa contributed to immunocytochemistry
and teratoma formation assay.
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Figure 1.4: Cardiac differentiation of iPSCs and characterization of iPSC-derived
cardiomyocytes. (A) Outline of the monolayer cardiac differentiation protocol. (B) Phase contrast
image of Timothy syndrome monolayer cardiomyocytes (day 13, TS1-E3-5). Scale bar, 250 μm.
(C) Fluorescence-activated cell sorting (FACS) analysis for monolayer control (Ctrl) and Timothy
syndrome (TS) cardiomyocytes at day 19 using the antibody to sarcomeric alpha-actinin.
Unstained samples were first used to adjust the voltage of forward-scattered light (FSC), side-
scattered light (SSC), and 488. Gate was set based on negative samples with only secondary
antibodies. Live cells were also examined to make sure that there was no change in cell size
(FSC) and SSC before and after fixation and permeabilization. n=12 per group from four lines. n.s.
no significant difference with Student’s t-test. (D) Gene expression of cardiac myofilaments,
ACTN2, MYH7 and TNNT2, in control (Ctrl) and Timothy syndrome (TS) cells at day 4 (in the
middle of differentiation) and day 19 (after differentiation) using real-time RT-PCR. The data were
normalized to GAPDH expression. n=12 per group from four lines. ** P<0.01 with Student’s t-test
between day 4 and day 19. (E) Representative images from the immunocytochemistry staining of
control (NH-E1-1) and Timothy syndrome (TS-E2-1) single cardiomyocyte using the antibody to
sarcomeric alpha-actinin. Cardiomyocytes derived from four control iPSC lines and four Timothy
syndrome iPSC lines were used for immunocytochemistry. Normal sarcomere formation was
observed in both types of cardiomyocytes from different iPSC lines. The fluorescent images were
captured using 40x objective lens using antibodies to sarcomeric alpha-actinin (red) and nuclei
stain (blue). Scale bar, 50μm. This figure is reproduced from Song, et al 54.
Acknowledgment: Dr. Masayuki Yazawa operated the FACS Canto system at the last step of the
FACS analysis and Dr. J Feng analyzed the FACS results blindly.
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Figure 1.5: Calcium imaging of spontaneous calcium transients in control and Timothy
syndrome cardiomyocytes using the genetically encoded calcium indicator R-GECO1. (A, B)
Representative traces of spontaneous calcium transient recordings using the genetically encoded
calcium indicator R-GECO1 (Red) in control (Ctrl, A) and Timothy syndrome (TS, B)
cardiomyocytes at day 23 and 40. Dynamic changes of cellular phenotypes were observed in TS
cardiomyocytes. Y-axis, ΔF/F0 for R-GECO1. (C) Representative spontaneous calcium transient
recordings in single Timothy syndrome cardiomyocyte before, during and after the treatment with 5
μM Roscovitine (Ros). Ros treatment alleviated the abnormal calcium transients in single Timothy
syndrome cardiomyocyte. This figure is reproduced from Song, et al 54.
Acknowledgment: Daniel W Awari and Seon-Hye E. Park contributed to the construction of R-
GECO1 lentiviral construct and the preparation of R-GECO1 lentivirus. Dr. Masayuki Yazawa
contributed to the calcium imaging of cardiomyocytes using the calcium indicator R-GECO1.
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Table 1.1: A summary of patient information from whom the fibroblasts were used for
cellular reprogramming to generate iPSCs.
* All identified mutations are de novo.
**Congenital diaphragmatic hernia (CDH) is also found in the patients, in addition to congenital
heart diseases.
This table is reproduced from Song, et al 54.
Acknowledgment: Drs. Wendy K. Chung, P. Lanzano and J. Wynn provided the fibroblasts of
patients with congenital heart diseases (CHD). Drs. W. Froehlich-Santino, J. Bernstein, J.




  Table 1.2: A summary of the primers used for RT-PCR in chapter 1.  
 




  Table 1.3: A summary of the optimization of the dose of GSK3 inhibitors (BIO and CHIR99021) 
and oxygen concentration for the monolayer cardiac differentiation protocol. 
 
Arrow heads indicate cardiomyocytes. The optimization was conducted with one control iPSC line. 
We found that a combination of 1 μM BIO and 5 μM CHIR provided more cardiomyocytes in the wells 
compared with the single use of 1 μM BIO or 5 μM CHIR between day 1-4 for the cardiac 
differentiation. We also found that 5% oxygen conditions had a negative impact on the cardiac 
differentiation of iPSCs and 20% oxygen condition was more ideal for the cardiac differentiation. 2 
μM IWP-3 was used between day 5-10 based on the suggestion from a collaborator (Dr. Itsunari 
Minami). The media used for the protocol was developed based on the EB-based differentiation 
protocol reported in Yazawa, et al 24. The finalized protocol was shown in Figure 1.4A. With further 
optimization of iPSC preparation, we were able to use the protocol for differentiating both control and 





HEK 293T cells were cultured in Dulbecco’s Modified Eagle Media (DMEM, high glucose, #10313-
021/039) with 1% GlutaMax I and 100 unit / ml penicillin and 100 μg / ml streptomycin (P.S., all reagents 
from Life Technologies) and 10% fetal bovine serum (FBS, not heat-inactivated, HyClone, #SH30071.03, 
Lot #AYE161479, Thermo Scientific) under normoxia (20% O2, 5% CO2, at 37oC) using HERAcell (Thermo 
Scientific) and Biosafety Cabinet Class II type A2 tissue culture hood (Labconco) for culture procedures.  
Human embryonic lung fibroblast IMR90 (ATCC), patient dermal fibroblasts and normal adult human dermal 
fibroblasts (NHDF, Life Technologies) were cultured in DMEM (high glucose as above) with 1% GlutaMax 
I, P.S. and 10% or 20% FBS under normoxia.  The skin fibroblasts of two long QT syndrome patients 
(LQTS, type 8, Timothy syndrome #TS7643 and #TS9862) were transferred from Stanford University under 
material transfer agreement.  Congenital heart disease (CHD) patient fibroblasts were obtained by taking a 
small piece of skin at the incision at the time of surgery following a protocol approved by the Columbia 
Institutional Review Board (IRB, for W.K.C.).   
Feeder-free iPSC lines were cultured in E8 media 55: Essential 8 basal media (prototype: 
A14625DJ, Lot #1350709 & #1376319; Current ones, A15169-01, Lot #1445548 & #1505926) with 
Essential 8 supplement (prototype, and current version A15171-01, Lot #14455555 & #1493471, Life 
Technologies) under hypoxia(5% O2, 5% CO2, at 37oC) and normoxia conditions on plates or dishes 
(Corning) coated with Geltrex following the manufacturer’s instruction (#A14133-022, Life Technologies).  
During passaging, the iPSC lines under hypoxia and normoxia were incubated with 1 mg / ml dispase (Life 
Technologies) for 4-5 min at 37 oC, washed three times using E8 media (3x 1ml per well) and then add 1.5 
ml E8 media supplemented with 10 μM Y27632 (CalbioChem #688000 and TOCRIS #1254/50) in case of 
6-well plate.  Under a stereoscopy (Nikon, SMZ745) in Purifier Horizontal Clean bench (Labconco), we 
picked up 3-4 uniformed (ESC-like) colonies using small needle (27G, 1/2 inch, BD) and then transferred 
to 1.5 ml tube using filter tip (GP-L200F, Rainin).  The cells were gently dissociated using filtered tips (#GP-
L1000F, Rainin) with 8-10 times pipetting and then plated on a well in Geltrex-coated 6-well plate when 
new iPSCs were at passage 1-3.  Once the morphology of the iPSC colony became uniformed and stable, 
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mechanical picking up under the microscope was no longer required.  The amount of culture media required 
for culture everyday was aliquoted into 15/50 ml tubes and warmed up at 37 oC in order to keep the original 
media bottles cold until they are expired.  Block heaters for 15/50ml tubes (VWR) in the culture hood were 
used for media warming.  The heaters allowed us to provide cells with warmed media although culture 
procedures became longer.  Also, they helped us to minimize the risk of contamination compared to using 
water bath for media warming.  Each well in a 6-well plate contains 2.5ml culture media. To change media 
daily, approximately 2 ml per well (80%) was aspirated from each well and then freshly prepared media (~2 
ml) was added to keep cells always covered by at least 0.5 ml media in 6-well plates, in order to avoid the 
exposure of cells to ambient air and minimize stress.  One day before passaging, media volume was 
changed to in total 3.5 ml per well in 6-well plate to provide sufficient nutrition and avoid spontaneous 
differentiation due to high confluency.  Regularly, mycoplasma tests were performed using an automated 
96-well luminometer (GloMax 96, Promega) with mycoplasma detection kit (MycoAlert PLUS, Lonza).  In 
addition, osmolality in all media was monitored using Osmette (model 5002, Precision System). 
To get iPSC lines adapted to normoxia for tests on cardiac differentiation, semi-confluent culture 
(30-50%) of feeder-free iPSC lines was directly transferred from an incubator under hypoxia (5% O2) to 
another incubator under normoxia (20% O2).  However, many dead cells were observed due to oxygen 
stress during the transition and it took a long time to get cells recovered and adapted completely to 
normoxia.  Therefore, an alternative procedure is recommended as follows: 1) plate feeder-free iPSC lines 
on CF-1 feeders with E8 media or conventional iPSC media containing knock out serum; 2) 2-3 days after 
plating, transfer the plates from hypoxia to normoxia; 3) pick up uniformed iPSC colonies enzymatically and 
mechanically and then replace the colonies on Geltrex-coated plates using E8 media with Y27632 under 
normoxia.  To get reproducible results on monolayer cardiac differentiation, passaging cells for 4-5 times 
after the transition (in total it takes additional 2-3 weeks) is recommended. 
 
iPSC generation 
The three episomal vectors established by the Yamanaka group 9 (Addgene, #27077, 27078 and 
27080) were used for the reprogramming of control and patient fibroblasts to iPSCs.  NHDF (adult normal 
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human dermal fibroblasts, Life Technologies) was used as a control.  Briefly, ~2.5 x 104 cell / ml were first 
plated on 4 wells (0.5 ml per well) in non-coated 24-well plate (Corning) using 20% FBS-containing DMEM 
(high glucose, Glutamax I, with P.S.) under normoxia, and lipofection was performed at day 2 using 
Lipofectamine LTX (LF-LTX) as follows: the plasmid DNA (0.9 μg per well, ratio=1:1:1, in 50 μl OptiMEM) 
and 0.9 μl of Plus Reagent were incubated with LF-LTX (2 μl per well, in 50 μl OptiMEM) for 40 min in 
OptiMEM (Life Technologies), and then the mixture (total ~103 μl) was transferred to a well containing 
human fibroblasts immediately after changing DMEM to OptiMEM (0.5 ml per well) in the culture plates.  
Thirty minutes after lipofection, the media was completely changed to 20% FBS containing DMEM (high 
glucose, Glutamax I, without P.S.).  Further media changes were conducted the next day (day 3) using 20% 
FBS containing DMEM (high glucose, Glutamax I, with P.S.).  On day 5-6, before the fibroblasts became 
100% confluent, the cells in a well in 24-well plates were re-plated on a Geltrex-coated well in a 6-well plate.  
The next day after cell passage, the culture media was switched to E8 media under hypoxia.  Further media 
changes using E8 were conducted every day while change media even every other day until day 14 did not 
affect the efficiency of iPSC generation.  Although at day 14-21 some iPSC-like colonies were already 
observed, picking up colonies was done at day 22-27 for most of the wells of the patient lines.  To dissociate 
colonies, the cells were incubated with dispase (~1 mg / ml, 1 ml per well) for four min and washed three 
times using E8 media, and then 1.5 ml of E8 media with 10 μM Y27634 was added to the well.  To pick up 
colonies, 27G needle and P200 filtered pipette tip were used under stereomicroscope described as above 
for the regular passage of feeder-free iPSCs.  Further mechanical dissociation using pipetting was not 
required for P0 colonies.  Modified protocol is also available using Matrigel (BD Bioscience) and mTeSR1 
media (Stem Cell Technologies) for the reprogramming of human skin fibroblasts (data not shown).  In case 
of the reprogramming of human hair follicle keratinocytes (FK, ScienCell, #2440), culturing the cells in 20% 
FBS-containing DMEM (at day 2-6) after lipofection provided iPSC colonies while culturing the cells in the 
regular keratinocyte culture media (ScienCell, #2101) did not work for cellular reprogramming.  
For the initial testing of the lipofection reagents during the optimization of the iPSC generation 
protocol described above, every reagent was prepared and tested following the recommended protocol 





To examine the expression of pluripotent markers, we placed the iPSCs on 15-mm round coverslips 
(Warner Instruments, CS-15R) coated with Geltrex in 24-well plates. The iPSCs were fixed using 4% 
paraformaldehyde (PFA, Electron Microscopy Sciences, EM grade), 2% sucrose in phosphate buffered 
saline (PBS) for 20 min at room temperature and washed three times with PBS.  The cells were then blocked 
with a solution containing 3% bovine serum albumin (BSA, Sigma-Aldrich) and 0.1% Triton X-100 (Sigma-
Aldrich) in PBS for 30 min at room temperature for anti-TRA-1-60 and TRA-1-81 antibody staining. The 
samples were then washed three times using 1% BSA in PBS and incubated with the anti- TRA-1-60 
antibody or anti-TRA-1-81 antibody (both, 1/200 dilution in 3% BSA in PBS, Millipore) for at least 24 h at 4 
oC.  After the incubation with primary antibodies, the iPSC samples were washed three times, and incubated 
in secondary antibody, Alexa Fluor 594 (Molecular Probes, 1/1,000 dilution in 3% BSA in PBS, 2 mg / ml) 
for 30 min at room temperature, washed with 1% BSA in PBS three times (~5 min each), stained with 
Hoechst 33285 (Molecular Probes, 1/10,000 dilution in PBS) and washed with 1% BSA in PBS six time and 
with PBS once and then mounted on slides using Poly/Mount (Thermo Scientific). Images were acquired 
using a 20x objective lens (CFI Plan Apochromat Lambda DM, NA 0.75, Nikon) on the stage of a Nikon 
Eclipse TiU inverted microscope operated by MetaMorph (Molecular Devices). 
Karyotyping of iPSCs was conducted in WiCell (Wisconsin).  We found that many feeder-free iPSCs 
that had been maintained under hypoxia died during the shipping to WiCell due to oxygen stress.  Therefore, 
the iPSCs were plated on CF-1 feeder using conventional iPSC media containing knock out serum in T25 
flasks and then shipped out to WiCell.  For RT–PCR using primer sets 9, 56, cell lysate of the embryonic 
stem cell line H9 was a gift from the stem cell core facility at Columbia University. RNA from embryonic 
stem cell line H9, fibroblasts and iPSCs was prepared using the RNeasy Mini kit and RNase-Free DNase 
set (Qiagen).  cDNA was synthesized from 1 μg RNA using the SuperScript III First-Strand Synthesis 
System for RT–PCR (Life Technologies).  The cDNA (21 μl) was diluted with DNase-free water (Invitrogen) 
at 1:5 and 1 μl of each sample was used for conventional RT–PCR with Ex taq polymerase 
(Clontech/TaKaRa Bio).  For quantitative RT–PCR, SYBR Advantage qPCR Premix (Clontech/TaKaRa Bio) 




Teratoma formation assays were performed by injecting confluent iPSCs (in a 10 cm dish) in 20 % 
E8 media, 30% FBS, 50% Geltrex and 10 uM Y-27632 (Calbiochem or TOCRIS) into 8-week-old severe 
combined immunodeficient (SCID) beige male mice (Charles River Laboratories) subcutaneously.  The 
SCID-beige mice were sacrificed at 5-8 weeks after injection. The tumors were weighted, dissected, fixed 
with PBS containing 4% PFA and 10–30% sucrose and embedded in Tissue-Tek OCT compound (Sakura 
Finetek).  Sections were stained with Hematoxylin and Eosin-Y (Thermo Scientific).  All animal protocols 
and handling for the teratoma formation assay were performed following the guidelines established by 
Columbia Institutional Animal Care and Use Committee under our approved protocol (for Y.Y and M.Y, 
#AC-AAAF5655).  To examine the differentiation potentials of the newly-generated iPSC lines used for 
further experiments, neural differentiation was conducted as reported previously, using human recombinant 
proteins, EGF, BDNF and NT-3 (all from Peprotech) 57. 
 
Monolayer cardiac differentiation and characterization: 
CHIR99021 (CHIR, GSK3 inhibitor, #1386, Lot #6 & #7, Axon MedChem) and BIO (GSK3 inhibitor 
IX, #361550, Lot #D00148116, Calbiochem) 49, IWP-3 (Wnt inhibitor, #SML0533, Lot # 102m4613V, Sigma-
Aldrich) resolved in Dimethyl Sulfoxide (DMSO, #276855, Sigma-Aldrich) were used for the monolayer 
differentiation of iPSCs plated on Geltrex coated 6-well plates or 10 cm dishes.  To prepare differentiating 
culture media, only one freeze and thaw cycle was confirmed for all aliquots of small compounds CHIR and 
BIO.  Twice freeze and thaw cycle was fine for IWP-3 aliquots.  For the differentiation protocol, DF20/5 
media was used for the cardiac differentiation and culture: DMEM/F-12 (with GlutaMax I) containing 20% 
or 5% Hyclone FBS, 1% non-essential amino acid, P.S. and 0.1 mM beta-mercaptoethanol (bME).   
Additional D-glucose was added to only DF20 to make high glucose media (final 4.5 g / l) and enhance 
mesoderm differentiation from Day 1 to Day 4.  The treatment of BIO and CHIR was conducted at day 2-4.  
The media with BIO and CHIR was changed everyday. For 2 μM IWP-3 treatment at day 5-11, media was 
changed every other day.  At day 5-7, DF20 media was used with IWP-3.  DF5 media was used at day 7~ 
for IWP-3 treatment and maintenance, and the media was changed every other day.  Changing media with 
small compounds required ~3 ml per well in 6-well and ~15 ml per 10 cm dish every day or every other day 
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since adding 2-2.5 ml of fresh media to a well of 6-well plates was not sufficient for cells at a high confluency 
during the differentiation into cardiomyocytes, resulting in a lower efficiency of cardiac differentiation.  
Several lots of USDA-approved FBS (from Thermo, Hyclone and Gibco) were tested after we found that 
CHIR/BIO in DEME/F-12 worked with FBS, and Hyclone FBS was only used for further monolayer 
differentiation since we found that this lot of Hyclone FBS provided a slightly higher efficiency to generate 
cardiomyocytes reproducibly than other FBS.  All images and movies of the monolayer cardiomyocytes 
were taken in the tissue culture room using TS100F-LED microscope operated by Nikon NIS-Elements with 
objectives (4x, CFI Plan Fluor DL, NA 0.13; 10x, CFI Achromat ADL, NA0.25; 20x, CFI Achromat LWD 
ADL, NA 0.4, Nikon).   
The antibody to sarcomeric alpha-actinin (clone #EA-53, Sigma-Aldrich) was used for the 
immunocytochemistry of human cardiomyocytes (3-4 weeks later after cardiac differentiation). The cells 
were fixed using 4% paraformaldehyde (PFA, Electron Microscopy Sciences, EM grade), 2% sucrose in 
phosphate buffered saline (PBS) for 30 min at room temperature and washed three times with PBS.  The 
cells were then blocked with a solution containing 3% bovine serum albumin (BSA, Sigma-Aldrich) and 
0.1% Triton X-100 (Sigma-Aldrich) in PBS for 30 min at room temperature.  The samples were washed 
three times using PBS and incubated with the anti-sarcomeric alpha-actinin antibody (1/200 dilution in 3% 
BSA in PBS) for at least 24 h at 4 oC.  After the incubation with the primary antibody, the samples were 
washed three times with PBS, and incubated in secondary antibody, Mouse Alexa Fluor 594 (Molecular 
Probes, 1/1,000 dilution in 3% BSA in PBS, 2 mg / ml) for 30 min at room temperature, washed with PBS 
three times (~1 min each), stained with Hoechst 33285 (Molecular Probes, 1/10,000 dilution in PBS) and 
washed with PBS five times and then mounted on slides using Poly/Mount (Thermo Scientific). Images 
were acquired using a 20x objective lens (CFI Plan Apochromat Lambda DM, NA 0.75, Nikon) on the stage 
of a Nikon Eclipse TiU inverted microscope operated by MetaMorph (Molecular Devices). 
 Fluorescence activated cell sorting (FACS) analyses were performed in Columbia Center for 
Translational Immunology (CCTI) using a BD FACS Calibur using control and patient cardiomyocytes at 
day 19.  Cell dissociation was conducted following the protocol for human iPSC-derived cardiomyocytes 58.  
After cell dissociation, a standard protocol for FACS was used first with 0.5% saponin (Sigma-Aldrich) for 
permeabilization at blocking step and next with anti-sarcomeric alpha-actinin antibody (1/200 dilution) and 
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goat anti-mouse Alexa Fluor 488 secondary antibody (Life Technologies, 1/500) in FACS buffer (0.1% 
saponin, 2% FBS and 2mM EDTA in Hanks buffer in HEPES, HBSS).  The FACS data analyses were 
blindly performed by J. Feng.  The identical cell samples at day 19 were also collected prior fixation, for 
RNA/cDNA preparation and gene expression profiling using Real-time RT-PCR (qPCR). RNA from the 
samples was prepared using the RNeasy Mini kit and RNase-Free DNase set (Qiagen).  cDNA was 
synthesized from the RNA using the SuperScript III First-Strand Synthesis System for RT–PCR (Life 
Technologies).  The cDNA (21 μl) was diluted with DNase-free water (Invitrogen) at 1:1 and 1 μl of each 
sample was used for qPCR. SYBR Advantage qPCR Premix (Clontech/TaKaRa Bio) and StepOnePlus real 
time PCR systems (Life Technologies) were used for qPCR.  Primer information is listed in Table 1.2. 
 
R-GECO1 preparation and imaging 
The plasmid of R-GECO1 (Addgene #32462) 59 was used as a template to amplify the cDNA using 
Phusion polymerase (Thermo Scientific) with primer sets that allowed us to add the restriction enzyme site 
EcoRI and Kozak sequence before the start codon (without the nuclear localization signal for R-GECO1) 
and another site XhoI after the stop codon.  The PCR product was subcloned into a lentiviral vector that 
was prepared from LV-SD-Cre (Addgene, #12105, no longer available currently) digested with EcoRI and 
XhoI.  XL-10 gold competent cells (Agilent) transformed with these LV-SD vectors were inoculated at 24-
30 oC.  Next the LV-SD vectors were purified using Qiagen miniprep kit. The purified LV-SD vectors were 
transfected together with pCMV-dR8.2 dvpr and pCMV-VSV-G (Addgene #8455 & 8454) as follows: 
HEK293T cells that were plated at the density of 5 x 105 cell / ml (2 ml per well) one day before were 
transfected with 3.4 μg DNA per well (ratio, LV-SD: dR8.2: VSV-G= 8 : 8 : 1) and LF-2K (8.0 μl per well) in 
a 6-well plate.  The next day the media was changed.  Two days after transfection, culture media was 
harvested (again fresh media was added to transfected HEK 293T cells) and filtered using 0.45 μm PES 
filter (VWR) and then directly added to wells containing isolated monolayer cardiomyocytes (at 2-3 weeks 
after cardiac differentiation). No polybrene was used for viral infection. Seventy-two hours after transfection, 
the culture media was again collected and used as a secondary infection.  The next day, media was 
changed to DF5 media for the infected cardiomyocytes. Three to five days after the secondary infection, 
isolated monolayer cardiomyocytes were transferred to 
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No. 1.5 glass) coated with Geltrex for imaging. Some of the cardiomyocytes were dissociated into single 
cells for single cell based calcium imaging. For the calcium imaging, Nikon Ti-U epi-fluorescent microscope 
connected to EMCDD Digital Monochrome camera (Evolve, EVO-512-M-FW-16-AC, 512x512, 
Photometrics) was used with LED light source (Lumencore Spectra X 6 line LED system, with Chroma 
excitation mounted filters, ET395/25x, ET470/30, ET550/15x, ET640/30x;) with dichroic mirror and 
emission filter (dichroic mirror, D/F/Cy3/Cy5pc; emission, ET430/36 513/44 595/41 719/105) operated by 
MetaFlour (Molecular Devices, acquisition: exposure time, 20 ms; gain 3 (6x); transfer speed, 5MHz, Image 
size: 512x512; binning, 1.0). Normal Tyrode solution containing 140mM NaCl, 5.4mM KCl, 1mM MgCl2, 
10mM glucose, 1.8mM CaCl2 and 10mM HEPES (pH7.4 with NaOH at 25 oC) supplemented with 10% FBS 
was used as bath solution.  Temperature of the bath solution (Tyrode) was maintained at approximately 35 
oC using a digital temperature controller (TC-344B, Warner Instruments, setup at 37 oC) for the duration of 
the experiment.  Nikon objective lens 40x (CF1 S Fluor, NA 0.90) for cell clusters and 60x (CFI Plan Apo 
Lambda H, NA 1.40) for single cells were used to capture the fluorescent signal from R-GECO1(illumination 
control, 10 in 0-255, cy3). (R)-Roscovitine (5mM stock in DMSO) was diluted with the bath solution to 5 μM 
and used for fluorescent imaging. 
 
Statistics 
The statistics used for every figure have been indicated in the corresponding figure legends. The 
Student’s t-test (unpaired) was conducted with the t-test function in Microsoft Excel software. F-test was 
conducted before the t-test to determine whether the samples have equal variance in Microsoft Excel 
software. The Student’s t-test was two tails. One-way ANOVA with Bonferroni posthoc for multiple 
comparisons was conducted with the Graphpad prism software. All the data meet the assumptions of the 
statistical tests. All the samples used in this study were biological repeats, not technical repeats. We did 





















The basic function of the heart is to pump blood through the pulmonary and systemic vasculature.  
In order to do that, the heart has to beat in a controlled manner and one of the mechanisms that contributes 
to the controlled beating of the heart is a process called cardiac excitation-contraction coupling (EC 
coupling). Cardiac EC coupling refers to a process that starts from an electrical stimulus (excitation) and 
ends in the contraction of the cardiac muscle 60. During EC coupling, the electrical stimulus induces the 
opening of L-type calcium channels and an influx of calcium into the cell. The small calcium influx triggers 
ensuing calcium release from sarcoplasmic reticulum (SR) through ryanodine receptors (RyR), which 
contributes significantly to the increase in intracellular calcium concentration. The calcium ions in the cell 
bind to troponin C that initiates actin-myosin interaction, which leads to the contraction of the cardiomyocyte. 
In this process, L-type calcium channels play an important role.  
The major pore-forming subunit of the L-type calcium channels in the myocardium is the alpha 1C 
subunit (also known as CaV1.2) 61. CaV1.2 is a protein that is encoded by the CACNA1C gene and consists 
of four transmembrane domains (I-IV) that form the pore through which calcium ions pass into the cell. 
Each transmembrane domain contains six transmembrane segments (S1-S6). The missense mutations in 
the CACNA1C gene are associated with Timothy syndrome, a multisystem disorder that is featured by LQT 
syndrome and syndactyly 25-28.  
In general, there are two types of Timothy syndrome, the classical type (Type 1) and the atypical 
type (Type 2). Timothy syndrome Type 1 is caused by mutations in exon 8a, an alternatively spliced exon, 
and the most common mutation in CaV1.2 caused by the gene mutation in exon 8a is the G406R mutation 
25.  Patients with Timothy syndrome Type 1 all have syndactyly and cardiac arrhythmias, and many patients 
who survive to the age that can be evaluated demonstrate traits of autism spectrum disorder. Timothy 
syndrome Type 2 is caused by mutations in exon 8, which has a higher expression than exon 8a, and the 
most common mutations in CaV1.2 caused by the gene mutations in exon 8 are G406R and G402S 62. 
Patients with Timothy syndrome Type 2 have more heterogeneous phenotypes and the phenotypes are 
usually more severe potentially due to the high expression of exon 8 in the heart, brain, and several other 
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tissues compared with exon 8a. Within the scope of this work, we focused on investigating the pathogenesis 
of Timothy syndrome Type 1 caused by the G406R mutation in CaV1.2 using an iPSC-based disease model.  
From a mechanistic point of view, the G406R mutation has been hypothesized to affect the voltage-
dependent inactivation of CaV1.2 because the mutation is located close to the segment six of domain I 
(D1S6), which is important for the voltage-dependent inactivation of the channel 63. In support of this 
hypothesis, a previous study that utilized heterologous expression systems (Chinese hamster ovary (CHO) 
cells and Xenopus oocytes) to investigate the effects of the G406R mutation on CaV1.2 channel functions 
revealed that the G406R mutation significantly delayed the voltage-dependent inactivation of CaV1.2 
channels 25. The results from this study also indicated that CaV1.2 with the G406R mutation remains 
sensitive to calcium channel blockers such as nisoldipine, although a higher concentration was needed to 
block the mutant channels compared with wild-type channels. Based on the findings, calcium channel 
blockers could potentially be used for treating Timothy syndrome and one clinical report also supported this 
finding 29. There are several other research studies and clinical reports indicating that the treatment of 
sodium channel blockers such as ranolazine 30, 64 and mexiletine 65 and beta-blockers 66 alleviates the 
cardiac arrhythmias in Timothy syndrome patients. However, in actual practice, all the regimens are still 
insufficient to prevent the lethal arrhythmias in Timothy syndrome patients 31-33 and new therapeutics are 
still needed for this disease.  
In chapter 1, we generated iPSCs from two Timothy syndrome patients that carry the G406R 
mutation in CaV1.2 and demonstrate a prolonged QT interval (600ms-700ms) in their electrocardiograms 
(ECGs). We also differentiated the iPSCs into cardiomyocytes and examined one of the phenotypes in 
Timothy syndrome cardiomyocytes. We observed abnormal calcium transients in Timothy syndrome 
cardiomyocytes and the treatment of Roscovitine showed beneficial effects on the abnormal calcium 
transients in Timothy syndrome cardiomyocytes, which was consistent with the previous report 24. In this 
chapter, we first validated the cause of the disease and disease phenotypes by generating isogenic control 
iPSCs from Timothy syndrome iPSCs using a gene editing technology, and examining the phenotypes in 
isogenic control iPSC-derived cardiomyocytes. Secondly, we conducted a phenotypic screen to screen 
through twenty Roscovitine analogs and four CDK inhibitors to search for additional new therapeutic 
compounds for Timothy syndrome and investigate the mechanisms underlying the beneficial effects of 
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Roscovitine. Lastly, we validated the new therapeutic target, CDK5, for Timothy syndrome using two 
approaches and explored the mechanisms underlying the beneficial effects of CDK5 inhibition on the 
phenotypes in Timothy syndrome cardiomyocytes. The results provide new insights into the molecular 
bases of cardiac calcium channel regulation and the development of novel therapeutics for Timothy 
syndrome patients in the future.   
 
Results 
The generation of isogenic control iPSCs for Timothy syndrome iPSCs 
The two patients that we derived iPSCs from both carry the G1216A mutation in the CACNA1C 
gene leading to the G406R mutation in CaV1.2. To confirm the cause of this disease and obtain ideal 
controls for the Timothy syndrome iPSCs, we generated isogenic control iPSCs from the Timothy syndrome 
iPSCs using the transcription activator-like effector nuclease (TALEN) technology, and characterized the 
isogenic control iPSCs (Figure 2.1). The isogenic control iPSCs demonstrated a normal karyotype and 
pluripotency, and the cardiomyocytes derived from the isogenic control iPSCs showed regular calcium 
transients in calcium imaging and normal voltage-dependent inactivation percentage values in voltage 
clamp recordings, which are comparable to the calcium transients and voltage-dependent inactivation 
percentage values from the cardiomyocytes derived from non-isogenic control iPSCs generated from the 
skin fibroblasts of healthy donors (Figure 2.1A-2.1J). The results indicated that the correction of the G406R 
mutation could rescue all the previously-reported phenotypes in Timothy syndrome cardiomyocytes.  
Roscovitine analog and CDK inhibitor tests 
To search for new Roscovitine analogs that are more potent or less toxic than Roscovitine and 
explore the mechanisms underlying the effects of Roscovitine on Timothy syndrome cardiomyocytes, we 
tested twenty Roscovitine analogs and four CDK inhibitors with different specificities against CDKs on 
Timothy syndrome cardiomyocytes. As cell clusters or monolayer cardiomyocytes, Timothy syndrome 
cardiomyocytes demonstrated slow and irregular contractions 24, 54. Thus we used a contraction assay with 
MATLAB-based analysis 24, 67 to efficiently examine the effects of the chemical compounds on the slow and 
irregular contractions in Timothy syndrome cardiomyocytes (Figure 2.3A). Two rounds of chemical test 
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were conducted to examine the effects of the compounds. The first round of chemical test was conducted 
using Timothy syndrome cardiomyocyte clusters isolated from the monolayer cardiomyocytes to screen 
and identify the positive compounds. Two parameters were used to define the effects of the compounds 
and the two parameters were the spontaneous beating rate and the contraction irregularity. The 
spontaneous beating rate refers to the beating rate of the cardiomyocyte clusters. The contraction 
irregularity is a parameter that had been used previously to define the irregular contractions of Timothy 
syndrome cardiomyocytes 24 and the value was calculated as the ratio of the standard deviation to the mean 
of the time intervals between contractions. The compounds that could significantly increase the 
spontaneous beating rate and decrease the contraction irregularity of the Timothy syndrome cardiomyocyte 
clusters were defined as positive compounds in the first round of test (Figure 2.2A-2.2C and Table 2.1). 
The subsequent test was conducted using the intact monolayer cardiomyocytes to validate the beneficial 
effects of the positive compounds on the irregular contractions in Timothy syndrome cardiomyocytes and 
to eliminate the potential bias that could be caused by isolating the cardiomyocytes from the original culture 
(Figure 2.3B-2.3D). From the two rounds of chemical test, we identified two Roscovitine analogs, CR8 and 
Myoseverin-B, and two CDK inhibitors, PHA-793887 and DRF053, that have beneficial effects on Timothy 
syndrome cardiomyocytes (Figure 2.2, Figure 2.3B-2.3D and Table 2.1). When we summarized the CDK 
targets of all positive compounds, it was found that four (Roscovitine, CR8, PHA-793887 and DRF053) of 
the five positive compounds have been reported to inhibit CDK5 36, 68-70 (Figure 2.3B), suggesting that 
CDK5 could be involved in the molecular mechanisms underlying Timothy syndrome. We validated the 
inhibitory effects of Roscovitine, CR8, PHA-793887 and DRF053 on CDK5 activity, and examined the effect 
of the other positive compound Myoseverin-B, which has not been reported to affect CDK5 activity before, 
on CDK5 activity using an in vitro CDK5 assay (Figure 2.3E and 2.3F). The results demonstrated that 
Myoseverin-B did not significantly inhibit CDK5 activity at micromolar dose but significantly inhibit CDK5 
activity at milimolar dose. Since Myoseverin-B demonstrated a beneficial effect on the irregular contractions 
in Timothy syndrome cardiomyocytes at the dose of 5 μM, the mechanisms underlying the beneficial effect 
of Myoseverin-B on the irregular contractions in Timothy syndrome cardiomyocytes could be independent 
from the inhibition of CDK5. 
The effects of CDK5 inhibition on Timothy syndrome cardiomyocytes 
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To examine whether CDK5 inhibition is beneficial for Timothy syndrome cardiomyocytes, we first 
constructed a lentivirus containing the dominant negative (DN) mutant of CDK5. The dominant negative 
mutant of CDK5 carries a kinase dead mutation (D144N) and the expression of CDK5 DN inhibits the 
functions of endogenous CDK5 through competitive inhibition. We used patch-clamp recordings and 
calcium imaging to assess the physiological properties of the Timothy syndrome cardiomyocytes infected 
with the CDK5 DN lentivirus. The phenotypes of Timothy syndrome cardiomyocytes include a delayed 
voltage-dependent inactivation of CaV1.2 channels, abnormal action potentials and abnormal calcium 
transients, as we reported previously 24, 54. The Timothy syndrome cardiomyocytes with CDK5 DN 
expression demonstrated a significantly enhanced voltage-dependent inactivation of CaV1.2 channels 
compared with the cardiomyocytes without CDK5 DN expression (Figure 2.4A-2.4C). Moreover, the 
expression of CDK5 DN rescued the abnormal spontaneous action potentials and significantly shortened 
the paced action potential duration in Timothy syndrome cardiomyocytes (Figure 2.4D-2.4G and Table 
2.3). In addition, we examined the effects of CDK5 DN expression on the calcium currents in Timothy 
syndrome cardiomyocytes. The results showed that Timothy syndrome cardiomyocytes demonstrated more 
late calcium currents compared with control cardiomyocytes, and the expression of CDK5 DN significantly 
reduced the late calcium currents in Timothy syndrome cardiomyocytes (Figure 2.4H-2.4J). Finally, CDK5 
DN expression alleviated the prolonged spontaneous calcium transients and reduced the percentage of cell 
with irregular timing of calcium transients in Timothy syndrome cardiomyocytes (Figure 2.4K-2.4N). CDK5 
DN expression also alleviated the prolonged paced calcium transients, and significantly reduced the 
calcium transient duration and calcium transient half decay time in the paced Timothy syndrome 
cardiomyocytes (Figure 2.4O-2.4W). Overall, the results indicated that CDK5 DN expression could alleviate 
all the previously-reported phenotypes in Timothy syndrome cardiomyocytes.  
To validate our findings using another approach, we designed short hairpin RNA (shRNA) lentiviral 
constructs that target CDK5 and confirmed the knockdown efficiency of the constructs (Figure 2.5A-2.5C). 
We then infected Timothy syndrome cardiomyocytes with the CDK5 shRNA lentivirus and examined the 
effects of CDK5 shRNA expression on the reported phenotypes in Timothy syndrome cardiomyocytes. The 
results showed that CDK5 shRNA expression significantly enhanced the voltage-dependent inactivation of 
CaV1.2 in Timothy syndrome cardiomyocytes (Figure 2.5D and 2.5E). In addition, CDK5 shRNA expression 
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alleviated the prolonged spontaneous calcium transients and reduced the percentage of cell with irregular 
timing of calcium transients in Timothy syndrome cardiomyocytes (Figure 2.5F-2.5I). The effects of CDK5 
shRNA expression on Timothy syndrome cardiomyocytes were thus similar to the effects of CDK5 DN 
expression on Timothy syndrome cardiomyocytes, indicating that CDK5 inhibition is beneficial for Timothy 
syndrome cardiomyocytes and may contribute to the potential therapeutic efficacy of Roscovitine. 
One of the molecular mechanisms underlying the effects of CDK5 inhibition on Timothy syndrome 
cardiomyocytes 
To further explore the signaling pathways underlying the effects of CDK5 inhibition on Timothy 
syndrome cardiomyocytes, we measured the mRNA expression of CDK5 and its activator p35 (CDK5R1) 
and p39 (CDK5R2) in control and Timothy syndrome cardiomyocytes. We found a significant increase in 
the mRNA expression of p35 in Timothy syndrome cardiomyocytes compared with controls (Figure 2.6A 
and 2.6B). We next found that the increased p35 mRNA expression led to an increased p35 protein 
expression and a hyper-activation of CDK5 in Timothy syndrome cardiomyocytes (Figure 2.6C and 2.6D).  
We then examined whether wild-type CDK5 over-expression alters CaV1.2 channel functions in control 
cardiomyocytes. We observed that wild-type CDK5 over-expression significantly delayed the voltage-
dependent inactivation of CaV1.2 (Figure 2.6E and 2.6F). 
In summary of the results above, one of the potential mechanisms underlying the beneficial effects 
of CDK5 inhibition on Timothy syndrome cardiomyocytes is that in Timothy syndrome cardiomyocytes, the 
increased expression of p35 causes CDK5 hyper-activation, which enhances the delayed inactivation of 
the mutant CaV1.2 channels, leading to more severe phenotypes in the Timothy syndrome cardiomyocytes. 
Thus, CDK5 inhibition using CDK5 inhibitors, DN or shRNA alleviates the phenotypes in Timothy syndrome 
cardiomyocytes (Figure 2.6G). 
 
Discussion  
In this chapter, we used human cardiomyocytes derived from the iPSC lines generated from the 
skin fibroblasts of two Timothy syndrome patients to identify new potential therapeutic compounds based 
on Roscovitine, our previously reported lead compound for Timothy syndrome 24, 54. We tested the 
hypothesis that the beneficial effects of Roscovitine on Timothy syndrome cardiomyocytes are associated 
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with its inhibitory effect on CDKs. We revealed a new role of CDK5 in the pathogenesis of Timothy syndrome 
and a new mechanism underlying the therapeutic effects of Roscovitine on Timothy syndrome 
cardiomyocytes, which is that Roscovitine exhibits its effects in part by inhibiting CDK5. Roscovitine has 
been reported to enhance the voltage-dependent inactivation of CaV1.2 with Timothy syndrome mutations 
in a heterologous over-expression system (HEK 293 cells)  34, 71, 72.  The previous report indicated a potential 
direct regulation of CaV1.2 by Roscovitine, while it did not exclude the possibility of an indirect regulation of 
CaV1.2 by Roscovitine since a high CDK5 activity in HEK cells has been reported 73, 74. In our study, we 
used Timothy syndrome cardiomyocytes derived from iPSCs to examine the effects of Roscovitine in a 
more physiologically-relevant cardiac environment, which allowed us to identify new key mediators such as 
CDK5 that is involved in the regulation of CaV1.2 channels in cardiomyocytes. Although there are several 
recent updates that provide new insights into the structural and functional changes in the CaV1.2 channels 
caused by Timothy syndrome mutations 75, 76 and a few previous reports indicating the potential regulation 
of CaV1.2 by CDK5 in pancreatic beta cells and a neuronal progenitor cell line 77, 78, our findings are the first 
to demonstrate that CDK5 plays an important role in regulating CaV1.2 functions in cardiomyocytes and 
that the inhibition of CDK5 is beneficial for Timothy syndrome cardiomyocytes.  
Although our findings provided new insights into the pathogenesis of Timothy syndrome, they also 
raised many interesting questions that are worthwhile to investigate in the future. For example, although 
we found a new role of CDK5 in cardiac calcium channel regulation, exactly how CDK5 regulates the 
functions of CaV1.2 channels and alleviates the phenotypes in Timothy syndrome cardiomyocytes remains 
unclear. One of the hypotheses is that CDK5 directly phosphorylates CaV1.2 and regulates its functions. 
The basis for this hypothesis is that CDK5 has been reported to phosphorylate serine or threonine in two 
consensus sequences, S/T-P-X-R/H/K and P-X-S/T-P (X is any amino acid) 79, 80. When we examined the 
protein sequences of CaV1.2, we found five consensus sequences located at the II-III loop and the Carboxyl-
terminus (C-term), which are conserved in both human and rodent (Figure 2.7A). One previous study also 
demonstrated that CDK5 phosphorylates the II-III loop of CaV1.2 in vitro (in MIN6 cells, an insulinoma cell 
line from mouse) and in vivo (in mouse brain and islets) 78.  Therefore it would be important in the future to 
validate the previous study and to examine the potential phosphorylation and regulation of CaV1.2 by CDK5 
in cardiomyocytes using biochemical approaches and electrophysiological recordings with the addition of 
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ATP in the solutions to avoid the loss of phosphates in the potential phosphorylation sites. Another 
hypothesis is that CDK5 regulates the trafficking and surface expression of CaV1.2 channels. The two 
Timothy syndrome patients both carry the G1216A mutation in exon 8a in one of the alleles and thus the 
mutant CaV1.2 channels contribute to a proportion but not all of the CaV1.2 channels expressed on the cell 
membrane. By affecting the trafficking of CaV1.2 channels, CDK5 may change the ratio of mutant CaV1.2 
channels over total CaV1.2 channels on the cell membrane and alleviate the phenotypes in Timothy 
syndrome cardiomyocytes. In alignment with this hypothesis, one CDK5 consensus sequence is found in 
the beta subunit of CaV1.2 channels, which has been widely known to play an important role in regulating 
the trafficking and surface expression of CaV1.2 channels 81. Whether CDK5 regulates the trafficking and 
surface expression of CaV1.2 channels remains to be investigated in the future. In addition, the iPSC-
derived cardiomyocytes have been known to be immature and similar to human embryonic or fetal 
cardiomyocytes at an early stage of differentiation, and gradually become relatively mature and resemble 
adult cardiomyocytes at a late stage of differentiation 82. We used the iPSC-derived cardiomyocytes at a 
relatively early stage of differentiation for this study since Timothy syndrome is an early onset disease and 
Timothy syndrome patients are usually infants or children. However, the role of CDK5 in the regulation of 
CaV1.2 channel functions may differ at different developmental stages and it would be interesting to 
investigate the potential different roles of CDK5 in the regulation of CaV1.2 channels at different stages of 
differentiation using iPSC-derived cardiomyocytes.  The role of CDK5 in the regulation of CaV1.2 channel 
functions may also differ in different types of cells and it would be interesting to investigate and compare 
the role of CDK5 in the regulation of CaV1.2 channels in different cell types such as cardiomyocytes, 
neurons and pancreatic beta cells. Furthermore, based on the consensus sequences that CDK5 targets, 
CDK5 may have effects on the functions of other ion channels such as HCN4 and Nav1.5, which play 
important roles in cardiac function. It would also be important in the future to explore the potential regulation 
of other ion channels by CDK5. 
Another important direction for further investigation is to elucidate the upstream signaling pathways 
that lead to the increase in p35 expression and the over-activation of CDK5 in Timothy syndrome 
cardiomyocytes. Based on the literature, many signaling pathways can potentially lead to an increase in 
the transcription of CDK5R1 (p35) and one of the major signaling pathways is the ERK-EGR1 signaling 
	
42 
pathway 40, 83. Some supporting evidence for the potential role of the ERK-EGR1 signaling in the 
pathogenesis of Timothy syndrome is that in Timothy syndrome neurons, there was an increase in the 
EGR1 gene expression 57. Further investigation is needed to examine whether the ERK-EGR1 signaling 
contributes to the increase in CDK5R1 (p35) expression in Timothy syndrome cardiomyocytes and whether 
other signaling pathways also play an important role in this process. 
Timothy syndrome cardiomyocytes carry the G406R mutation that delays the inactivation of CaV1.2 
channels. Our results indicated that the over-activation of CDK5 in Timothy syndrome cardiomyocytes also 
delays the inactivation of CaV1.2 channels. One question that can be raised from this observation is whether 
there is an association between the G406R mutation and the effects of CDK5 on CaV1.2 channels in 
Timothy syndrome cardiomyocytes. From the point of view of cellular functional changes, we found that the 
correction of the G406R mutation completely rescued the phenotypes in Timothy syndrome cardiomyocytes 
and the expression of CDK5 DN and shRNA only partially rescued the phenotypes in Timothy syndrome 
cardiomyocytes (Figure 2.1, Figure 2.4 and Figure 2.5). The result indicates that the G406R mutation has 
a more significant impact on the functions of CaV1.2 channels and the effects of the mutation could not be 
completely eliminated by inhibiting CDK5. Further investigation is needed to understand whether there 
could be a synergic effect between the G406R mutation and CDK5 in Timothy syndrome cardiomyocytes. 
Moreover, based on gene expression profiling, the cardiomyocytes from the isogenic control iPSCs 
demonstrated an expression of the CDK5R1 (p35) gene that is comparable to the expression of the 
CDK5R1 (p35) gene in cardiomyocytes from regular non-isogenic control iPSCs (Figure 2.7B), and lower 
than the CDK5R1 (p35) expression in Timothy syndrome cardiomyocytes. The result indicates that from 
the point of view of gene expression, the increase in CDK5R1 (p35) expression is associated with the 
G406R mutation in Timothy syndrome cardiomyocytes. One hypothesis is that the increase in CDK5R1 
(p35) expression is a secondary consequence of excessive calcium influx from the mutant CaV1.2 channels 
in Timothy syndrome cardiomyocytes. Further investigation, especially a time-course analysis of the gene 
expression of mutant CaV1.2 channels, CDK5 and p35, is needed to test this hypothesis.  
Another interesting question concerning the potential interactions between CDK5 and CaV1.2 is 
whether CDK5 regulates the functions of CaV1.2 channels in normal cardiomyocytes. This question could 
potentially be addressed by examining the effects of CDK5 DN expression on CaV1.2 functions in control 
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human iPSC-derived cardiomyocytes or in heterologous over-expression systems such as HEK293 cells. 
If CDK5 regulates the functions of CaV1.2 channels in normal cardiomyocytes, it would also be interesting 
in the future to compare the effects of CDK5 on the functions of CaV1.2 channels with and without the 
G406R mutation in control human iPSC-derived cardiomyocytes or in heterologous over-expression 
systems, to investigate whether the potential effects of CDK5 on CaV1.2 channel functions would be 
affected by the G406R mutation.  
Lastly, we focused on Timothy syndrome Type I that is caused by the single mutation in exon 8a 
leading to the G406R mutation in CaV1.2 in this work. There are other mutations such as the G402S 
mutation in CaV1.2 that are also associated with Timothy syndrome or LQT syndrome Type 8 in general.  It 
would be interesting in the future to examine the effects of CDK5 inhibition on the potential phenotypes of 
iPSC-derived cardiomyocytes from patients with Timothy syndrome or LQT syndrome Type 8 that are 
caused by other mutations in CaV1.2.  
In summary, the results presented in this chapter demonstrate that CDK5 is a new potential 
therapeutic target for Timothy syndrome and chemical inhibitors with a selectivity for CDK5 are the lead 
compounds that can be optimized and developed into novel therapeutic compounds for Timothy syndrome 
in the future.  
 
Outcome of the study 
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  Figure 2.1: Isogenic control iPSC generation and characterization. (A) The forward and reverse 
sequencing results confirmed the successful generation of isogenic control iPSC lines. (B) Phase 
contrast image of isogenic control iPSCs. Scale bar, 100μm. (C) A representative calcium transient 
trace from the single cardiomyocyte derived from the isogenic control iPSCs using the genetically 
encoded calcium indicator R-GECO1. The cardiomyocytes demonstrated normal calcium transients. 
Y-axis, ΔF/F0 for R-GECO1. (D) Comparison of the spontaneous beating rate, calcium transient half 
decay time and calcium transient duration between the cardiomyocytes derived from two non-
isogenic control iPSC lines (n=9), two isogenic control iPSC lines (n=22) and two Timothy syndrome 
iPSC lines (n=11). The parameters were comparable between the cardiomyocytes derived from the 
non-isogenic control iPSCs and the isogenic control iPSCs (n.s. not significant. **P<0.01, 
***P<0.005, ****P<0.001; One-way ANOVA with Bonferroni post-hoc; Data are mean ± s.e.m.). (E) 
RT-PCR to confirm the expression of NANOG in isogenic control clones. The non-specific band of 
NANOG has been shown previously with the same primer set 54. (F) Representative voltage-clamp 
recordings of Ba2+ currents in single cardiomyocyte derived from non-isogenic control iPSCs or 
isogenic control iPSCs. “1.0 (relative)” means that the data points were normalized to the 
corresponding peak current value to make the traces. (G, H) The current-voltage relationship and 
voltage-dependent inactivation percentage value quantification in cardiomyocytes derived from 
isogenic control iPSCs and non-isogenic control iPSCs (n=12 for the isogenic control group from 
three lines and n=10 for the non-isogenic control group from two lines. Student’s t-test; n.s. not 
significant). No significant differences were found in the current-voltage relationship and voltage-
dependent inactivation percentage value quantification between the two groups. (I) The isogenic 
control iPSCs demonstrated normal karyotype. (J) Teratoma formation with isogenic control clones. 
The hematoxylin and eosin staining demonstrated all three germ layers. Scale bar, 100μm. Please 
see Table 2.2 for the detailed information of the iPSC lines used for each experiment. 
This figure is reproduced from Song, et al 84. 
Acknowledgment: Dr. Masayuki Yazawa conducted the Ba2+ current recordings and contributed to 









Figure 2.2: A summary of the chemical tests of Roscovitine analogs and CDK inhibitors using 
Timothy syndrome cardiomyocyte clusters. (A) Representative traces from the MATLAB-based 
analysis of contractions in Timothy syndrome cardiomyocyte clusters before treatment and 24 hours 
after the treatment of each positive compound. (B) The analysis of the beating rate of Timothy 
syndrome cardiomyocyte clusters before treatment and 24 hours after the treatment of each 
compound (n=24 for Ros, n=11 for CR8, n=12 for Myo-B, n=10 for PHA, n=11 for NSC43067, n=17 
for PD0332991, from one Timothy syndrome patient line. *P<0.05, ***P<0.005, ****P<0.001; 
Student’s t-test, paired). The beating rate value after treatment was normalized to the corresponding 
beating rate value before treatment for each sample in each group for the presentation in this figure. 
The statistical analysis was conducted using the raw data. Note that the DRF053 compound was 
directly tested on monolayer Timothy syndrome cardiomyocytes but not on Timothy syndrome 
cardiomyocyte clusters. (C) The analysis of the contraction irregularity of Timothy syndrome 
cardiomyocytes before treatment and 24 hours after the treatment of each compound (n=16 for Ros, 
n=6 for CR8, n=10 for Myo-B, n=9 for PHA, n=10 for NSC43067, n=6 for PD0332991, from one 
Timothy syndrome patient line. *P<0.05; Student’s t-test, paired). The irregularity value after 
treatment was normalized to the corresponding irregularity value before treatment for each sample 
in each group for the presentation in this figure. The statistical analysis was conducted using the raw 
data. Note that DRF053 compound was directly tested on monolayer Timothy syndrome 
cardiomyocytes but not on Timothy syndrome cardiomyocyte clusters. Please also see Figure 2.3D 
for additional tests of positive compounds on intact monolayer Timothy syndrome cardiomyocytes. 
Please see Table 2.2 for the detailed information of the iPSC lines used for each experiment. This 






Figure 2.3: A summary of Roscovitine analog and CDK inhibitor tests. (A) Schematic illustration 
of Roscovitine analog and CDK inhibitor tests. (B) A summary of the CDK targets of the positive 
Roscovitine analogs and CDK inhibitors. Eighteen other Roscovitine analogs did not show positive 
effects (See Table 2.1). n.d., CDK targets are not determined yet. (C) Representative traces from 
the MATLAB-based analysis of monolayer Timothy syndrome (TS) cardiomyocyte contractions 
before treatment and 2 hours after the treatment of 2 μM CR8. (D) The analysis of contraction 
irregularity of monolayer TS cardiomyocytes before treatment and 2 hours after the treatment of each 
positive compound (n=10 for the chemical compounds and n=5 for DMSO control from one TS iPSC 
line. The irregularity value after treatment was normalized to the corresponding irregularity value 
before treatment for each sample in each group for the presentation in this figure. The statistical 
analysis was conducted using the raw data. *P<0.05, **P<0.01; Student’s t-test, paired). (E) The 
effects of the positive compounds on CDK5 activity. Ros, CR8, PHA and DRF053 reduced CDK5 
activity in vitro at the dose of 50nM. Myo-B significantly inhibited CDK5 activity in vitro at 1mM (n=3 
for Ros, CR8, PHA, Myo-B and DMSO control group, n=4 for DRF053; ***P<0.005, ****P<0.001; 
One-way ANOVA with Dunnett’s post-hoc analysis). (F) The effect of Myo-B on CDK5 activity at 
different doses. Myo-B exhibited an inhibitory effect on CDK5 at mM dose, but not μM dose (n=3 for 
each dose; Data are mean ± s.d.). Ros, Roscovitine. Myo-B, Myoseverin-B. PHA, PHA-793887. 
Please see Table 2.2 for the detailed information of the iPSC lines used for each experiment. This 







Figure 2.4: The expression of the dominant negative (DN) mutant of CDK5 alleviated the 
phenotypes in Timothy syndrome (TS) cardiomyocytes. (A) Representative voltage-clamp 
recordings of Ba2+ currents in the TS cardiomyocyte with (+CDK5 DN) and without (-CDK5 DN) CDK5 
DN expression. “1.0 (relative)” means that the data points were normalized to the corresponding 
peak current value to make the traces. (B) Voltage-dependent inactivation percentage (VDI%) 
quantification in TS cardiomyocytes with (n=19) and without CDK5 DN expression (n=7). Dashed 
line indicates the average VDI% of control iPSC-derived cardiomyocytes.  Data are mean ± s.d. (C) 
The current-voltage relationships of the Ba2+ currents in TS cardiomyocytes with (squares, n=19) 
and without CDK5 DN expression (circles, n=7) are statistically not significantly different.  (D) 




  Arrowheads show putative delayed afterdepolarizations (DADs). Dashed lines show 0 mV. (E) Action 
potential duration quantification in TS cardiomyocytes with (n=13 from two lines) and without CDK5 
DN expression (n=11 from two lines). APD50 and APD 90, action potential duration at 50% and 90% 
of repolarization. (F) Representative paced (0.2 Hz) action potential recordings in the CDK5 DN 
lentivirus infected (+CDK5 DN) and uninfected TS cardiomyocyte.  (G) Action potential duration at 
90% of repolarization (APD90) quantification in the control cardiomyocytes (n=10 from three lines) 
and the TS cardiomyocytes with (n=10 from two lines) and without CDK5 DN expression (n=8 from 
two lines) (One-way ANOVA with Bonferroni post-hoc). (H) Representative calcium current 
recordings in the control cardiomyocyte and the CDK5 DN lentivirus infected (+CDK5 DN) and 
uninfected TS cardiomyocyte. (I) Late calcium current percentage (defined by normalizing the 
calcium current intensity at 350ms from the peak to the peak current intensity) quantification in the 
control cardiomyocytes (n=13 from three lines) and the TS cardiomyocytes with (n=10 from two lines) 
and without CDK5 DN expression (n=14 from two lines; One-way ANOVA with Bonferroni post-hoc). 
(J) The current-voltage relationships of the calcium currents in the control cardiomyocytes (Green, 
circle, n=13 from three lines) and the TS cardiomyocytes with (Blue, square, n=10 from two lines) 
and without CDK5 DN expression (Red, triangle, n=14 from two lines) were statistically not 
significantly different. (K) Representative spontaneous calcium transient traces of single TS 
cardiomyocyte infected with the R-GECO1 lentivirus and the YFP lentivirus or the YFP-CDK5 DN 
lentivirus. The expression of CDK5 DN alleviated the abnormal spontaneous calcium transients in 
TS cardiomyocytes. Y-axis, ΔF/F0 for R-GECO1 (calcium fluorescent indicator). (L, M) The analysis 
of calcium transient half decay time and the percentage of cells with irregular timing of calcium 
transients in the TS cardiomyocytes with (n=25 from three lines from three rounds of experiments) 
and without CDK5 DN expression (n=32 from three lines from three rounds of experiments). The 
expression of CDK5 DN reduced the percentage of cells with irregular timing of calcium transients in 
three rounds of experiments and calcium transient half decay time in TS cardiomyocytes. (N) The 
percentage of single TS cardiomyocyte with long and short calcium transients in each group from 
the experiments in Figure 2.4K-2.4M. The definition of long calcium transients is the calcium 
transients with calcium transient half decay time that is over two seconds, which is similar to the 
calcium transient half decay time of single TS cardiomyocyte and longer than the calcium transient 
half decay time of single isogenic control iPSC-derived cardiomyocyte. The expression of CDK5 DN 
increased the percentage of the TS cardiomyocytes with short calcium transients in the group, 
compared with the yellow fluorescent protein (YFP) control group. (O) Representative Ca2+ transient 
traces of paced (0.5Hz) single TS cardiomyocyte infected with the R-GECO1 lentivirus and the YFP 
lentivirus or the YFP-CDK5 DN lentivirus. Blue dots indicate electrical pulses (2ms, bipolar pulse, 4 
volts). The expression of CDK5 DN alleviated the abnormal paced Ca2+ transients in TS 
cardiomyocytes. Y-axis, ΔF/F0 for R-GECO1. (P, Q, R, S) The analysis of Ca2+ transient duration, 
half decay time, amplitude and integrated calcium transients (area under curve) in the paced TS 
cardiomyocytes with and without CDK5 DN expression (n=7 for the group without CDK5 DN, n=17 
for the group with CDK5 DN). (T) Representative calcium transient traces of partially responded 
paced single TS cardiomyocyte infected with the R-GECO1 lentivirus and the YFP lentivirus or the 
YFP-CDK5 DN lentivirus. Blue dots indicate electrical pulses (2ms, bipolar pulse, 4 volts) and arrow 
heads indicate that the cell did not respond to a specific pulse. TS cardiomyocytes either fully 
responded or partially responded to the electrical pulses. The expression of CDK5 DN alleviated the 
abnormal paced calcium transients in TS cardiomyocytes that partially responded to electrical pulses. 
Y-axis, ΔF/F0 for R-GECO1. (U) The analysis of the percentage of cells responded to electrical 
pulses in the group with CDK5 DN expression and the group without CDK5 DN expression (YFP 
group) from three rounds of experiments (n=40 for each group). (V, W) The analysis of induced 
calcium transient duration and calcium transient half decay time in the partially responded paced TS 
cardiomyocytes with and without CDK5 DN expression (n=33 for the group without CDK5 DN, n= 23 
for the group with CDK5 DN). Data are mean ± s.e.m. and data were from two lines unless otherwise 
stated. Student’s t-test was used for statistics unless otherwise stated. *P<0.05, **P<0.01, 
***P<0.005. n.s., not significant. Please see Table 2.2 for the detailed information of the iPSC lines 
used for each experiment. This figure is reproduced from Song, et al 84. 
Acknowledgment: Dr. Masayuki Yazawa conducted the Ba2+/Ca2+ current recordings and the paced 







Figure 2.5: The expression of CDK5 shRNA alleviated the phenotypes in Timothy syndrome 
(TS) cardiomyocytes. (A) A scheme of the lentiviral CDK5 knockdown system. (B) qPCR results to 
confirm the CDK5 knockdown in HEK 293Ta cells (n=6 per group from three rounds of experiments. 
data are mean ± s.d.). (C) Representative images of GFP-positive TS cardiomyocytes with CDK5 
shRNA in patch clamp recordings. Scale bar, 10μm. (D) Representative recordings of Ba2+ currents 
in the TS cardiomyocyte with (+shRNA) and without (-shRNA) CDK5 shRNA expression. (E) Voltage-
dependent inactivation percentage (VDI%) quantification in TS cardiomyocytes with (n=13) and 
without CDK5 shRNA expression (n=9). Dashed line indicates the average VDI% of control iPSC-
derived cardiomyocytes. (F) Representative spontaneous calcium transient traces of single TS 
cardiomyocyte infected with the R-GECO1 lentivirus and the scrambled control shRNA lentivirus or 
the CDK5 shRNA lentivirus. The CDK5 shRNA expression alleviated the abnormal spontaneous 
calcium transients in TS cardiomyocytes. Y-axis, ΔF/F0 for R-GECO1(calcium fluorescent indicator). 
(G, H) The analysis of calcium transient half decay time and the percentage of cells with irregular 
timing of calcium transients in the TS cardiomyocytes with scrambled shRNA expression (n=33 from 
three rounds of experiments) or CDK5 shRNA expression (n=31 from three rounds of 
experiments).  The expression of CDK5 shRNA reduced the percentage of cells with irregular timing 
of calcium transients in three rounds of experiments and calcium transient half decay time in TS 
cardiomyocytes. (I) The percentage of single TS cardiomyocyte with short and long calcium 
transients in each group from the experiments in Figure 2.5F-2.5H. The definition of long calcium 
transients is the calcium transients with calcium transient half decay time that is over two seconds, 
which is similar to the calcium transient half decay time of single TS cardiomyocytes and longer than 
the calcium transient half decay time of single isogenic control iPSC-derived cardiomyocyte. The 
expression of CDK5 shRNA increased the percentage of the TS cardiomyocytes with short calcium 
transients in the group, compared with the scrambled shRNA control group. Data are mean ± s.e.m. 
and data were from two lines unless otherwise stated. Student’s t-test was used for statistics. 
**P<0.01. Please see Table 2.2 for the detailed information of the iPSC lines used for each 
experiment. This figure is reproduced from Song, et al 84. 






Figure 2.6: One of the potential mechanisms underlying the effects of CDK5 inhibition on 
Timothy syndrome cardiomyocytes. (A, B) GAPDH was used to normalize CDK5, CDK5R1 (p35) 
and CDK5R2 (p39) expression in the qPCR analysis (*P<0.05; Student’s t-test; data are mean ± 
s.e.m.). Cardiomyocyte samples from four control lines (Ctrl, n=12 including two isogenic control 
lines) and two Timothy syndrome lines (TS, n=14) were tested. (C) Representative image and 
quantification of p35 protein expression in Timothy syndrome (TS) cardiomyocytes and control (Ctrl) 
cardiomyocytes (n=12 for Ctrl from three lines and n=11 for TS from two lines, from four rounds of 
experiments. **P<0.01; Student’s t-test; data are mean ± s.e.m.). (D) Endogenous CDK5 activity in 
cardiomyocytes derived from embryonic stem cell line H9, control (Ctrl) iPSCs and Timothy 
syndrome (TS) iPSCs. Timothy syndrome cardiomyocytes demonstrated a significantly higher 
endogenous CDK5 activity compared with control cardiomyocytes (n=9 for H9, n=11 for Ctrl from 
two lines and n=9 for TS from two lines; *P<0.05, **P<0.01; n.s., not significant; One-way ANOVA 
with Bonferroni post-hoc; Data are mean ± s.e.m.). (E) Representative recordings of Ba2+ currents in 
control cardiomyocyte with and without CDK5 WT over-expression. (F) CDK5 WT over-expression 
significantly delayed the voltage-dependent inactivation of CaV1.2 in control cardiomyocytes (n=14 
for -CDK5 WT group and n=12 for +CDK5 WT group from two control lines. **P<0.01; Student’s t-
test; data are mean ± s.e.m.). (G) Schematic presentation of the proposed signaling pathway in 
Timothy syndrome cardiomyocytes. Please see Table 2.2 for the detailed information of the iPSC 
lines used for each experiment. This figure is reproduced from Song, et al 84. 






Figure 2.7: CDK5 consensus sequences in CaV1.2 and CDK5R1 expression in cardiomyocytes 
derived from isogenic control iPSCs and control iPSCs. (A) The structure of human CaV1.2/α1c 
subunit. The G406R mutation and five CDK5 consensus sequences in CaV1.2 are shown. (B) 
CDK5R1 (p35) expression normalized to GAPDH. The samples were all used as control samples in 
the qPCR analysis shown in Figure 2.6B. In this separate analysis of cardiomyocytes derived from 
isogenic control iPSCs (n=6 from two iPSC clones) and regular control iPSCs (n=6 from two iPSC 
clones), no significant difference was found between the two groups (n.s. not significant; Student’s 
t-test; TS average line was drawn according to the value in Figure 2.6B). This figure is reproduced 





Table 2.1: A summary of Roscovitine analog test. 
 



























































































































































































































































































































































































a Purvalanol A and Purvalanol B are also CDK inhibitors with the relative specificity for CDK5 and CDK2. 
The compounds significantly increased the beating rate of the Timothy syndrome cardiomyocyte clusters 
(**P<0.01, ***P<0.005) in the first round of chemical test. However, they failed to significantly improve the 
contraction irregularity of Timothy syndrome cardiomyocytes in the second round of chemical test at the 
dose of 5 μM (data not shown). So do the other two compounds named 7740639 and 7742481. Therefore, 
these Roscovitine analogs are not listed as positive compounds in the final analysis. The dose of each 
compound used in the first round of chemical test is 5μM. n=10-12 per group. The testing dose (5 μM) was 
determined based on a dose titration of Roscovitine, which determined the minimal dose of Roscovitine 
that exhibited beneficial effects on the irregular contractions in Timothy syndrome cardiomyocytes. 
Although Purvalanol A, Purvalanol B, 7740639 and 7742481 did not significantly improve the contraction 
irregularity of Timothy syndrome cardiomyocytes at the dose of 5 μM, they may exhibit a more significant 
beneficial effect on the irregular contractions in Timothy syndrome cardiomyocytes at a higher dose. It 
would be interesting to investigate the effects of Purvalanol A, Purvalanol B, 7740639 and 7742481 on the 
irregular contractions in Timothy syndrome cardiomyocytes at a higher dose in the future. 
 
The beating rate value after the treatment of the compound was normalized to the corresponding beating 
rate value before treatment for each sample and therefore the Y-axis was labeled as “Relative Beating 
Rate” for the presentation in the figures. The statistical analysis was conducted using the raw data. The 
compounds with names consisting of numbers were purchased from ChemBridge Corp. and the numbers 
are ChemBridge ID. Paired Student’s t-test was used for statistical analysis. *P<0.05, **P<0.01, ***P<0.005. 

































































Table 2.2: Detailed information of the iPS cell lines used for each experiment. 
 
Experiment Figure number The information of the cell lines used for the experiment 
Calcium imaging Figure 2.1C-2.1D Control cardiomyocytes were differentiated from clone IM-
E1-5 and NH-E5-4.  
Isogenic control cardiomyocytes were differentiated from 
isogenic control clone 1 and clone 2 that were generated 
from the TS iPSC clones (TS1-E3-5 and TS2-E7-1). 
TS cardiomyocyte samples were differentiated from clone 
TS1-E3-5 and TS2-E7-1. 
Voltage-clamp 
recording 
Figure 2.1F-2.1H Control cardiomyocytes were differentiated from clone IM-
E1-5 and NH-E5-4.   
Isogenic control cardiomyocytes were differentiated from 
isogenic control clone 1, clone 2 and clone 4 that were 
generated from the TS iPSC clones (TS1-E3-5 and TS2-
E7-1). 
Contraction assay Figure 2.2A-2.2C TS cardiomyocyte clusters were differentiated from clone 
TS1-E3-5.  
Contraction assay Figure 2.3D TS monolayer cardiomyocytes were differentiated from 
clone TS1-E3-5.  
Voltage-clamp 
recording 







TS cardiomyocytes were differentiated from clone TS1-
E3-5 and TS2-E7-1. Control cardiomyocytes were 
differentiated both from clone IM-E1-5 and NH-E5-4 and 
from an embryonic stem cell line H9. 
The samples were collected from three rounds of 
differentiation and viral infection.  
Calcium imaging Figure 2.4K-2.4N TS cardiomyocytes were differentiated from clone TS1-
E3-5, TS2-E6-2 and TS2-E7-1.  
The samples were collected from three rounds of 
differentiation and viral infection. 
Calcium imaging Figure 2.4O-2.4W TS cardiomyocytes were differentiated from clone TS1-
E3-5 and TS2-E7-1. 
The samples were collected from three rounds of 






TS cardiomyocytes were differentiated from clone TS1-
E3-5 and TS2-E7-1. 
The samples were collected from three rounds of 
differentiation and viral infection.  
Calcium imaging Figure 2.5F-2.5I TS cardiomyocytes were differentiated from clone TS1-
E3-5 and TS2-E7-1.  
The samples were collected from three rounds of 
differentiation and viral infection. 
Quantitative PCR Figure 2.6A-2.6B The control cardiomyocyte samples were differentiated 
from non-isogenic iPSC clone IM-E1-5 and NH-E1-1, and 
isogenic control iPSC clone 1 and clone 2 that were 
generated from the TS iPSC clones (TS1-E3-5 and TS2-
E7-1).  
The TS cardiomyocyte samples were differentiated from 
clone TS1-E3-5 and TS2-E7-1. 
Western blot 
analysis 
Figure 2.6C The experiments were repeated four times with different 
samples to examine p35 protein expression. The control 
cardiomyocyte samples were collected from clone IM-E1-




Clone TS1-E3-5 was derived from one TS patient (TS1). Clone TS2-E6-2 and TS2-E7-1 were derived from 
another TS patient (TS2). Clone IM-E1-5 was derived from human embryonic lung fibroblast IMR90 
(ATCC). Clone NH-E1-1 and NH-E5-4 were derived from normal adult human dermal fibroblasts (NHDF, 
Life Technologies).  
 
We confirmed that the data from clone TS1-E3-5 and TS2-E7-1 derived from two TS patients are 
homogeneous and the data from the two clones are combined as TS group in the experiments. We 
confirmed that the data from the clone IM-E1-5, NH-E1-1 and NH-E5-4 derived from two commercially 
available healthy fibroblasts are homogeneous and the data from some of the clones are combined as 
control group in the experiments. We confirmed that cardiomyocytes derived from isogenic control iPSC 
clones were comparable to cardiomyocytes derived from non-isogenic control iPSC clones. In some 
experiments, the cardiomyocytes differentiated from isogenic control clones and non-isogenic control 
clones were both used as control group. 
 
This table is reproduced from Song, et al 84. 
 
  
cardiomyocyte samples were collected from clone TS1-
E3-5 and TS2-E7-1. 
CDK5 activity 
assay 
Figure 2.6D TS cardiomyocytes were differentiated from clone TS1-
E3-5 and TS2-E7-1. Control cardiomyocytes were 
differentiated both from clone IM-E1-5 and NH-E5-4 and 
from an embryonic stem cell line H9.  
The samples were collected from four rounds of 




Figure 2.6E-2.6F The control cardiomyocytes differentiated from clone IM-
E1-5 and NH-E5-4 were used.  
The samples were collected from four rounds of 
differentiation and viral infection. 
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Table 2.3: Raw data from the paced action potential recordings from single TS cardiomyocyte with 
and without CDK5 DN expression. 
 




TS cardiomyocytes without CDK5 DN -50.6 3.57 8 
TS cardiomyocytes with CDK5 DN -53.0 4.08 10 
Peak amplitude 
(mV) 
TS cardiomyocytes without CDK5 DN 29.3 3.5 8 
TS cardiomyocytes with CDK5 DN 27.3 3.4 10 
APD90a 
(ms) 
TS cardiomyocytes without CDK5 DN 1,624.4 182.0 8 
TS cardiomyocytes with CDK5 DN 801.3 93.7 10 
Time to peak 
(ms) 
TS cardiomyocytes without CDK5 DN 92.4 30.4 8 
TS cardiomyocytes with CDK5 DN 40.1 11.4 10 
Maximal upstroke 
velocity (mV/ms) 
TS cardiomyocytes without CDK5 DN 42.4 1.84 8 
TS cardiomyocytes with CDK5 DN 40.0 2.25 10 
 
aAPD90: Action Potential Duration at 90% of repolarization. The representative traces and APD90 
quantification were shown in Figure 2.4F and 2.4G.  
 







Control and Timothy syndrome iPSCs were generated using a virus-free method from the skin 
fibroblasts and characterized as described previously 54. Mycoplasma tests were conducted using 
MycoAlert (Lonza) when the iPSC lines were generated. Human embryonic stem cell (ESC) line H9 
(#WA09, NIH cell line code #0062) was obtained from WiCell Research Institute, Inc. (August 8th, 2014, 
Agreement # 15-W0039) as an additional control human pluripotent stem cell line. iPSCs or the ESC line 
H9 were cultured with Essential 8 media with 100 unit/ml penicillin and 100 μg/ml streptomycin on plates 
or dishes (Corning) coated with Geltrex (#A14133-022, from Life Technologies) following the 
manufacturer’s instruction. The iPSC lines or the ESC line H9 were maintained and passaged following the 
previously-reported protocol using dispase (Life technologies) 54. Human iPSC-derived cardiomyocytes 
were maintained in EB5 media: DMEM/F12 medium with GlutaMAX (Life Technologies) containing 5 % 
fetal bovine serum (FBS, Hyclone, Thermo Scientific), 1mM non-essential amino acids (Life Technologies), 
0.1mM beta-mercaptoethanol (Sigma-Aldrich), 100 unit/ml penicillin and 100 μg/ml streptomycin. Human 
embryonic kidney (HEK) 293T cells (ATCC) and 293Ta cells (Lenti-Pac, GeneCopoeia) were cultured in 
DMEM media (Life Technologies) supplemented with 10% FBS, 2mM L-glutamine (Life Technologies), 100 
unit/ml penicillin and 100 μg/ml streptomycin. All cells were cultured in HERAcell 150i (Thermo Scientific) 
incubators and culture procedures were conducted in the Biosafety Cabinet Class II type A2 tissue culture 
hoods (Labconco). 
 
The generation of isogenic controls 
The transcription activator-like (TAL) sequences for the isogenic control generation were 
synthesized using the service from Life technologies. The ordered TAL binding sequences were 
TCCCTTCCTACGGCATCAT corresponding to RVD (T)-HD-HD-HD-NG-NG-HD-HD-NG-NI-HD-NN-NN-
HD-NI-NG-HD-NI-NG for hCACNA1C_TAL_R, and TGCCTCACTAACTATCATT corresponding to RVD 
(T)-NN-HD-HD-NG-HD-NI-HD-NG-NI-NI-HD-NG-NI-NGHD-NI-NG-NG for hCACNA1C_TAL_L, where '(T)' 
indicates that the first binding repeat that is provided by the vector. The synthetic hCACNA1C_TAL_L and 
hCACNA1C_TAL_R were assembled from synthetic oligonucleotides and/or PCR products. Based on the 
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manufacturer’s protocol, the fragments were cloned into TALtrunc_FokI using 100% sequence verified 
subfragments. The resulting plasmids were purified from transformed bacteria and quantified by UV 
spectroscopy (Nanovue Plus, G.E. Healthcare Life Sciences). The final constructs were confirmed by 
sequencing. The synthesized TAL sequences were then released from the original vectors by digesting the 
vectors with NotI and HindIII. The isolated synthesized TAL sequences were sub-cloned into a pEF1a_MCS 
vector digested with NotI and HindIII. The pEF1a_MCS_TALEN_L and pEF1a_MCS_TALEN_R vectors 
were purified from transformed bacteria and quantified by UV spectroscopy. The final constructs were 
confirmed by sequencing. The donor DNA was cloned from the genomic DNA of a control iPSC line using 
the PCR reaction with Phusion polymerase (Thermo Scientific), a standard Phusion PCR protocol, and the 
primer set: Forward 5’-GTGCACATGAACAAAGCCCACGTTCAG-3’; Reverse 5’-
GCCCGGTTACTTCTACCACTTCTAACTTC-3’. The PCR product (1.2 kb) was purified using the QIAquick 
PCR purification kit (Qiagen) and the sequence was confirmed by sequencing to match the normal 
CACNA1C gene sequence. The TALEN_L plasmid, TALEN_R plasmid, donor DNA and a GFP plasmid 
(pmaxGFP ® from Lonza or AAVS1-CAG-hrGFP, Addgene: #52344) were transduced into Timothy 
syndrome iPSCs cultured in 6 well plates at the ratio of 15:15:1:5 (3.6 μg DNA/well) using transfection with 
Lipofectamine LTX with an optimized protocol described previously 54. The GFP positive cells were sorted 
out using CCTI flow cytometry service at Columbia University and returned to culture in a hypoxia incubator 
(5% oxygen) for recovery. The recovered clones were expanded and stocked. Genomic DNA from each 
clone was isolated using DNeasy Blood and Tissue Kit (Qiagen) and the region encoding CACNA1C exon 
8a was amplified using Phusion polymerase PCR and the primer set: Forward 5’-TACACTAATCAT 
CATAGGGTCAT-3’; Reverse 5’-TAGCGATTCCCAGTTTAGGTAC-3’. The PCR product (1.2 kb) was 
purified using the QIAquick PCR purification kit (Qiagen) and directly sequenced using the original forward 
primer and a new reverse primer (Ori-R-MY): 5’-CTCAGAGATAGACTGCTCAGTCTATG-3’. Positive 
clones from the screen were expanded and adapted to normoxia incubator (20% oxygen) for the following 
experiments. For isogenic control generation, we used three Timothy syndrome patient lines (clone#: TS1-
E3-5, TS2-E6-2 and TS2-E7-1) derived from two independent patients and picked up 91 single cell clones 
for screening. We obtained 91 single cell clones using the protocol described above. Among the 91 clones, 
we identified 9 isogenic control clones in total from TS1-E3-5 and TS2-E7-1. No positive clone was identified 
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from the 8 clones recovered from TS2-E6-2 following the protocol described above. Overall, the success 
rate is 9.9%. We used the isogenic control clone 1, 2, 3, 4 and 5 for gene expression profiling. We used 
clone 1, 2, 3 and 4 for karyotyping. We used the cardiomyocytes differentiated from clone 1 and clone 2 for 
calcium imaging. We used the cardiomyocytes differentiated from clone 1, clone 2 and clone 4 for 
electrophysiological recordings.  
 
The characterization of isogenic control iPSCs 
The karyotyping of the isogenic control iPSCs was performed by WiCell (Wisconsin). For the RT–
PCR of NANOG using the primer set (Forward 5’- CAGCCCCGATTCTTCCACCAGTCCC-3’ and Reverse 
5’- CGGAAGATTCCCAGTCGGGTTCACC-3’), RNA from the isogenic control iPSCs was prepared using 
the RNeasy Mini kit and RNase-Free DNase set (Qiagen). cDNA was synthesized from 1 μg RNA using 
the SuperScript III First-Strand Synthesis System for RT–PCR (Life Technologies). The cDNA (21 μl) was 
diluted with DNase-free water (Invitrogen) at 1:5 and 1 μl of the samples was used for conventional RT–
PCR with Ex taq (Clontech/TaKaRa Bio). The teratoma formation assays were performed following the 
previously-reported protocol 54 and the H.E. staining was performed by the pathological staining service at 
Columbia University. For the teratoma formation assays, two 8-week-old severe combined immunodeficient 
(SCID) beige male mice (Charles River Laboratories) were used for each line and the teratoma formation 
was observed in all mice that were injected with the iPSCs. All animal protocols and handling for the 
teratoma formation assays were performed following the guidelines established by Columbia Institutional 
Animal Care and Use Committee under our approved protocol (for LJ.S. and M.Y., #AC-AAAF5655). To 
examine the differentiation potentials of the isogenic control iPS lines used for further experiments, cardiac 
differentiation was conducted as reported previously 54. The calcium transients of the cardiomyocytes 
derived from isogenic control iPSCs, non-isogenic control iPSCs and Timothy syndrome iPSCs were 
imaged with the genetically encoded calcium indicator R-GECO1 as reported previously 54. The Ba2+ current 
recordings were obtained from the cardiomyocytes derived from isogenic control iPSCs and non-isogenic 





Preparation of chemical compounds 
(R)-Roscovitine (Purity: ≥ 98% (HPLC)) and the Roscovitine analogs (R)-CR8 (Purity: ≥ 95% 
(HPLC)), Myoseverin-B (Purity: ≥ 97% (HPLC)), Purvalanol A (Purity: ≥ 98% (HPLC)), Purvalanol B (Purity: 
≥ 97% (HPLC)), Olomoucine (Purity: ≥ 98% (HPLC)), N9-Isopropylolomoucine (Purity: ≥ 98% (HPLC)) and 
Bohemine (Purity: ≥ 95% (HPLC)) were purchased from Sigma-Aldrich and all the rest of the Roscovitine 
analogs (13 in total) were purchased from ChemBridge Corp. The ChemBridge compounds with 7-digit 
name were from EXPRESS-Pick™ Collection for which the minimum purity was 90% and the identity was 
confirmed using 1H-NMR and/or LC-MS/ELSD. The ChemBridge compounds with 8-digit name were from 
the CORE Library for which the minimum purity was 85% and the identity was confirmed using LC-
MS/ELSD. (R)-Roscovitine was dissolved in DMSO (dimethyl sulfoxide, Sigma-Aldrich, #276855-100ML). 
Except for Bohemine that was dissolved in methanol following manufacturer’s instructions, all the other 
Roscovitine analogs were dissolved in DMSO. For the CDK inhibitors, PD0332991 (Purity: ≥ 98% (HPLC)) 
and NSC43067 (Purity: ≥ 98% (HPLC)) were purchased from Sigma-Aldrich. (R)-DRF053 (Purity: ≥ 98% 
(HPLC)) was purchased from Abcam and PHA-793887 (Purity: ≥ 98% (HPLC)) was purchased from 
ApexBio. Except for PD0332991 that was dissolved in sterile distilled water, all the other CDK inhibitors 
were all dissolved in DMSO. The stock concentration for (R)-Roscovitine was 5mM and the stock 
concentration of all the other chemical compounds was 10mM. All the stock solutions were stored at -80 
oC and thawed only once after made.  
 
The analysis of cardiomyocyte contractions for compound tests 
The working solution of each compound was made by diluting the stock solution in EB5 media to a 
final concentration of 5 μM except for (R)-CR8, which was diluted to a final concentration of 1 or 2 μM. 0.1% 
or less DMSO (or methanol) did not have any significant effects on the phenotypes in Timothy syndrome 
cardiomyocytes. The contraction analysis was performed as reported previously 24. In brief, images were 
collected at a rate of 5 frames per second using the NIS-elements software (Nikon) and converted to multi-
frame TIFF images for analysis using the NIS-elements viewer. The multiple-frame TIFF images were 




all pixels. Movement was calculated by plotting the relative motion over time. Contractions were detected 
as a peak of relative motion and a second, typically smaller peak, corresponded to the relaxation of the 
cardiomyocytes. Peaks were selected manually and the rate of contraction was measured. The length of 
time between contractions was also measured and contraction irregularity was measured by calculating the 
ratio of the standard deviation to the mean of the intervals between contractions. The Timothy syndrome 
cardiomyocytes were used for the tests at day 21-22 after cardiac differentiation. The movies were taken 
before the treatment, and 24 hours after the treatment of each compound from the Timothy syndrome 
cardiomyocyte clusters in the first round of test for Roscovitine analogs and CDK inhibitors. The movies 
were taken before the treatment, and 2 hours after the treatment of each positive compound from the intact 
monolayer Timothy syndrome cardiomyocytes for a second round of test to validate the positive 
compounds. The compound DRF053 was directly tested in intact monolayer Timothy syndrome 
cardiomyocytes in the second round of test but it was not tested in the first round of test. The 
cardiomyocytes from one Timothy syndrome iPSC line (clone#: TS1-E3-5) were used mainly for the tests 
and the cardiomyocytes from another independent Timothy syndrome iPSC line (clone#: TS2-E7-1) were 
used for validation. The contraction rate and irregularity values of each sample before and after treatment 
were compared using paired Student’s t-test. The contraction rate and irregularity values of each sample 
after treatment were normalized to its respective values before treatment in the corresponding figures. 
 
Plasmid construction and the preparation of lentiviruses 
The CDK5 fragment was amplified from the cDNA samples of a control iPSC line using Phusion 
polymerase (Thermo Scientific) and with primer sets that allowed us to add the restriction enzyme site NotI 
and Kozak sequence before the start codon and another site XhoI after the stop codon. The fragment was 
subcloned into a pcDNA3 vector (Invitrogen) that was digested with NotI and XhoI for the following 
generation of CDK5 WT and CDK5 dominant negative (DN) lentiviruses. For the generation of CDK5 DN 
mutant, the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) was used to generate the mutation 
leading to the D144N mutation in CDK5 protein. The plasmid containing the CDK5 DN or CDK5 WT was 
used as the template to amplify the CDK5 DN or CDK5 WT sequence using Phusion polymerase and the 
primer sets that allowed us to add the restriction enzyme site EcoRI and Kozak sequence before the start 
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codon and another site XhoI after the stop codon. The PCR products were subcloned into a lentiviral vector 
that was prepared from LV-SD-Cre (Addgene, #12105, no longer available currently) digested with EcoRI 
and XhoI. XL-10 Gold competent cells (Agilent) transformed with the lentiviral LV-SD vectors were 
inoculated at 24-30 oC. The LV-SD vectors were purified from the transformed bacteria and the sequence 
was confirmed by sequencing. The purified LV-SD vectors were transfected together with pCMV-dR8.2 
dvpr and pCMV-VSV-G (Addgene #8455 & 8454) into HEK 293T cells for lentiviral production, following a 
protocol described previously 54. The shRNA constructs for CDK5 were purchased from GeneCopoeia 
along with the Lenti-Pac FIV Expression Packaging Kit (FPK-LvTR-40). The knockdown efficiency of the 
shRNAs was examined, and the scrambled shRNA (as a control) lentivirus and CDK5 shRNA lentivirus 
were prepared in the lentiviral 293Ta packaging cells (Lenti-Pac, #CLv-PK-01) purchased from 
GeneCopoeia, following the manufacturer’s instructions. The shRNA lentiviruses were concentrated 6 folds 
using the Lenti-X concentrator (Clontech) following the manufacturer’s instructions to infect the Timothy 
syndrome cardiomyocytes.  
 
Electrophysiology 
The control and Timothy syndrome iPSCs were differentiated into cardiomyocytes following a 
protocol reported previously 54. The cell clusters were isolated from the monolayer cardiomyocytes and re-
plated into gelatin-coated wells in 6-well plates at day 16. For the experiments to examine the effects of 
CDK5 DN expression in Timothy syndrome cardiomyocytes, the cells were infected with the YFP-CDK5 
DN lentivirus at day 19-21 after differentiation. For the experiments to examine the effects of CDK5 shRNA 
expression in Timothy syndrome cardiomyocytes, the cells were infected with CDK5 shRNA lentivirus at 
day 19-21 after differentiation. The CDK5 shRNA lentiviruses were concentrated using the lenti-X 
concentrator (Clontech) by 6 folds. The cells were dissociated into single cells for whole-cell patch clamp 
recordings at day 31 to 36 and plated into 35mm glass bottom culture dishes (7mm diameter No. 1.5 glass, 
MatTek, #P35G-1.5-7-C) coated with Geltrex. The patch-clamp recordings using cardiomyocytes infected 
with CDK5 DN construct were performed between day 35 and day 42 after differentiation while the 
recordings using cardiomyocytes infected with CDK5 shRNA construct were conducted between day 40 
and day 47. Whole-cell patch clamp recordings of iPSC-derived cardiomyocytes were conducted using a 
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MultiClamp 700B patch-clamp amplifier (Molecular Devices) and an inverted microscope equipped with 
differential interface optics (Nikon, Ti-U). The glass pipettes were prepared using borosilicate glass (Sutter 
Instrument, BF150-110-10) and a micropipette puller (Sutter Instrument, Model P-97). For Ba2+ current 
recordings, voltage-clamp measurements were conducted using an extracellular solution consisting of 5mM 
BaCl2, 160mM TEA-Cl and 10mM HEPES (pH7.4 at 25 oC) and a pipette solution of 125mM CsCl, 0.1mM 
CaCl2, 10mM EGTA, 1mM MgCl2, 0.3mM TrisGTP and 10mM HEPES (pH 7.4 adjusted with CsOH at 25 
oC). For Ca2+ current recordings, another extracellular solution was used: 5mM CaCl2, 137mM NMDG, 0.5 
mM MgCl2, 25mM CsCl, 10mM TEA-Cl, 10mM glucose, and 10mM HEPES (pH7.4 adjusted with HCl at 25 
oC). Two pulse protocols were used. One protocol was that cells were held at -90mV and then depolarized 
to -10mV for 400 ms at a rate of 0.1 Hz for the Ba2+ current recordings. The other protocol was that cells 
were held at -90mV and depolarized to -50mV for 2 seconds to eliminate the T-type current contamination, 
and then depolarized to +10/-10mV for 400 ms at a rate of 0.1 Hz for the Ca2+/Ba2+ current recordings to 
measure the L-type currents; Cells were held at -90 mV, stimulated with a 2-s family of pulses from -90 to 
+50/+20mV for the current-voltage relationship of the Ca2+/Ba2+ currents. The recordings were conducted 
under room temperature.  
The voltage-dependent inactivation percentage is defined as the Ba2+ current intensity at 350ms 
from the peak divided by the peak current intensity in Figure 2.4B, Figure 2.5E, and Figure 2.6F. The late 
calcium current percentage is defined as the calcium current intensity at 350ms from the peak divided by 
the peak current intensity in Figure 2.4I. The data points to plot the representative traces in Figure 2.4A, 
Figure 2.5D, and Figure 2.6E were normalized to the respective peak current value of the trace and 
therefore the traces were labeled as “1.0 (relative)”. The values used to plot the current-voltage relationship 
of the Ba2+ current recordings (Figure 2.4C) and Ca2+ current recordings (Figure 2.4J) were normalized to 
their respective peak current value before being used for the grouped analysis.  
Current-clamp recordings were conducted in normal Tyrode solution containing 140mM NaCl, 
5.4mM KCl, 1mM MgCl2, 10mM glucose, 1.8mM CaCl2 and 10mM HEPES (pH7.4 with NaOH at 25 oC) 
using the pipette solution: 120mM K D-gluconate, 25mM KCl, 4mM MgATP, 2mM NaGTP, 4mM Na2-
phospho-creatin, 10mM EGTA, 1mM CaCl2 and 10mM HEPES (pH 7.4 with HCl at 25 oC). The recordings 
were conducted at 37 oC. For the paced action potential recordings, cardiac action potentials were 
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stimulated (5ms, 0.3nA) in current clamp mode at 37 oC (0.2 Hz). First, we paced the patient cardiomyocytes 
at 0.5 Hz or 1 Hz for action potential recordings and we found that the cardiomyocytes could not respond 
the pacing frequencies due to the prolonged action potential phenotype (>2 seconds). Therefore, we 
decided to use a lower pacing frequency (0.2 Hz) and examined the effects of CDK5 DN expression on the 
paced action potentials in Timothy syndrome cardiomyocytes. Recorded action potentials were analyzed 
using Clampfit 10.4 (Axon Instruments). The spontaneous action potential duration (action potential 
duration at 50% of repolarization (APD50) and action potential duration at 90% of repolarization (APD90)) 
values from the Timothy syndrome cardiomyocytes with CDK5 DN expression in Figure 2.4E were 
normalized to the values from the Timothy syndrome cardiomyocytes without CDK5 DN expression, and 
therefore the Y-axis title was labeled as “Relative action potential duration”.  
 
Calcium imaging and the analysis of calcium transient traces 
The Timothy syndrome iPSCs, non-isogenic control iPSCs and isogenic control iPSCs were 
differentiated into cardiomyocytes following a protocol reported previously 54. The cell clusters were isolated 
from the monolayer cardiomyocytes and re-plated into gelatin-coated wells in 6-well plates at day 16 after 
differentiation. For the calcium imaging of the cardiomyocyte clusters derived from the non-isogenic control 
iPSCs, isogenic control iPSCs or Timothy syndrome iPSCs, the clusters were transferred to glass-bottom 
dishes (7mm diameter, No. 1.5 glass) coated with Geltrex at day 23 and the calcium imaging was conducted 
following the protocol described previously 54 between day 25 to day 31. For the single cell imaging of the 
cardiomyocytes derived from the isogenic control iPSCs, the cell clusters were dissociated into single cells 
at day 40 and the imaging was conducted following the protocol described previously 54 at day 43 and day 
44. For the single cell imaging of the Timothy syndrome cardiomyocytes infected with the YFP lentivirus or 
the YFP-CDK5 DN lentivirus, the cells were infected with the lentiviruses of R-GECO1, a genetically 
encoded calcium indicator, and the other corresponding lentiviral constructs at day 19-21 and dissociated 
into single cells at day 31 after differentiation. The calcium imaging was conducted following the protocol 
described previously 54 between day 35 and day 42. For the single cell imaging of the Timothy syndrome 
cardiomyocytes infected with the scrambled shRNA lentivirus or CDK5 shRNA lentivirus, the cells were 
infected with the R-GECO1 lentiviruses and the other corresponding constructs at day 19-21 and 
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dissociated into single cells at day 36 after differentiation. The scrambled shRNA or CDK5 shRNA 
lentiviruses were concentrated using the lenti-X concentrator (Clontech) by 6-fold and therefore it took one 
extra week for the cells to recover from the viral infection. The calcium imaging was conducted following 
the protocol described previously 54 between day 40 and day 47. In brief, the Nikon Ti-U epi-fluorescent 
microscope connected to EMCDD Digital Monochrome camera (Evolve, EVO-512-M-FW-16-AC, 512x512, 
Photometrics) was used with LED light source (Lumencore Spectra X 6 line LED system, with Chroma 
excitation mounted filters, ET395/25x, ET470/30, ET550/15x, ET640/30x;) with dichroic mirror and 
emission filter (dichroic mirror, D/F/Cy3/Cy5pc; emission, ET430/36 513/44 595/41 719/105) operated by 
MetaFlour (Molecular Devices, acquisition: exposure time, 20 ms; gain 3 (6x); transfer speed, 5MHz, Image 
size: 512x512; binning, 1.0). The normal Tyrode solution (see “Electrophysiology”) with 10% FBS was used 
as bath solution. Temperature of the bath solution was maintained at approximately 37 oC using a digital 
temperature controller (TC-344B, Warner Instruments) for the duration of the experiment. Nikon objective 
lens 40x (CF1 S Fluor, NA 0.90) for cell clusters and 60x (CFI Plan Apo Lambda H, NA 1.40) for single cells 
were used to capture the fluorescent signal from R-GECO1 (illumination intensity, 10 in 0-255, cy3) 
indicator. The traces from ventricular-like Timothy syndrome cardiomyocytes were used for analysis. The 
calcium transient half (50%) decay time and the percentage of cells with irregular timing of calcium 
transients were analyzed. The calcium transient half decay time is defined as the average time interval 
between the point of the peak and the point at 50% decay of the peak. The data for the percentage of cells 
with irregular timing of calcium transients were pooled from three rounds of experiment. The definition of a 
cell with irregular timing of calcium transients is that the time intervals between adjacent calcium transients 
from the cell were significantly different.  
For the paced calcium transient recordings to examine the effects of CDK5 DN expression on the 
abnormal paced calcium transients in Timothy syndrome cardiomyocytes, the cardiomyocytes were 
prepared with the same experimental schedule as described above. The Nikon automatic microscope 
(Nikon Eclipse TiE with a motorized stage) connected to sCMOS camera (Andor Zyla sCMOS 4.2 MP) 
together with a stage top incubator (at 37oC, 5% CO2 and 20% O2, controlled by TOKAI HIT Hypoxia gas 
delivery system) was used for this experiment. Nikon objective lens 40x (Nikon CFI Plan Apo Lambda, NA 
0.95) was used for single cell recordings and the normal Tyrode solution with 10% FBS was used as bath 
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solution. A stimulus isolation unit (Warner instruments, SIU-102) and a perfusion insert with electric field 
stimulation for 35mm dish (Warner instruments, RC-37FS) were used for electrical pacing. The stimulus 
isolation unit was set at bipolar pulse and 4 volts. The pulses were controlled by the Nikon NLS-element 
software and were given at a frequency of 0.5 Hz with a duration of 2ms. The parameters (Bipolar pulse, 4 
volts, 2ms, 0.5 Hz) used for the experiments were first optimized using control cardiomyocytes and the 
control cardiomyocytes responded to the electrical pulses given with this set of parameters. Identical pacing 
parameters and experimental setting were used for the Timothy syndrome cardiomyocytes with YFP 
expression and the Timothy syndrome cardiomyocytes with YFP-CDK5 DN expression. The traces from 
ventricular-like Timothy syndrome cardiomyocytes were used for analysis. The calcium transient duration 
and the calcium transient half (50%) decay time were analyzed. The calcium transient duration is defined 
as the average time interval between the starting point of the upstroke of the transient and the ending point 
by which the transient decayed back to the baseline. The amplitude of the transients was calculated as the 
percent change relative to the baseline fluorescence (F/F0).  Integrated calcium transients (Average area 
under the curve(AUC) of the transients) were analyzed using the Graphpad prism software.  
 
Western blot analysis 
Anti-p35 antibody (Rabbit polyclonal Ab, Catalog # sc-820, Clone # C-19, 1: 1,000 dilution, Santa 
Cruz) and anti-beta-tubulin antibody (Mouse mAb, Catalog # T5201, Clone # TUB 2.1, 1:4,000 dilution, 
Sigma-Aldrich) were used for western blotting.  
For western blot analysis, the cardiomyocytes were collected at day 26 or day 27 after 
differentiation and lysed with the cell lysis buffer containing 1% Triton X-100, 50mM Tris-HCl, 150mM NaCl, 
250mM sucrose, 1x protease inhibitor cocktail (Catalog # P8340, Sigma-Aldrich), pH 7.4. The cell lysates 
were frozen with liquid nitrogen immediately and stored at -80 oC. On the day of the western blot experiment, 
the samples were thawed on ice and the concentration of total proteins in each sample was measured 
using a standard bicinchoninic acid (BCA) assay kit (Pierce Biotechnology). Next, 20 μg of proteins from 
each sample were aliquoted and denatured with the sample buffer containing Urea (2x stock, 8M Urea, 40 
mM Tris-HCl, 2% sodium dodecyl sulfate (SDS), 10% beta-mercaptoethanol and 0.01% bromophenol blue) 
and being boiled for 5 minutes at 95 oC. The samples were loaded to the Tris-HCl based SDS-PAGE gels 
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with 5% stacking gel and 10% separation gel along with the ladder. The proteins were then electro-
transferred to PVDF-membranes using the XCell SureLockTM Mini-Cell system overnight. Next day, the 
membranes were blocked with the SuperBlock Blocking buffer (Thermo Scientific) for 30 minutes at room 
temperature and incubated with the primary antibody (diluted in the SuperBlock Blocking buffer) overnight 
at 4oC. On the third day, the membranes were incubated with the corresponding secondary antibody 
(1:8,000 dilution in the SuperBlock Blocking buffer) for 30 minutes at room temperature and then incubated 
with the Pierce ECL western blotting substrate followed by exposing to X-ray films in a dark room. For 
sequential immunoblotting, the membranes were stripped with the stripping buffer containing 62.5mM Tris-
HCl, 2% SDS, 114mM beta-mercaptoethanol at 42oC for 15-20 minutes, and washed six times with PBS. 
The stripped membranes were then re-blocked with the SuperBlock Blocking buffer for the next 
immunoblotting. For the immunoblotting of beta-tubulin, the membrane was stripped, re-blocked with the 
SuperBlock Blocking buffer and incubated with the anti-beta-tubulin antibody at room temperature for 30 
minutes. The rest of the steps were the same. The western blot analysis to examine p35 expression in 
control and Timothy syndrome cardiomyocytes were repeated four times with independent samples for 
validation. Western blot band intensities were quantified using Image J and the values were normalized to 
the corresponding beta-tubulin band intensities. The values from Timothy syndrome cardiomyocytes were 
normalized to the values from control cardiomyocytes in Figure 2.6C. 
 
In Vitro CDK5 activity assay 
For the test of chemical compounds on CDK5 activity, the CDK5 activity assay was conducted 
following the manufacturer’s protocol (CDK5/p35 kinase enzyme system, Catalog # V3271, ADP-GloTM 
kinase assay, Catalog # V9101, Promega) with some modifications. The reaction mixtures contain 1 μg 
Histone H1 (substrate), 1X Reaction Buffer A, 50 μM DTT, 50 μM ATP, 0.1 μg CDK5/p35 and 1ul compound 
solution or pure DMSO in distilled water. The compounds (Roscovitine, CR8, PHA-793887, DRF053 and 
Myoseverin-B) were made and diluted as stock solutions in DMSO at different concentrations before testing. 
The final dose for Roscovitine, CR8, PHA-793887 and DRF053 in the reaction mixtures was 50nM and 
Myoseverin-B were tested at the dose of 50nM, 500nM, 1 μM, 10 μM, 100 μM, 1mM and 5mM. DMSO was 
added to the control (Ctrl) reaction mixtures. The final concentration of DMSO for every reaction mixture 
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was 1%. A series of samples for a standard curve were prepared based on the manufacturer’s instructions 
to determine the ATP-ADP conversion values from the luminescence signals in every round of experiment. 
The kinase reaction tubes with the reaction mixtures were incubated at 26-27 oC for 60 minutes for the 
kinase reaction. The ADP-GloTM reagent was then added to the reactions for an incubation of 40 minutes 
at 26-27 oC to deplete the ATP in the reactions. Next the detection reagent was added to the reactions for 
an incubation of 45 minutes at 26-27 oC. 20ul of the sample from each tube was then transferred into a 96 
well microplate and the luminescence was measured with the GloMax® 96 Microplate Luminometer 
(Promega) with an integration time of 1.5s. The luminescence values were converted into the ATP-ADP 
conversion values based on the standard curve. The ATP-ADP conversion values normalized to the values 
from the control group (Luminescence) were used for data analysis in Figure 2.3E and Figure 2.3F. 
To examine the endogenous CDK5 activity, an CDK5 activity assay was conducted following the 
previously reported protocols 85, 86 with some modifications. iPSC-derived cardiomyocytes differentiated 
from control iPSCs, embryonic stem cell line H9 and Timothy syndrome iPSCs were collected at day 26 or 
day 27 for the assay. Cardiomyocytes were isolated from monolayer culture and lysed with the cell lysis 
buffer containing 1% NP-40, 20mM Tris-HCl, 137mM NaCl, 1x protease inhibitor cocktail, 1x phosphatase 
inhibitor cocktail 3 (Catalog # P0044, Sigma-Aldrich) and 1x phosphatase inhibitor cocktail (Catalog # 
P8340, Sigma-Aldrich), pH 7.4. Protein concentrations in the samples were measured using a standard 
bicinchoninic acid (BCA) assay kit. 40 μg of proteins from each sample were aliquoted and used as one 
sample for CDK5 immunoprecipitation. The samples were incubated with the CDK5 antibody-conjugated 
agarose beads (cdk5 (J-3) AC, catalog #:sc-6247 AC, Santa Cruz Biotechnology) for 2 hours at 4 oC 
(rocking continuously) for CDK5 immunoprecipitation. 5μl resuspended bead solution was used for the 
immunoprecipitation of CDK5 from each sample. Next, the beads were washed three times with cold TBS 
and twice with room-temperature TBS. A reaction mixture containing 1X Reaction Buffer A, 50 μM DTT, 50 
μM ATP, 1 μg Histone H1 in distilled water was added to each sample for detecting CDK5 activity. A series 
of samples for a standard curve were prepared based on the manufacturer’s instructions to determine the 
ATP-ADP conversion values from the luminescence signals in every round of experiment. The kinase 
reaction tubes with the reaction mixtures were incubated at 26-27 oC for 60 minutes for the kinase reaction. 
The ADP-GloTM reagent was then added to the reactions for an incubation of 40 minutes at 26-27 oC to 
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deplete the ATP in the reactions. Next the detection reagent was added to the reactions for an incubation 
of 45 minutes at 26-27 oC. 20ul of the sample from each tube was then transferred into a 96 well microplate 
and the luminescence was measured with the GloMax® 96 Microplate Luminometer (Promega) with an 
integration time of 1.5s. The luminescence values were converted into the ATP-ADP conversion values 
based on the standard curve. Four rounds of experiment were conducted. The values from each round of 
experiment were normalized to the average value of the control cardiomyocyte samples in the same round 
of experiment before being pooled together for the final analysis that is showed in Figure 2.6D.  
 
Quantitative RT–PCR 
RNA from the control and Timothy syndrome cardiomyocytes at day 19 after differentiation was 
prepared using the RNeasy Mini kit and RNase-Free DNase set (Qiagen). cDNA was synthesized from the 
RNA using the SuperScript III First-Strand Synthesis System for RT–PCR (Life Technologies). The cDNA 
(21 μl) was diluted with DNase-free water (Invitrogen) at 1:1 and 1 μl of each sample was used for qPCR 
analysis. SYBR Advantage qPCR Premix (Clontech/TaKaRa Bio) and StepOnePlus real time PCR systems 
(Life Technologies) were used for qPCR. The primer sets for detecting the CDK5, CDK5R1 (p35), CDK5R2 
(p39) and GAPDH transcripts were as follows: CDK5 Forward 5’- GGCTTCAGGTCCCTGTGTAG-3’, 
Reverse 5’- ATGGTGACCTCGATCCTGAG-3’; CDK5R1 (p35), Forward 5’- 
ATGCATTGAATCCTTGAGCC-3’, Reverse 5’- CTTCTCCGACCTGAAGAACG-3’; CDK5R2 (p39), Forward 
5’- GCACCTCAGTCGATCCAAAT-3’, Reverse 5’- CCACTTGTGTCAGCTTGCAT-3’; GAPDH, Forward 5’- 
GATGACATCAAGAAGGTGGTGA-3’, Reverse 5’- GTCTACATGGCAACTGTGAGGA-3’. The CT value of 
each sample at 50% of the amplification curve was used and GAPDH was used to normalize the expression 
of CDK5, CDK5R1 (p35) and CDK5R2 (p39). All the samples are biological repeats from two to three rounds 
of independent cardiac differentiation. 
 
Statistics 
The statistics used for every figure have been indicated in the corresponding figure legends. The 
Student’s t-test (paired and unpaired) was conducted with the t-test function in Microsoft Excel software. F-
test was conducted before the t-test to determine whether the samples have equal variance in Microsoft 
	
73 
Excel software. The Student’s t-test was two tails. One-way ANOVA with Bonferroni post-hoc or Dunnett’s 
post-hoc analyses for multiple comparisons was conducted with the Graphpad prism software. All the data 
meet the assumptions of the statistical tests. All the samples used in this study were biological repeats, not 














The treatment of sigma-1 receptor agonists alleviates the abnormal functionality  





In chapter 2, we identified CDK5 as a new therapeutic target and CDK5-specific inhibitors as new 
therapeutic compounds for Timothy syndrome.  However, most of the currently-available inhibitors for CDK5 
have a relatively low selectivity for CDK5 over CDK2 due to the fact that the inhibitors are ATP-competitive 
inhibitors and the ATP binding pockets of CDK5 and CDK2 are very similar 87, 88. Another concern is that 
many of the currently-available inhibitors with the selectivity for CDK5 are under development as new anti-
cancer treatments and they have a common effect of inducing cell apoptosis 87, 88, which makes them 
unsuitable as new therapeutics for cardiac diseases. Moreover, some of the inhibitors with the selectivity 
for CDK5 such as PHA-793887, which showed beneficial effects on the phenotypes in Timothy syndrome 
cardiomyocytes in our tests, demonstrated significant side effects in clinical trials 89.  Overall, due to the 
concerns mentioned above, currently-available CDK5 inhibitors are not ideal as lead compounds to be 
developed into new therapeutics for cardiac diseases. Thus it is still necessary for us to search for new 
therapeutic targets and compounds for Timothy syndrome. A therapeutic compound that is effective and 
has little or tolerable side effects, ideally an FDA-approved drug, would be preferred as new therapeutics 
for Timothy syndrome.  
In addition to a direct inhibition of CDK5, inhibiting the CDK5 activator p35 will also lead to a 
reduction in CDK5 activity in Timothy syndrome cardiomyocytes, which will alleviate the phenotypes in 
Timothy syndrome cardiomyocytes through the mechanism we proposed in chapter 2.  We found that there 
is no currently-available chemical inhibitors for p35 and we searched for alternative approaches to affect 
p35 protein expression. A previous report indicated that the sigma-1 receptor could be involved in the 
regulation of the protein degradation of CDK5 activator p35 in neurons and the knock-down of the sigma-1 
receptor induced an accumulation of p35 protein in neurons 90.  This report drew our attention to the sigma-
1 receptor.  
The sigma-1 receptor is encoded by the SIGMAR1 gene in human and is one of two sigma receptor 
subtypes. The sigma receptor was first identified in 1976 and mis-classified as a subclass of opioid 
receptors due to the fact that it responded to the opioid receptor agonist SKF-10,047 91. Further studies 
indicated that the SKF-10,047 compound is a racemic compound. (–)-SKF-10,047 binds to and activates 
the Mu (µ) and Kappa (κ) types of opioid receptors. (+)-SKF-10,047 has a low affinity for opioid receptors 
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but has a high affinity for the sigma receptor 92. This finding revealed that the sigma receptor is a distinct 
class of receptors. So far two types of sigma receptor have been reported based on their different molecular 
weight and affinity for (+)-benzomorphans, and they are named as the sigma-1 receptor and the sigma-2 
receptor 93. Among the two types, the sigma-1 receptor is better characterized while the structure and 
function of the sigma-2 receptor are still under intensive investigation.  
Based on the public database, the sigma-1 receptor is expressed in many organs and tissues 
including the brain and the heart 94. Inside a cell, without the stimulation of an agonist, the sigma-1 receptor 
is a endoplasmic reticulum (ER) protein that localizes to the mitochondrion-associated ER membrane 
(MAM) 95. The sigma-1 receptor does not have its own signaling cascade but acts through translocation 
and interaction with its targets to modulate the activity of the targets. Under the stimulation of an agonist, 
the sigma-1 receptor can translocate from the MAM to plasma membrane, cytoplasm and nuclear envelope 
to interact with other receptors, ion channels, kinases and chromatin-remodeling factors to exhibit its effects 
96. It has been called “a pluripotent modulator” due to the fact that it interacts with various cellular targets 
and it has been implicated in the pathogenesis of many diseases such as Alzheimer’s disease, Parkinson’s 
disease, stroke, neuropathic pain and cancer 96. Many studies have also reported the potential beneficial 
effects of sigma-1 receptor agonists in treating neurodegenerative diseases 97, 98 and neuropsychiatric 
diseases 99, 100. 
As mentioned before, one previous study indicated that the sigma-1 receptor could be involved in 
the regulation of the protein degradation of CDK5 activator p35 in neurons and the knock-down of the 
sigma-1 receptor induced an accumulation of p35 protein in neurons 90. In addition, one of the proposed 
mechanisms underlying the beneficial effects of sigma-1 receptor activation on neurodegenerative diseases 
is to modulate calcium homeostasis.  Previous reports demonstrated that the treatment with sigma-1 
receptor agonists such as 1,3-di-o-tolyl-guanidine (DTG), carbetapnetane, (+)-pentazocine, (+)-SKF-
10,047 and PRE-084 attenuated the abnormal increase in intracellular calcium concentration in an in vitro 
model of ischemia, and the potassium chloride (KCl) or glutamate stimulated increase in intracellular 
calcium concentration in rat neurons 101, 102. Based on the literature, we hypothesized that the treatment of 
sigma-1 receptor agonists would be beneficial for Timothy syndrome cardiomyocytes, which feature an 
increased expression of p35 protein and a dysregulation of calcium homeostasis.  
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We chose two sigma-1 receptor agonists and examined their effects on the phenotypes in Timothy 
syndrome cardiomyocytes. The two sigma-1 receptor agonists are Fluvoxamine and PRE-084. The 
rationale to choose Fluvoxamine is that it is a FDA-approved selective serotonin reuptake inhibitor (SSRI) 
for treating obsessive compulsive disorder in the United States 103.  Clinical trials and practice demonstrate 
that Fluvoxamine is a relatively safe drug that has no significant side effects on the cardiac parameters and 
it has been approved to be used in children for treating obsessive compulsive disorder 103. Recent studies 
show that aside from being an SSRI, Fluvoxamine is also a potent sigma-1 receptor agonist, and the sigma-
1 receptor agonism induced by Fluvoxamine treatment has been putatively linked to the improved cognitive 
functions in patients treated with Fluvoxamine 104.  If the treatment of Fluvoxamine is beneficial for Timothy 
syndrome cardiomyocytes, the drug could be potentially used directly to treat the cardiac arrhythmias in 
Timothy syndrome patients who are usually children in the future. The other compound PRE-084 is a highly-
selective sigma-1 receptor agonist with a 50,000-fold higher selectivity for the sigma-1 receptor over any 
other receptors 105. If the treatment of PRE-084 is beneficial for Timothy syndrome cardiomyocytes, the 
compound could be further optimized and developed into novel therapeutic compounds for Timothy 
syndrome in the future.  
In this chapter, we first examined the effects of Fluvoxamine and PRE-084 on the reported 
phenotypes in Timothy syndrome cardiomyocytes. Next we investigated the effects of Fluvoxamine and 
PRE-084 on the functions of control cardiomyocytes. The results reveal that the sigma-1 receptor could be 
a new potential therapeutic target for Timothy syndrome, and Fluvoxamine or PRE-084 treatment alleviates 
the phenotypes in Timothy syndrome cardiomyocytes.  
 
Results 
The effects of Fluvoxamine on the phenotypes in Timothy syndrome cardiomyocytes 
We first examined the effects of Fluvoxamine on the reported phenotypes in Timothy syndrome 
cardiomyocytes. The results showed that Fluvoxamine treatment significantly decreased the contraction 
irregularity and increased the spontaneous beating rate of Timothy syndrome cardiomyocytes in the 
contraction assay (Figure 3.1A and 3.1B). Moreover, the treatment of Fluvoxamine significantly enhanced 
the voltage-dependent inactivation of CaV1.2 channels in Timothy syndrome cardiomyocytes (Figure 3.1C-
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3.1E). Lastly, Fluvoxamine treatment alleviated the abnormal spontaneous calcium transients in Timothy 
syndrome cardiomyocytes (Figure 3.1F-3.1H). Overall, the results reveal that the treatment of Fluvoxamine 
is beneficial for Timothy syndrome cardiomyocytes.  
To investigate whether the beneficial effects of Fluvoxamine on Timothy syndrome cardiomyocytes 
are associated with its effect in activating the sigma-1 receptor,  we examined the effects of Fluvoxamine, 
NE-100106 and paroxetine107 on the irregular and slow contractions in Timothy syndrome cardiomyocytes. 
The results demonstrated that the beneficial effects of the sigma-1 receptor agonist Fluvoxamine on the 
irregular and slow contractions in Timothy syndrome cardiomyocytes were blocked by a co-treatment of the 
sigma-1 receptor antagonist NE-100 with Fluvoxamine. The treatment of Paroxetine, which has a low 
affinity for the sigma-1 receptor and the same affinity as Fluvoxamine for the serotonin reuptake transporter, 
did not significantly change the irregular and slow contractions in Timothy syndrome cardiomyocytes 
(Figure 3.1I and 3.1J). Overall, the results validated the sigma-1 receptor as the primary target that 
accounts for the beneficial effects of Fluvoxamine on the phenotypes in Timothy syndrome cardiomyocytes.  
The effects of PRE-084 on the phenotypes in Timothy syndrome cardiomyocytes 
We next examined the effects of PRE-084 on the phenotypes in Timothy syndrome 
cardiomyocytes. We found that PRE-084 treatment significantly decreased the contraction irregularity and 
increased the spontaneous beating rate in Timothy syndrome cardiomyocytes (Figure 3.2A and 3.2B). 
Moreover, two-hour 5 μM PRE-084 treatment significantly enhanced the voltage-dependent inactivation of 
CaV1.2 channels in Timothy syndrome cardiomyocytes while the acute treatment (less than one min) of 
5 μM PRE-084 did not significantly change the voltage-dependent inactivation of CaV1.2 channels in 
Timothy syndrome cardiomyocytes (Figure 3.2C-3.2F). In addition, PRE-084 treatment rescued the 
abnormal spontaneous action potentials in Timothy syndrome cardiomyocytes (Figure 3.2G and 3.2H). 
Finally, PRE-084 treatment alleviated the abnormal spontaneous calcium transients in Timothy syndrome 
cardiomyocytes (Figure 3.2I-3.2K). Overall, the results indicate that PRE-084 has beneficial effects on the 
reported phenotypes in Timothy syndrome cardiomyocytes. 
The effects of Fluvoxamine and PRE-084 on the functions of control cardiomyocytes 
To investigate whether Fluvoxamine or PRE-084 treatment has significant side effects on cardiac 
function, we examined the effects of Fluvoxamine and PRE-084 on the functions of control cardiomyocytes 
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derived from the iPSCs generated from healthy donors. We first examined the effects of these two 
compounds on the contractions of control cardiomyocytes. The treatment of 5 μM Fluvoxamine or PRE-
084 for two hours significantly enhanced the spontaneous beating rate of control cardiomyocytes but did 
not significantly affect the contraction regularity of the control cardiomyocytes (Figure 3.3A and 3.3B). We 
next examined the effects of Fluvoxamine and PRE-084 on the spontaneous normal calcium transients in 
control cardiomyocytes. We found that the treatment of Fluvoxamine or PRE-084 did not significantly affect 
the normal calcium transients, calcium transient duration or half decay time in control cardiomyocytes 
(Figure 3.3C-3.3H). In summary, the results indicate that there is no significant side effects of Fluvoxamine 
or PRE-084 treatment on the regular contractions and calcium transients in control cardiomyocytes.  
The effects of Fluvoxamine and PRE-084 on the protein expression of p35 and the activity of CDK5 in 
Timothy syndrome cardiomyocytes 
As mentioned in the introduction, a previous study indicated that the sigma-1 receptor could be 
involved in the regulation of the protein degradation of CDK5 activator p35 in neurons 90. Thus we tested 
the hypothesis that the treatment of Fluvoxamine or PRE-084 alleviates the phenotypes in Timothy 
syndrome cardiomyocytes by reducing p35 protein expression. We examined the protein expression of p35 
before and two hours after the treatment of 5 μM Fluvoxamine or PRE-084 in Timothy syndrome 
cardiomyocytes, and found that the protein expression of p35 was not significantly changed by the two-
hour treatment of 5 μM Fluvoxamine or PRE-084 (Figure 3.4A and 3.4B). This result demonstrates that 
changing the p35 protein expression is not one of the mechanisms underlying the beneficial effects of two-
hour 5 μM Fluvoxamine or PRE-084 treatment on the phenotypes in Timothy syndrome cardiomyocytes. 
We next examined the effect of two-hour 5 μM PRE-084 treatment on the endogenous CDK5 activity in 
Timothy syndrome cardiomyocytes. We found that two-hour 5 μM PRE-084 treatment significantly 
decreased the endogenous CDK5 activity in Timothy syndrome cardiomyocytes compared with the Timothy 
syndrome  cardiomyocytes without treatment (Figure 3.4C), indicating that one of the potential mechanisms 
underlying the beneficial effects of PRE-084 on the phenotypes in Timothy syndrome cardiomyocytes could 
be that the treatment of PRE-084 reduced the endogenous CDK5 activity in Timothy syndrome 
cardiomyocytes and alleviated the phenotypes in Timothy syndrome cardiomyocytes through the 




In this chapter, we tested the hypothesis that the treatment of sigma-1 receptor agonist 
Fluvoxamine or PRE-084 is beneficial for Timothy syndrome cardiomyocytes. We found that Fluvoxamine 
treatment and PRE-084 treatment alleviated the previously-reported phenotypes in Timothy syndrome 
cardiomyocytes potentially through activating the sigma-1 receptor. As the first attempt to investigate the 
mechanisms underlying the beneficial effects of Fluvoxamine and PRE-084 on Timothy syndrome 
cardiomyocytes, we tested the hypothesis that the treatment of Fluvoxamine or PRE-084 alleviates the 
phenotypes in Timothy syndrome cardiomyocytes by reducing p35 protein expression. Although the result 
showed that two-hour 5 μM Fluvoxamine or PRE-084 treatment did not significantly change p35 protein 
expression in Timothy syndrome cardiomyocytes, we found that the two-hour 5 μM PRE-084 treatment 
significantly reduced the endogenous CDK5 activity in Timothy syndrome cardiomyocytes. Overall, the 
result indicated that one of the potential mechanisms underlying the beneficial effects of PRE-084 treatment 
on the phenotypes in Timothy syndrome cardiomyocytes could be reducing CDK5 activity and acting 
through the mechanism we proposed in chapter 2. Although we found that the treatment of sigma-1 receptor 
agonist PRE-084 could reduce CDK5 activity in Timothy syndrome cardiomyocytes, exactly how PRE-084 
treatment or sigma-1 receptor activation modulates CDK5 activity remains unclear and further investigation 
is needed to elucidate the mechanisms. Further investigation is also required to fully characterize the 
mechanisms underlying the beneficial effects of the sigma-1 receptor agonists or sigma-1 receptor 
activation on the phenotypes in Timothy syndrome cardiomyocytes. 
We also speculate that sigma-1 receptor activation may alleviate the phenotypes in Timothy 
syndrome cardiomyocytes by modulating calcium homeostasis. Previous studies have provided evidence 
about the potential interactions between the sigma-1 receptor and molecules that play important roles in 
calcium handling in cardiomyocytes such as the L-type calcium channel and the inositol 1,4,5-trisphosphate 
receptor (IP3R).  First of all, the sigma-1 receptor has been shown to co-immunoprecipitate with CaV1.2 
channels and the sigma-1 receptor agonist SKF-10,047 has been shown to inhibit KCl-induced calcium 
influx in a rat primary retinal ganglion cell line potentially by affecting the L-type calcium channels 108, 
indicating a potential direct interaction between the sigma-1 receptor and CaV1.2 channels. Moreover, 
previous studies have indicated a role of the sigma-1 receptor in regulating the functions of IP3R. The 
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sigma-1 receptor has been shown to associate with IP3R under ER stress and modulate the calcium 
signaling from ER to mitochondria to promote cell survival in CHO cells 95. In addition, two previous studies 
also demonstrated that the sigma-1 receptor modulated the calcium release from ER in a neuronal cell line 
109, 110. Furthermore, another previous study indicated that the treatment of a selective sigma-1 receptor 
agonist  caused an activation of phospholipase C, an elevation of intracellular inositol trisphosphate (IP3) 
level and a release of calcium from sarcoplasmic reticulum in adult rat ventricular cardiomyocytes 111.  
Although all of the previous studies are conducted under normal physiological conditions instead of disease 
conditions, the findings indicate that the sigma-1 receptor may modulate the functions of IP3R and affect 
calcium homeostasis under disease conditions. Further studies are needed to characterize the mechanisms 
underlying the beneficial effects of the sigma-1 receptor agonists on Timothy syndrome and the potential 
effects of sigma-1 receptor activation in modulating calcium homeostasis in cardiomyocytes in the future. 
In addition, we found that PRE-084 or Fluvoxamine treatment significantly enhanced the 
spontaneous beating rate of control cardiomyocytes (Figure 3.3A). Two previous studies also indicated 
that the treatment of sigma-1 receptor ligands increased the contractility of neonatal and adult rat 
cardiomyocytes 112, 113.  However the results from the previous reports are difficult to interpret because the 
studies were conducted before the highly-selective sigma-1 receptor agonists were available and the 
sigma-1 receptor ligands used in the studies were not very selective 112, 113,114,.  Our study is the first to 
examine the effects of a highly-selective sigma-1 receptor agonist PRE-084 on the contractions and calcium 
transients in control cardiomyocytes derived from iPSCs generated from healthy donors, although further 
investigation is necessary to characterize the effects of the sigma-1 receptor agonists on the functions of 
control cardiomyocytes comprehensively. The fact that the treatment with Fluvoxamine or PRE-084 
enhanced the spontaneous beating rate of control cardiomyocytes raises a concern for tachycardia 
potentially induced by the treatment. It would be important to examine the effects of Fluvoxamine or PRE-
084 on the cardiac functions of rodents to evaluate the potential side effects of Fluvoxamine or PRE-084 
treatment in vivo in the future.  
In summary, the results presented in this chapter demonstrate that Fluvoxamine and PRE-084 are 
promising lead compounds that can be optimized and developed into new future therapeutics for Timothy 
syndrome, and that the sigma-1 receptor is a new potential therapeutic target for the disease. 
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Outcome of the study 
U.S. provisional application: 







Figure 3.1: Fluvoxamine treatment alleviated the phenotypes in Timothy syndrome 
cardiomyocytes. (A, B) The analysis of the contraction irregularity and the beating rate of Timothy 
syndrome cardiomyocytes before and 2 hours after 5μM Fluvoxamine (Fluvo) treatment (n=10 from 
one Timothy syndrome line. ***P<0.005; Student’s t-test, paired). The values after the treatment of 
Fluvoxamine were normalized to the corresponding values before the treatment of Fluvoxamine for 
the presentation in this figure. The statistical analysis was conducted using the raw data. (C) 
Representative recordings of Ba2+ currents in the Fluvoxamine (Fluvo, 5μM, 2hr treatment) treated 
and untreated Timothy syndrome cardiomyocyte. (D) Voltage-dependent inactivation percentage 
(VDI%) quantification in the Fluvoxamine (Fluvo, 5μM, 2hr) treated and untreated Timothy syndrome 
cardiomyocytes (n=5 per group from two Timothy syndrome lines. **P<0.01; Student’s t-test). 
Dashed line indicates the average VDI% of control iPSC-derived cardiomyocytes. (E) The current-
voltage relationship of the Ba2+ currents in Timothy syndrome cardiomyocytes with and without 
Fluvoxamine treatment (Fluvo, 5μM, 2hr, n=5 per group from two Timothy syndrome lines). (F) 
Representative spontaneous calcium transient traces from single Timothy syndrome cardiomyocyte 
before and 30 minutes after the treatment of 5μM Fluvoxamine. Fluvoxamine treatment (5μM, 30min) 
alleviated the abnormal spontaneous calcium transients in Timothy syndrome cardiomyocytes. (G, 
H) Quantification of spontaneous calcium transient duration and half decay time in Timothy syndrome 
cardiomyocytes before and after the treatment of 5μM Fluvoxamine for 30 minutes. Fluvoxamine 
treatment (Fluvo, 5μM, 30min) significantly reduced the spontaneous calcium transient duration and 
half decay time in Timothy syndrome cardiomyocytes (n=52 from two Timothy syndrome lines. 
*P<0.05; Student’s t-test, paired).  (I, J) The analysis of the contraction irregularity and the beating 
rate of Timothy syndrome cardiomyocytes before and 2 hours after the treatment of compound(s). 
The beneficial effects of Fluvoxamine (Fluvo, 5μM, 2hr) were blocked by a co-treatment of a sigma-
1 receptor antagonist NE-100 (5μM, 2hr). Paroxetine (5μM, 2hr) did not have any significant effects 
on the abnormal contractions in Timothy syndrome cardiomyocytes (n=10 from one Timothy 
syndrome line. **P<0.01, ****P<0.001; Student’s t-test, paired).  The values after the treatment of the 
compound(s) were normalized to the corresponding values before the treatment of the compound(s) 
for the presentation in this figure. The statistical analysis was conducted using the raw data. All data 
are mean ± s.e.m. 





Figure 3.2: PRE-084 treatment alleviated the phenotypes in Timothy syndrome 
cardiomyocytes. (A, B) The analysis of the contraction irregularity and the beating rate of Timothy 
syndrome cardiomyocytes before and 2 hours after 5μM PRE-084 treatment (n=10 from one Timothy 
syndrome line. *P<0.05, ****P<0.001; Student’s t-test, paired). The values after the treatment of PRE-
084 were normalized to the corresponding values before the treatment of PRE-084 for the 
presentation in this figure. The statistical analysis was conducted using the raw data. (C) 
Representative recordings of Ba2+ currents in the PRE-084 (PRE, 5μM, 2hr treatment) treated and 
untreated Timothy syndrome cardiomyocyte. (D) Voltage-dependent inactivation percentage (VDI%) 
quantification in the PRE-084 (5μM, 2hr) treated and untreated Timothy syndrome cardiomyocytes 
(n=4 for the control group without treatment, and n=5 for the group with PRE-084 treatment, from 
two Timothy syndrome lines. **P<0.01; Student’s t-test). Dashed line indicates the average VDI% of 
control iPSC-derived cardiomyocytes. (E) Representative recordings of Ba2+ currents in the PRE-
084 (PRE, 5μM, <1min, acute treatment) treated and untreated Timothy syndrome cardiomyocyte. 
(F) Voltage-dependent inactivation percentage quantification in the acute PRE-084 treated and 
untreated Timothy syndrome cardiomyocytes (acute treatment of PRE-084, <1min; n=4 per group 
from two Timothy syndrome lines. n.s., not significant; Student’s t-test). (G) Representative action 
potential recordings from Timothy syndrome cardiomyocyte with and without PRE-084 treatment 
(5μM, 2hr). Arrowheads show putative delayed afterdepolarizations (DADs). (H) Quantification of 
action potential durations (APD50 and APD90) from Timothy syndrome cardiomyocytes with and 
without PRE-084 treatment (5μM, 2hr) (n=4 for the control group without treatment, and n=5 for the 
group with PRE-084 treatment, from two Timothy syndrome lines. **P<0.01; Student’s t-test). (I) 
Representative spontaneous calcium transient traces from single Timothy syndrome cardiomyocyte 
before and 30 minutes after the treatment of 5μM PRE-084. PRE-084 treatment (5μM, 30min) 
alleviated the abnormal spontaneous calcium transients in Timothy syndrome cardiomyocytes. (J, 
K) Quantification of spontaneous calcium transient duration and half decay time in Timothy syndrome 
cardiomyocytes before and after the treatment of 5μM PRE-084 for 30 minutes. PRE-084 treatment 
(5μM, 30min) significantly reduced the spontaneous calcium transient duration and half decay time 
in Timothy syndrome cardiomyocytes (n=44 from two Timothy syndrome lines. **P<0.01; Student’s 
t-test, paired). All data are mean ± s.e.m. 
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Figure 3.3: The effects of PRE-084 or Fluvoxamine treatment on the functions of control 
cardiomyocytes. (A, B) The analysis of the contraction irregularity and the beating rate of control 
cardiomyocytes before and 2 hours after 5μM Fluvoxamine (Fluvo) or PRE-084 treatment (n=25 from 
three control lines. ***P<0.005; Student’s t-test, paired). The values after the treatment of 
Fluvoxamine or PRE-084 were normalized to the corresponding values before the treatment of 
Fluvoxamine or PRE-084 for the presentation in this figure. The statistical analysis was conducted 
using the raw data. (C) Representative spontaneous calcium transient traces from single control 
cardiomyocyte before and 30 minutes after the treatment of 5μM Fluvoxamine. Fluvoxamine 
treatment (5μM, 30min) did not have significant effects on the calcium transients in control 
cardiomyocytes. (D, E) Quantification of spontaneous calcium transient duration and half decay time 
in control cardiomyocytes before and after the treatment of 5μM Fluvoxamine (Fluvo) for 30 minutes. 
Fluvo treatment (5μM, 30min) did not have significant effects on the spontaneous calcium transient 
duration and half decay time in control cardiomyocytes (n=35 from two control lines. n.s., not 
significant; Student’s t-test, paired). (F) Representative spontaneous calcium transient traces from 
single control cardiomyocyte before and 30 minutes after the treatment of 5μM PRE-084. PRE-084 
treatment (5μM, 30min) did not have significant effects on the calcium transients in control 
cardiomyocytes. (G, H) Quantification of spontaneous calcium transient duration and half decay time 
in control cardiomyocytes before and after the treatment of 5μM PRE-084 for 30 minutes. PRE-084 
treatment (5μM, 30min) did not have significant effects on the spontaneous calcium transient duration 
and half decay time in control cardiomyocytes (n=36 from two control lines. n.s., not significant; 






Figure 3.4: The effect of Fluvoxamine or PRE-084 treatment on p35 protein expression and 
the activity of CDK5 in Timothy syndrome cardiomyocytes. (A) Representative images of p35 
protein expression before and after the treatment of 5μM Fluvoxamine (Fluvo) or PRE-084. (B) 
Quantification of p35 protein expression before and 2 hours after the treatment of 5μM Fluvoxamine 
(Fluvo) or PRE-084 (n=14 for TS control and n=9 for Fluvo or PRE-084 treated group from one 
Timothy syndrome line. n.s., not significant; One-way ANOVA with Dunnett’s post-hoc; Data are 
mean ± s.e.m.). (C) The effect of two-hour 5μM PRE-084 treatment on the endogenous CDK5 activity 
in Timothy syndrome (TS) cardiomyocytes. TS cardiomyocytes were either untreated or treated with 
5μM PRE-084 for two hours before being collected for CDK5 kinase activity assay (n=8 for TS control 
group and n=8 for PRE-084 treated TS group from one Timothy syndrome line. *P<0.05; Student’s 






Control and Timothy syndrome iPSCs were generated using a virus-free method from the skin 
fibroblasts and characterized as described previously 54. Mycoplasma tests were conducted using 
MycoAlert (Lonza) when the iPSC lines were generated. iPSCs were cultured with Essential 8 media with 
100 unit/ml penicillin and 100 μg/ml streptomycin on plates or dishes (Corning) coated with Geltrex 
(#A14133-022, from Life Technologies) following the manufacturer’s instruction. The iPSC lines were 
maintained and passaged following the previously-reported protocol using dispase (Life technologies) 54. 
The iPSCs were differentiated into cardiomyocytes following the monolayer-based protocol reported 
previously 54. Human iPSC-derived cardiomyocytes were maintained in EB5 media: DMEM/F12 medium 
with GlutaMAX (Life Technologies) containing 5 % fetal bovine serum (FBS, Hyclone, Thermo Scientific), 
1mM non-essential amino acids (Life Technologies), 0.1mM beta-mercaptoethanol (Sigma-Aldrich), 100 
unit/ml penicillin and 100 μg/ml streptomycin. All cells were cultured in HERAcell 150i (Thermo Scientific) 
incubators and culture procedures were conducted in the Biosafety Cabinet Class II type A2 tissue culture 
hoods (Labconco). 
 
Preparation of chemical compounds 
Fluvoxamine maleate (F2802, Sigma-Aldrich, >98 % HPLC) and Paroxetine hydrochloride 
hemihydrate (P9623, Sigma-Aldrich, >98 % HPLC) were purchased from Sigma-Aldrich and dissolved in 
distilled water. The stock concentration is 10 mM. PRE-084 hydrochloride (Cat. No. 0589, >99 % HPLC) 
and NE-100 hydrochloride (Cat. No. 3133, >98 % HPLC) were purchased from TOCRIS and dissolved in 
distilled water. The stock concentration is 25 mM. All the stock solutions were stored at -80 oC and thawed 
only once or twice after made. 
 
The analysis of cardiomyocyte contractions for compound tests 
The working solution of each compound was made by diluting the stock solution in EB5 media to a 
final concentration of 5 μM. The contraction analysis was performed as reported previously 24. In brief, 
images were collected at a rate of 5 frames per second using the NIS-elements software (Nikon) and 
	
88 
converted to multi-frame TIFF images for analysis using the NIS-elements viewer. The multiple-frame TIFF 
images were processed using the Image Processing Toolbox in MATLAB R2009b (Mathworks). Relative 
motion between successive frames was quantified by subtracting each frame from the preceding frame and 
summing across all pixels. Movement was calculated by plotting the relative motion over time. Contractions 
were detected as a peak of relative motion and a second, typically smaller peak, corresponded to the 
relaxation of the cardiomyocytes. Peaks were selected manually and the rate of contraction was measured. 
The length of time between contractions was also measured and contraction irregularity was measured by 
calculating the ratio of the standard deviation to the mean of the intervals between contractions. The 
Timothy syndrome cardiomyocytes were used for the tests at day 21-22 after cardiac differentiation. The 
movies were taken before the treatment, and 2 hours after the treatment. The cardiomyocytes from one 
Timothy syndrome iPSC line (clone#: TS1-E3-5) were used mainly for the tests and the cardiomyocytes 
from another independent Timothy syndrome iPSC line (clone#: TS2-E7-1) were used for validation. The 
contraction rate and irregularity values of each sample before and after treatment were compared using 
paired Student’s t-test. The contraction rate and irregularity values of each sample after treatment were 
normalized to its respective values before treatment in the corresponding figures. 
 
Electrophysiology 
The Timothy syndrome iPSCs were differentiated into cardiomyocytes following a protocol reported 
previously 54. The cell clusters were isolated from the monolayer cardiomyocytes and re-plated into gelatin-
coated wells in 6-well plates at day 16. The cells were dissociated at day 31 after differentiation and used 
for electrophysiological recordings between day 35 to day 45. The before-treatment recordings were 
obtained from Timothy syndrome cardiomyocytes without treatment, except for the acute effect test of 5 μM 
PRE-084. The after-treatment recordings were conducted with Timothy syndrome cardiomyocytes treated 
with 5 μM PRE-084 or Fluvoxamine in EB5 media for two hours, except for the acute effect test of 5 μM 
PRE-084. For the acute effect test of 5 μM PRE-084 treatment, the basal recording was first obtained from 
the cell and the cell was then treated with 5 μM PRE-084 in the extracellular solution for less than 1 minute. 
Next a second recording was obtained from the same cell.  
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Whole-cell patch clamp recordings of Timothy syndrome iPSC-derived cardiomyocytes were 
conducted using a MultiClamp 700B patch-clamp amplifier (Molecular Devices) and an inverted microscope 
equipped with differential interface optics (Nikon, Ti-U). The glass pipettes were prepared using borosilicate 
glass (Sutter Instrument, BF150-110-10) and a micropipette puller (Sutter Instrument, Model P-97). 
Voltage-clamp measurements were conducted using an extracellular solution consisting of 5mM BaCl2, 
160mM TEA-Cl and 10mM HEPES (pH7.4 at 25 oC) and a pipette solution of 125mM CsCl, 0.1mM CaCl2, 
10mM EGTA, 1mM MgCl2, 0.3mM TrisGTP and 10mM HEPES (pH 7.4 adjusted with CsOH at 25 oC). The 
protocol was that cells were held at -90mV and then depolarized to -10mV for 400 ms at a rate of 0.1 Hz 
for the Ba2+ current recordings; cells were held at -90 mV, stimulated with a 2-s family of pulses from -90 to 
+20mV for the current-voltage relationship of Ba2+ currents. The recordings were conducted under room 
temperature.  The voltage-dependent inactivation percentage is defined as the Ba2+ current intensity at 
350ms from the peak divided by the peak current intensity. The data points to plot the representative traces 
were normalized to the respective peak current value of the trace and therefore the traces were labeled as 
“1.0 (relative)”. The values used to plot the current-voltage relationship of the Ba2+ currents were normalized 
to their respective peak current value before being used for the grouped analysis, and therefore the Y axis 
of Figure 3.1E was labeled as “Relative Ba2+ current”. 5 μM PRE-084 or Fluvoxamine were added to the 
extracellular solution during the recordings.  
Current-clamp recordings were conducted in normal Tyrode solution containing 140mM NaCl, 
5.4mM KCl, 1mM MgCl2, 10mM glucose, 1.8mM CaCl2 and 10mM HEPES (pH7.4 with NaOH at 25 oC) 
using the pipette solution: 120mM K D-gluconate, 25mM KCl, 4mM MgATP, 2mM NaGTP, 4mM Na2-
phospho-creatin, 10mM EGTA, 1mM CaCl2 and 10mM HEPES (pH 7.4 with HCl at 25 oC). The recordings 
were conducted at 37 oC. Recorded action potentials were analyzed using Clampfit 10.4 (Axon 
Instruments). The spontaneous action potential duration (action potential duration at 50% of repolarization 
(APD50) and action potential duration at 90% of repolarization (APD90)) values from the Timothy syndrome 
cardiomyocytes before and after the treatment of 5 μM PRE-084 were analyzed and compared using 






Calcium imaging and the analysis of calcium transient traces 
The control and Timothy syndrome iPSCs were differentiated into cardiomyocytes following a 
protocol reported previously 54. The cell clusters were isolated from the monolayer cardiomyocytes and re-
plated into gelatin-coated wells in 6-well plates at day 16. The cells were dissociated at day 31 after 
differentiation and used for calcium imaging between day 35 to day 45. The Nikon automatic microscope 
(Nikon Eclipse TiE with a motorized stage) connected to sCMOS camera (Andor Zyla sCMOS 4.2 MP) 
together with a stage top incubator (at 37oC, 5% CO2 and 20% O2, controlled by TOKAI HIT Hypoxia gas 
delivery system) was used for this experiment. Nikon objective lens 40x (Nikon CFI Plan Apo Lambda, NA 
0.95) was used for single cell recordings and EB5 media were used as bath solution. The cells were loaded 
with Fluoforte calcium dye for calcium imaging following the manufacturer’s instruction (ENZ-51016, Enzo 
Life Sciences). A basal recording was acquired from each cell before the treatment of each compound and 
after the basal recording, the solution was changed to EB5 media with 5 μM Fluvoxamine or PRE-084. 30 
minutes after the treatment of 5 μM Fluvoxamine or PRE-084, a second recording was acquired from the 
same cell. We found that the functions of the single cell were damaged by dye toxicity at two hours after 
any treatment and many cells were no longer recordable at two hours after treatment. Therefore the 
experiments to examine the effects of two-hour 5 μM Fluvoxamine or PRE-084 treatment on the calcium 
transients in Timothy syndrome cardiomyocytes or control cardiomyocytes were not conducted. The 
calcium transient duration and the calcium transient half (50%) decay time from the recordings before and 
after treatment were analyzed. The calcium transient duration is defined as the average time interval 
between the starting point of the upstroke of the transient and the ending point by which the transient 
decayed back to the baseline. The calcium transient half decay time is defined as the average time interval 
between the point of the peak and the point at 50% decay of the peak. Paired student’s t-test was used for 
statistics.  
 
Western blot analysis 
Anti-p35 antibody (Rabbit polyclonal Ab, Catalog # sc-820, Clone # C-19, 1: 1,000 dilution, Santa 
Cruz) and Anti-beta-tubulin antibody (Mouse mAb, Catalog # T5201, Clone # TUB 2.1, 1:4,000 dilution, 
Sigma-Aldrich) were used for western blotting.  
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For western blot analysis, the cardiomyocytes were used at day 26 or day 27 after differentiation. 
Some of the Timothy syndrome cardiomyocytes were treated with 5 μM PRE-084 or Fluvoxamine in EB5 
media for one or two hours before being collected for western blot analysis. The Timothy syndrome 
cardiomyocytes without treatment from the same round of differentiation were collected as controls. The 
cells were isolated from the monolayer and lysed with the cell lysis buffer containing 1% Triton X-100, 50mM 
Tris-HCl, 150mM NaCl, 250mM sucrose, 1x protease inhibitor cocktail (Catalog # P8340, Sigma-Aldrich), 
pH 7.4. The concentration of total proteins in each sample was measured using a standard bicinchoninic 
acid (BCA) assay kit (Pierce Biotechnology). Next, 20 μg of proteins from each sample were aliquoted and 
denatured with the sample buffer containing Urea (2x stock, 8M Urea, 40 mM Tris-HCl, 2% sodium dodecyl 
sulfate (SDS), 10% beta-mercaptoethanol and 0.01% bromophenol blue) and being boiled for 5 minutes at 
95 oC. The samples were loaded to the Tris-HCl based SDS-PAGE gels with 5% stacking gel and 10% 
separation gel along with the ladder. The proteins were then electro-transferred to PVDF-membranes using 
the XCell SureLockTM Mini-Cell system overnight. Next day, the membranes were blocked with the 
SuperBlock Blocking buffer (Thermo Scientific) for 30 minutes at room temperature and incubated with the 
primary antibody (diluted in the SuperBlock Blocking buffer) overnight at 4oC. On the third day, the 
membranes were incubated with the corresponding secondary antibody (1:8,000 dilution in the SuperBlock 
Blocking buffer) for 30 minutes at room temperature and then incubated with the Pierce ECL western 
blotting substrate followed by exposing to X-ray films in a dark room. For sequential immunoblotting, the 
membranes were stripped with the stripping buffer containing 62.5mM Tris-HCl, 2% SDS, 114mM beta-
mercaptoethanol at 42oC for 15-20 minutes, and washed six times with PBS. The stripped membranes 
were then re-blocked with the SuperBlock Blocking buffer for the next immunoblotting. For the 
immunoblotting of beta-tubulin, the membrane was stripped, re-blocked with the SuperBlock Blocking buffer 
and incubated with the anti-beta-tubulin antibody at room temperature for 30 minutes. The rest of the steps 
were the same. The western blot analysis to examine p35 protein expression in Timothy syndrome 
cardiomyocytes before and after 5 μM Fluvoxamine treatment was repeated eight times with independent 
samples from different rounds of differentiation for validation. The western blot analysis to examine p35 
expression in Timothy syndrome cardiomyocytes before and after 5 μM PRE-084 treatment was repeated 
seven times with independent samples from different rounds of differentiation for validation. Western blot 
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band intensities were quantified using Image J and the values were normalized to the corresponding beta-
tubulin band intensities. The values from Timothy syndrome cardiomyocytes two hours after the treatment 
of 5 μM PRE-084 or Fluvoxamine were normalized to the values from Timothy syndrome cardiomyocytes 
without treatment for the presentation in Figure 3.4B.  
 
In Vitro CDK5 activity assay 
To examine the effect of 5 μM PRE-084 treatment on the endogenous CDK5 activity, an CDK5 
activity assay was conducted following the previously reported protocols 85, 86 with some modifications. 
Cardiomyocytes differentiated from Timothy syndrome iPSCs were used at day 26 or day 27 for the assay. 
Timothy syndrome cardiomyocytes were not treated or treated with 5 μM PRE-084 for two hours in EB5 
media before being isolated from monolayer culture and lysed with the cell lysis buffer containing 1% NP-
40, 20mM Tris-HCl, 137mM NaCl, 1x protease inhibitor cocktail, 1x phosphatase inhibitor cocktail 3 
(Catalog # P0044, Sigma-Aldrich) and 1x phosphatase inhibitor cocktail (Catalog # P8340, Sigma-Aldrich), 
pH 7.4. Protein concentrations in the samples were measured using a standard bicinchoninic acid (BCA) 
assay kit. 40 μg of proteins from each sample were aliquoted and used as one sample for CDK5 
immunoprecipitation. The samples were incubated with CDK5 antibody-conjugated agarose beads (cdk5 
(J-3) AC, catalog #:sc-6247 AC, Santa Cruz Biotechnology) for 2 hours at 4 oC (rocking continuously) for 
CDK5 immunoprecipitation. 5μl resuspended bead solution was used for the immunoprecipitation of CDK5 
from each sample. Next, the beads were washed three times with cold TBS and twice with room-
temperature TBS. A reaction mixture containing 1X Reaction Buffer A, 50 μM DTT, 50 μM ATP, 1 μg Histone 
H1 in distilled water was added to each sample for detecting CDK5 activity. A series of samples for a 
standard curve were prepared based on the manufacturer’s instructions to determine the ATP-ADP 
conversion values from the luminescence signals in every round of experiment. The kinase reaction tubes 
with the reaction mixtures were incubated at 26-27 oC for 60 minutes for the kinase reaction. The ADP-
GloTM reagent was then added to the reactions for an incubation of 40 minutes at 26-27 oC to deplete the 
ATP in the reactions. Next the detection reagent was added to the reactions for an incubation of 45 minutes 
at 26-27 oC. 20ul of the sample from each tube was then transferred into a 96 well microplate and the 
luminescence was measured with the GloMax® 96 Microplate Luminometer (Promega) with an integration 
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time of 1.5s. The luminescence values were converted into the ATP-ADP conversion values based on the 
standard curve. Four rounds of experiment were conducted. The values from each round of experiment 
were normalized to the average value of the Timothy syndrome cardiomyocyte samples without PRE-084 
treatment in the same round of experiment before being pooled together for the final analysis that is showed 
in Figure 3.4C.  
 
Statistics 
The statistics used for every figure have been indicated in the corresponding figure legends. The 
Student’s t-test (paired and unpaired) was conducted with the t-test function in Microsoft Excel software. F-
test was conducted before the t-test to determine whether the samples have equal variance in Microsoft 
Excel software. The Student’s t-test was two tails. The One-way ANOVA with Dunnett’s post-hoc analyses 
for multiple comparisons was conducted with the Graphpad prism software. All the data meet the 
assumptions of the statistical tests. All the samples used in this study were biological repeats, not technical 



















Chapter 4:  
Conclusions and future directions 




Human iPSC-based models of cardiac diseases, which compensate for the scarcity of primary 
human cardiomyocytes, have been widely used for scientific research in recent decades. Many studies 
have used human iPSC-based models of cardiac diseases to examine disease phenotypes and confirm 
the association of a specific mutation with the phenotypes. Very few studies, if any, have used human iPSC-
based models of cardiac diseases to search for new therapeutics for cardiac diseases. This thesis presents 
a proof of concept that the iPSC-based models of cardiac diseases can be used to generate novel insights 
into disease pathogenesis, and to identify new therapeutic targets and compounds for cardiac diseases, 
and in particular for Timothy syndrome.  
In chapter 1, we developed new protocols for the generation of iPSCs from human somatic cells 
and the differentiation of iPSCs into cardiomyocytes. The new protocols are technically simple and generally 
applicable for samples from both healthy donors and patients with cardiac diseases. Using the monolayer 
cardiac differentiation protocol, we were able to stably generate a large amount of cardiomyocytes from 
both control iPSCs and Timothy syndrome iPSCs at an acceptable cost, which became the foundation for 
the subsequent chemical tests and mechanistic studies. In addition, we found that Timothy syndrome 
cardiomyocytes demonstrated slow and irregular contractions as isolated cell clusters or in the original 
monolayer culture. This phenotype was not affected by the non-cardiomyocyte cell population in the culture, 
which allowed us to use the intact monolayer or the isolated cell clusters for a phenotypic screen to search 
for additional therapeutic compounds for Timothy syndrome.  
In chapter 2, we first conducted a phenotypic screen of chemical compounds (Roscovitine analogs 
and CDK inhibitors) using Timothy syndrome cardiomyocytes. The outcome of the phenotypic screen 
revealed that CDK5 could be involved in the pathogenesis of Timothy syndrome. To validate CDK5 as a 
new therapeutic target for Timothy syndrome, we used two approaches, the expression of a dominant 
negative mutant of CDK5 and the expression of CDK5 shRNA, to inhibit CDK5 in Timothy syndrome 
cardiomyocytes and examined the changes in the phenotypes.  We found that the two approaches exhibited 
similar beneficial effects on the phenotypes of Timothy syndrome cardiomyocytes, indicating that CDK5 
inhibition is beneficial for Timothy syndrome cardiomyocytes.  To investigate the mechanisms underlying 
the beneficial effects of CDK5 inhibition on Timothy syndrome cardiomyocytes, we examined the 
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expression of CDK5 activator p35 and the activity of CDK5. Our results demontrated that Timothy syndrome 
cardiomyocytes showed a higher expression of CDK5 activator p35 and a higher activity of CDK5 compared 
with control cardiomyocytes, indicating an over-activation of CDK5 in Timothy syndrome cardiomyocytes. 
We also found that CDK5 over-expression induced a delay in the inactivation of CaV1.2 channels in control 
cardiomyocytes, which indicated the potential functional changes that an over-activation of CDK5 could 
cause to CaV1.2 channels. Taken together, we propose that in Timothy syndrome cardiomyocytes, there is 
an over-activation of CDK5 caused by an increased expression of p35, which further delays the already-
delayed inactivation of the mutant CaV1.2 channels in the cells. Therefore the inhibition of CDK5 alleviates 
the phenotypes in Timothy syndrome cardiomyocytes. It was also found that CDK5 inhibition only partially 
rescued the phenotypes in Timothy syndrome cardiomyocytes while the correction of the G406R mutation 
in CaV1.2 completely rescued the phenotypes in Timothy syndrome cardiomyocytes. We speculate that the 
treatment with a CDK5-specific inhibitor would alleviate but not completely eliminate the arrhythmias in 
Timothy syndrome patients based on the findings, and additional therapeutics would be required to be used 
in combination with a CDK5-specific inhibitor to completely eliminate the risk of lethal arrhythmias in 
Timothy syndrome patients.  Overall, based on the results, we reasoned that CDK5-specific inhibitors could 
be developed into new therapeutics for Timothy syndrome. However there are several concerns associated 
with the currently-available CDK5-specific inhibitors such as the lack of a high selectivity for CDK5 and 
potential side effects in clinical trials. Optimization of the currently-available CDK5 inhibitors or development 
of new CDK5-specific inhibitors is necessary for the future development of the compounds into new 
therapeutics for Timothy syndrome.  
Chapter 3 focused on the identification of Fluvoxamine and PRE-084 as new therapeutic 
compounds, and the sigma-1 receptor as a new therapeutic target for Timothy syndrome. Due to the 
concerns associated with currently-available CDK5 inhibitors, we made an effort to search for additional 
therapeutics for Timothy syndrome. We reasoned that instead of directly inhibiting CDK5, we could 
potentially alleviate the phenotypes in Timothy syndrome cardiomyocytes by affecting the CDK5 activator 
p35 and this idea led us to the sigma-1 receptor. After we looked into the sigma-1 receptor, we found that 
in addition to being reported to modulate p35 protein level, the sigma-1 receptor had also been reported to 
modulate calcium homeostasis, which is another favorable effect for Timothy syndrome cardiomyocytes. 
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Therefore we hypothesized that the activation of the sigma-1 receptor could be beneficial for Timothy 
syndrome cardiomyocytes, which feature an increased expression of p35 and a dysregulation of calcium 
homeostasis. To test this hypothesis, we examined the effects of two sigma-1 receptor agonists, 
Fluvoxamine and PRE-084, on the phenotypes in Timothy syndrome cardiomyocytes. The results 
demonstrated that the treatment of either agonist could alleviate the phenotypes in Timothy syndrome 
cardiomyocytes. Next, we examined the effects of the agonists on the contractions and calcium transients 
in control cardiomyocytes to evaluate the potential side effects and we found that Fluvoxamine and PRE-
084 treatment did not significantly alter the regular contractions and normal calcium transients in control 
cardiomyocytes at the dose that they exhibited beneficial effects on the phenotypes in Timothy syndrome 
cardiomyocytes. In addition, we investigated whether the treatment of Fluvoxamine or PRE-084 alleviated 
the phenotypes in Timothy syndrome cardiomyocytes by reducing p35 protein expression or CDK5 activity. 
We found that the p35 protein expression in Timothy syndrome cardiomyocytes was not significantly 
changed before and after the treatment of Fluvoxamine or PRE-084, but the endogenous CDK5 activity in 
Timothy syndrome cardiomyocytes was significantly reduced by PRE-084 treatment. The result indicated 
that one of the potential mechanisms underlying the beneficial effects of PRE-084 treatment on the 
phenotypes in Timothy syndrome cardiomyocytes could be reducing CDK5 activity. Further investigation is 
needed to understand exactly how PRE-084 treatment or sigma-1 receptor activation reduces CDK5 activity 
without affecting p35 protein expression. Although the mechanisms underlying the beneficial effects of 
Fluvoxamine and PRE-084 on Timothy syndrome cardiomyocytes are not fully characterized, the overall 
results indicate that with further optimization, Fluvoxamine and PRE-084 could be developed into new 
therapeutics for Timothy syndrome in the future.  
In conclusion, this work is an important step towards the development of novel therapeutics for 
Timothy syndrome. Although there are still some limitations such as the immaturity of the iPSC-derived 
cardiomyocytes that need to be addressed to improve human iPSC-based models of cardiac diseases, 
human iPSC-based disease model is a useful tool for modeling human cardiac diseases, identifying novel 






We have made significant progress in understanding the pathogenesis of Timothy syndrome and 
identifying new therapeutics for Timothy syndrome using iPSCs. However, there are still many interesting 
questions that remain and are worth investigating in the future. This section will address certain strengths 
and limitations of the work presented here and propose some future directions to move the project forward.  
The optimization of the monolayer cardiac differentiation protocol 
One of the limitations of the cardiac differentiation protocol that we introduced in chapter 1 is that 
the protocol involves the use of FBS, which masks the hypertrophic phenotype in patient-specific 
cardiomyocytes 50. To address this limitation, we developed a serum-free version of the monolayer-based 
differentiation protocol (Figure 4.1A). The differentiation efficiency of the serum-free protocol is 
approximately 35% for both control and Timothy syndrome iPSCs (Figure 4.1B).  The protocol with the 
current differentiation efficiency is sufficient for preparing serum-free cardiomyocytes for single cell based 
experiments such as immunohistochemistry and patch clamp electrophysiology. However, with the current 
differentiation efficiency, the protocol could not provide sufficient cells for experiments such as high 
throughput chemical screen or heart regeneration that requires a large amount of serum-free 
cardiomyocytes. Thus further optimization is necessary to enhance the differentiation efficiency. To 
examine whether Timothy syndrome cardiomyocytes have a hypertrophic phenotype, we used both the 
serum-containing protocol and the serum-free protocol to derive cardiomyocytes from control and Timothy 
syndrome iPSCs. Next we conducted immunostaining with an antibody against sarcomeric alpha-actinin to 
examine the potential difference in cell size between control cardiomyocytes and Timothy syndrome 
cardiomyocytes. The results demonstrated that Timothy syndrome cardiomyocytes differentiated and 
maintained under serum-free condition showed an increase in cell size and a hypertrophic phenotype 
compared with control cardiomyocytes, and the hypertrophic phenotype was masked in Timothy syndrome 
cardiomyocytes differentiated and maintained under serum-containing condition (Figure 4.1C-4.1E), which 
is consistent with the previous report 50. The serum-free protocol allowed us to identify the hypertrophic 
phenotype in Timothy syndrome cardiomyocytes and provided a way to unveil the potential hypertrophic 
phenotype in cardiomyocytes derived from patients with cardiac diseases.  The sigma-1 receptor agonists 
such as Fluvoxamine have been reported to alleviate the phenotypes in surgery-induced myocardial 
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hypertrophy rodent models 115-118. It would be interesting to examine the effect of the treatment of sigma-1 
receptor agonists, such as Fluvoxamine or PRE-084, on the hypertrophic phenotype in Timothy syndrome 
cardiomyocytes in the future. Future work will also focus on the optimization of this protocol and enhancing 
the differentiation efficiency. 
The role of CDK5 in cardiac physiology 
In chapter 2, we found that CDK5 is involved in the pathogenesis of Timothy syndrome and the 
regulation of CaV1.2 channel functions. However the potential role of CDK5 in cardiac physiology and the 
regulation of ion channel functions under normal physiological conditions is still not characterized. It would 
be interesting to investigate the role of CDK5 in cardiac physiology and the regulation of ion channel 
functions using transgenic mouse models, heterologous over-expression systems and iPSC-based disease 
models in the near future.  
The optimization of Fluvoxamine and PRE-084 as new therapeutic compounds for Timothy syndrome 
In chapter 3, we found that the sigma-1 receptor agonist Fluvoxamine and PRE-084 have beneficial 
effects on Timothy syndrome cardiomyocytes. Fluvoxamine is a FDA-approved drug for treating obsessive-
compulsive disorder. It does not show significant side effects on cardiac system in clinical practice 119 and 
two previous clinical trials demonstrated that Fluvoxamine treatment could be beneficial for adults and 
children with autism 120, 121. It would be important and interesting in the future to evaluate the effects of 
Fluvoxamine on the cardiac and neuronal phenotypes in Timothy syndrome mouse models and Timothy 
syndrome iPSC-derived neurons, to further characterize the effects of Fluvoxamine on Timothy syndrome.  
In addition, Fluvoxamine has been reported to inhibit sodium currents at the dose of approximately 
50 μM and exhibit a pro-arrhythmic potential in one patient with a nonsense mutation in SCN5A encoding 
cardiac sodium channel 122.  In that report, Fluvoxamine did not demonstrate any significant inhibitory effect 
on sodium current at the dose lower than 10 μM in HEK293 cells expressing cardiac sodium channels 122. 
In our study, Fluvoxamine demonstrated beneficial effects on the phenotypes in Timothy syndrome 
cardiomyocytes at the dose of 5 μM. It would be important in the future to examine the potential effects of 
Fluvoxamine on the cardiac phenotypes in Timothy syndrome mouse models and investigate whether this 
drug has any pro-arrhythmic potentials.  
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The other compound PRE-084 is a highly selective sigma-1 receptor agonist. In addition to the high 
selectivity, another distinct advantage of PRE-084 is that it has been shown to have little effects on sodium 
channels 123 while several other sigma-1 receptor agonists such as SA4503 demonstrated an inhibitory 
effect on sodium channels 123-125. PRE-084 demonstrated neuroprotective effects in several preclinical 
studies 126-128 but the compound had not been developed into clinical studies. One of the major challenges 
is that the chemical structure of PRE-084 is highly susceptible to esterase degradation and the compound 
therefore is relatively unstable. A research group in Italy reported a new highly selective sigma-1 receptor 
agonist named RC-33 that was developed based on the chemical structure of PRE-084 and had a 
significantly enhanced in vitro metabolic stability compared with PRE-084 129-131 (Figure 4.2). RC-33 has a 
lipophilic chemical structure and a pharmacokinetic analysis demonstrated that RC-33 showed a relatively 
high distribution in the central nervous system in mouse 129. Both the treatment of RC-33 and the treatment 
of PRE-084 potentiated nerve growth factor (NGF)-induced neurite growth 128, 131,  indicating potentially 
similar cellular effects induced by the treatment of each compound. Dr. Yazawa’s laboratory has been 
working with the chemical core facility at Columbia University to synthesize RC-33 and plans to examine 
the effects of RC-33 on the phenotypes in Timothy syndrome cardiomyocytes in the near future. If RC-33 
treatment shows beneficial effects on the phenotypes in Timothy syndrome cardiomyocytes, future work 
will also focus on the optimization of the chemical structure of RC-33 such as adding polar groups to prevent 
its penetration through the blood-brain barrier into the central nervous system, in order to develop novel 





Figure 4.1: A monolayer based serum-free differentiation protocol. (A) Outline of the monolayer 
serum-free cardiac differentiation protocol.  (B) Fluorescence-activated cell sorting (FACS) analysis 
using the antibody against sarcomeric alpha-actinin for the monolayer cardiomyocytes at day 19 after 
differentiation using the serum-free protocol (Data are mean ± s.d.; n=12 from two control lines and 
two Timothy syndrome patient lines). (C, D, E) Immunocytochemistry using the antibody against 
sarcomeric alpha-actinin of control (Ctrl, left) and Timothy syndrome cardiomyocytes (TS, center and 
right) that were prepared using the serum-free protocol. While there was no significant difference in 
the cell size under serum-containing culture (D), the cell size of Timothy syndrome cardiomyocytes 
was significantly increased compared with the cell size of control cardiomyocytes under serum-free 
condition (E) (*P<0.0001 with Student’s t-test; Data are mean ± s.d.; Samples were from four control 
lines and three Timothy syndrome lines). Scale bar, 50μm. 







Figure 4.2: Chemical structure of compound PRE-084 and RC-33. The arrow head indicates the 
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